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￿
Erweiterung  des  BMD-Verfahrens  auf  zensierte  Tumorinzidenzzeiten  für  die 
Risikobeurteilung von Karzinogenen 
 
Zusammenfassung 
Das Benchmark Dose (BMD)-Verfahren, erstmals 1984 von K. Crump vorgeschlagen [CRUMP 
(1984)] ist in der Risikobeurteilung von Substanzen heute ein viel genutztes Instrument für 
die Ableitung von Grenzwerten für gesundheitsgefährdende Substanzen in der Umwelt und in 
der  Nahrung.  Das  BMD-Verfahren  bestimmt  dazu  einen  Referenzpunkt  (RfP)  auf  der 
statistisch  geschätzten  Dosis-Wirkungs-Kurve,  für  den  das  Risiko  ausreichend  sicher 
bestimmt  werden  kann.  Ausgehend  von  diesem  RfP  wird  dann  im  Schritt  einer 
Risikocharakterisierung  auf  der  Grundlage  toxikologischer  Betrachtungen  ein  Grenzwert 
ermittelt.  Das  Verfahren  konnte  sich  insbesondere  deshalb  profilieren,  weil  es  einige 
Nachteile  des  traditionell  genutzten  No-Observed-Adverse-Health-Effect-Level  (NOAEL)-
Ansatzes vermeidet [EFSA (2009)]. Im Gegensatz zu dem NOAEL-Verfahren, das diejenige 
Expositionsdosis als Referenzpunkt festlegt, bei der kein statistisch signifikanter Unterschied 
in der Reaktion (Zielvariable) verglichen mit der Kontrollgruppe nachgewiesen werden kann, 
basiert  das  BMD-Verfahren  auf  der  Anpassung  eines  Dosis-Wirkungs-Modells  auf  alle 
vorliegenden  Daten  auf  Grundlage  einer  Wahrscheinlichkeitsverteilung  für  den  Endpunkt. 
Letztlich reflektiert die BMD dann die Dosis, bei der eine zuvor spezifizierte Steigerung der 
gesundheitsschädlichen Reaktion (die sogenannte Benchmarkresponse) zu erwarten ist. Das 
Verfahren gliedert sich in vier Schritte: 
1.) Ein statistisches Verteilungsmodell der Zielvariablen und ein empirisch begründetes  
Modell der Dosiswirkung werden an experimentelle Daten angepasst. 
2.) Eine  Benchmark  Response  (BMR)  wird  festgelegt,  die  die  kleine,  aber  messbare 
Änderung  in  der  gesundheitsschädlichen  Reaktion  widerspiegelt.  Bei  dichotomen 
Zielvariablen  ist  der  Standardwert  der  BMR  eine  Änderung  um  10%,  bei 
kontinuierlichen eine Änderung um 5% verglichen mit der vorhergesagten Reaktion 
der nicht-exponierten Individuen (d.h. bei Hintergrundbelastung). 
3.) Die Dosis, für die diese BMR durch das Modell vorhergesagt wird, wird über die 
Modellanpassung bestimmt und wird  als Benchmark Dose (BMD) bezeichnet. 
4.) Eine (einseitige) untere 95% Konfidenzschranke wird geschätzt und als sogenannte 
BMDL (Benchmark Dose Lower Limit) als Referenzpunkt bestimmt.  ￿
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Üblicherweise  wird der BMD und die BMDL aus Daten von Tierstudien bestimmt und es 
erfolgt dann eine Extrapolation vom Tier auf den Menschen und von den noch relativ hohen 
Expositionsdosen auf so niedrige Dosen, dass die Chance für das Auftreten einer Reaktion 
beim Menschen noch einmal deutlich niedriger ist als die BMR. Das BMD-Verfahren kann 
auch auf Beobachtungsdaten beim Menschen direkt angewendet werden, was den Vorteil hat, 
dass  dann  die  Extrapolation  vom  Tier  auf  den  Menschen  entfällt.  Auch  wenn  dies  im 
Folgenden nicht weiter erörtert wird, besitzen die in dieser Arbeit entwickelten Methoden das 
Potential, auch in solchen Fällen angewendet zu werden.  
 
Eine Illustration des Verfahrens bietet die folgende Graphik. 
 
Fig.1: Schlüsselkonzepte des BMD Verfahrens, illustriert mit hypothetischen kontinuierlichen Daten, entnommen 
aus  EFSA    (2009)  1150,  10.  Die  Dreiecke  stellten  die  beobachteten  mittleren  Reaktionen  in  den 
unterschiedlichen  Dosisgruppen  dar  und  sind  mit  ihren  95%  Konfidenzintervallen  eingezeichnet.  Die 
durchgezogene Linie repräsentiert das angepasste Dosis-Wirkungs-Modell. Die BMD gehört zu einer BMR von 
5% Änderung relativ zu der modellierten Hintergrund-Reaktion der nicht-exponierten Individuen. Die untere 
gestrichelte Kurve gibt die untere Konfidenzgrenze eines einseitigen 95% Konfidenzintervalls an. Manchmal 
wird zusätzlich auch die einseitige obere 95% Konfidenzgrenze verwendet, die hier durch die obere gestrichelte 
Kurve repräsentiert wird. 
 
Das  BMD-Verfahren  ist  bisher  nur  für  dichotome  und  kontinuierliche  Zielvariablen 
beschrieben  worden.  In  der  Risikoabschätzung  von  Karzinogenen  sind  aber  insbesondere 
sogenannte  Ereigniszeiten  (time-to-event  Daten)  von  großem  Interesse,  da  sie  mehr 
Informationen  über  die  Tumorentstehung  enthalten  als  quantale  Inzidenzdaten.  In  vielen 
Tierexperimenten wurde die Zeit bis zum Auftreten eines Tumors (time-to-tumor) erfasst, ￿
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aber dieser Endpunkt nur selten auf die Dosis-Wirkungsbeziehung bei Risikoabschätzungen 
untersucht.  Diese  Zielvariable  ist  um  einiges  komplizierter,  da  Zensierungen  in  Betracht 
gezogen werden müssen. In der vorliegenden Arbeit soll das BMD-Verfahren für solche TTT 
Daten erweitert werden.  
In Anlehnung an die oben skizzierten Schritte können Inhalt und Ergebnisse der Arbeit wie 
folgt zusammengefasst werden:  
1.) Modell für die Zielvariable ist die Weibull-Verteilung (mit der Exponentialverteilung als 
Spezialfall).  Sie  hat  die  Überlebensfunktion  ￿￿￿￿ ￿ exp ￿￿￿￿
￿
￿,  wobei  ￿,￿,￿ ￿ 0.  Die 
Hazardfunktion  ergibt  sich  zu  ￿￿￿￿ ￿ ￿￿￿
￿
￿
￿
  und  die  Dichtefunktion  ist  durch  ￿￿￿￿ ￿
 ￿￿￿
￿
￿
￿
 exp ￿￿￿￿
￿
￿ gegeben. Für ￿ ￿ 1 erhält man die Exponentialverteilung. 
Reparametrisiert man ￿ mittels exp ￿￿
￿ ￿ ￿
￿ ￿ ￿￿￿￿￿￿ oder äquivalent durch exp ￿￿￿ ￿
￿ ￿
￿ ￿
￿ ￿ ￿￿￿￿￿￿,  erhält  man  ein  Regressionsmodell,  das  zwei  im  Fachgebiet  der 
Überlebenszeitanalyse wesentliche Annahmen erfüllt, die der proportional hazards (PH) und 
die  der  accelerated  failure  times  (AFT).  PH-Modelle  nehmen  an,  dass  der  Effekt  der 
Kovariablen (in unserem Fall die Dosis) proportional in Bezug auf das Risiko eines Tumors 
ist (hazard) und AFT-Modelle gehen davon aus, dass der Effekt der Kovariablen proportional 
in Bezug auf die „Überlebenszeit“ (d.h. Zeit bis zu einem Tumor) ist. Anders formuliert, wird 
in  AFT-  Modellen  angenommen,  dass  die  Überlebenszeit  mit  zunehmender  Dosis 
„beschleunigt“ wird. Die Weibull-Verteilung ist die einzige Verteilung, die sowohl die PH- 
als  auch  die  AFT-Annahme  erfüllt  (vorausgesetzt,  der  Parameter  ￿  ist  wirklich  wie 
angenommen für alle Dosisgruppen gleich) [KALBFLEISCH (2002), 45f.]. 
 
2.)  Für  die  Definition  einer  BMR  sind  bei  Ereigniszeiten  unterschiedliche  Möglichkeiten 
denkbar, die sich allerdings nicht alle als gleich günstig erweisen. Eine Möglichkeit besteht 
darin, die BMR als Reduktion in der Überlebenswahrscheinlichkeit zu einem festen Zeitpunkt 
￿
￿
 zu definieren. Die Reduktion kann dann entweder absolut oder relativ bezogen auf die 
(durch das Modell geschätzte) Überlebenswahrscheinlichkeit der Kontrollgruppe angegeben 
werden. Die BMD ist dann 
￿:   ￿￿￿
￿
,￿￿ ￿ ￿￿￿
￿
,0￿ ￿ ￿  für die Formulierung als absolute Reduktion 
bzw. 
￿:   ￿￿￿
￿
,￿￿ ￿ ￿1 ￿ ￿￿ ￿￿￿
￿
,0￿ für die Formulierung als relative Reduktion. 
 ￿
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Eine andere Möglichkeit besteht darin, die BMR als Reduktion in medianer Überlebenszeit 
anzugeben.  Offensichtlich  könnte  man  auch  jedes  andere  Quantil  zugrunde  legen,  wir 
beschränken uns an dieser Stelle aber auf den Median als meist genutzten Parameter in der 
Praxis. 
Auch hier kann die Reduktion wieder absolut oder relativ definiert werden. Für die BMD 
erhält man 
￿:   ￿
￿
￿
￿￿￿￿ ￿ ￿
￿
￿
￿￿0￿ ￿ ￿ für die Formulierung als absolute Reduktion 
bzw. 
￿:   ￿
￿
￿
￿￿￿￿ ￿ ￿1 ￿ ￿￿ ￿
￿
￿
￿￿0￿ für die Formulierung als relative Reduktion. 
 
Es spricht nun einiges dafür, die BMR als relative Reduktion in einem Überlebensquantil zu 
definieren.  Denn  in  diesem  Fall  ist  wegen  der  AFT-Eigenschaft  des  Weibull-Modells  die 
errechnete  BMD  unabhängig  von  dem  Quantil,  das  man  zugrunde  gelegt  hat.  Andere   
Definitionen  einer  BMR  scheinen  nur  dann  sinnvoll,  wenn  bestimmte  Umstände  dafür 
sprechen,  ein  gewisses  Quantil  oder  einen  bestimmten  Zeitpunkt  für  die  Analyse  zu 
betrachten. 
 
3.) Für die Bestimmung der BMD für eine gegebene BMR wird die Maximum-Likelihood-
Schätzmethode vorgeschlagen. Die entsprechenden Formeln wurden getrennt für Exponential- 
und Weibull-Modelle berechnet. 
 
4.)  Um  auch  ein  Konfidenzintervall  für  die  BMD  angeben  zu  können,  wird  eine  Re-
parametrisierung  des  Modells  vorgeschlagen,  so  dass  die  BMD  selbst  zu  einem 
Modellparameter  wird.  Dann  ist  es  möglich,  ein  sogenanntes  Profil-Likelihood-
Konfidenzintervall zu schätzen. Man kann zeigen, dass für ￿ ￿ ￿￿￿ die Menge 
 ￿: ! "
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ein  approximatives  (zweiseitiges)  ￿1 ￿ ￿￿  Konfidenzintervall  für  die  BMD  bildet. 
Wichtigster Baustein des Beweises ist die asymptotische Normalverteilung des Maximum- 
Likelihood-Schätzers.  Bezeichnet  ! "
"￿￿￿  die  logarithmierte  relative  Profil-Likelihood  
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0., so ist der Grundgedanke einer Profil-Likelihood-Funktion der, bei 
einer Likelihood-Funktion, die von mehreren Parametern abhängt, nur einen Parameter zu ￿
V￿
￿
untersuchen und für jeden festen Wert dieses interessierenden Parameters die  Likelihood-
Funktion zu maximieren:  
+
1￿￿￿ ￿ max
2 +￿￿,1￿ ￿ +2￿,1̂
3
4￿￿￿4. 
In unserem Fall bezeichnet dann ￿ die BMD und alle anderen Parameter des Dosis-Wirkungs-
Modells werden in 1, einem weiteren Regressionsparameter(vektor) des reparametrisierten 
Modells zusammengefasst, der für unsere Analyse nicht von Belang ist (nuisance parameter). 
Um die untere Grenze des (einseitigen) Konfidenzintervalls  6￿￿￿+,∞￿ zu finden, muss man 
schließlich 
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5￿￿￿ ￿ ￿
6
7 %
8
9
:
;
<
￿1￿; 
bestimmen. Man beachte hierbei, dass für das einseitige Konfidenzintervall das ￿1 ￿ 2￿)- 
Quantil statt des ￿1 ￿ ￿)-Quantils der Chiquadrat-Verteilung verwendet werden muss. 
 
Der Ansatz mit den oben beschriebenen Methoden wurde auf die Daten einer am Deutschen 
Krebsforschungszentrum  vorgenommenen  Studie  von  Schmähl,  Port  und  Wahrendorf  aus 
dem Jahr 1977, die die Kanzerogenität von Ethylcarbamat (Urethan) im Tierexperiment an 
Mäusen  und  Ratten  untersucht,  angewendet,  für  das  die  originalen  Tumordaten,  genauer 
gesagt die Zeiten bis zum Tod mit Tumor(en), vorlagen. Das Experiment untersuchte zwei 
Spezies (Mäuse und Ratten) und zwei Geschlechter (männlich und weiblich), weshalb es in 
vier  Teilexperimente  untergliedert  wurde:  Männliche  Mäuse,  weibliche  Mäuse,  männliche 
Ratten  und  weibliche  Ratten.  In  jedem  Teilexperiment  wurden  fünf  Dosisgruppen 
unterschieden: 0 (Kontrolle), 100, 500, 2500, 12500 µg Urethan/kg BW/day. Die BMD10-
Werte für das Weibull-Modell lagen im Bereich von 4030 bis 8523 µg/kg BW/day bei einer 
BMR von 10% (relativem) Verlust in jedem Überlebensquantil. Die entsprechenden BMDL10-
Werte deckten einen Bereich zwischen 2590 und 3666 µg/kg BW/day ab. Das Exponential-
Modell führte (vermutlich aufgrund des schlechteren Modellfits) zu kleineren Schätzern. Die 
BMD10-Werte  lagen  hier  zwischen  786.6  und  2198  µg/kg BW/day,  die  BMDL10-Werte 
zwischen 541.7 und 902.8 µg/kg BW/day. Alle errechneten BMDs und BMDLs wurden mit 
den Ergebnissen für dichotome Modelle (Loglogistic und Weibull) sowie mit Werten aus der 
Literatur auf Konsistenz verglichen. Es zeichnete sich der Trend ab, dass die dichotomen 
Modelle,  die  weniger  der  vorliegenden  Information  ausnutzen,  zu  niedrigeren  BMD-  und 
BMDL-Werten führen. Zu beachten ist bei einem solchen Vergleich allerdings, dass die für ￿
VI￿
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TTT- und dichotome Modelle jeweils zugrundegelegten BMRs nicht unbedingt äquivalent 
sind.   
 
Abschließend wurde in einer Simulationsstudie der Einfluss des Zensierungsprozentsatzes auf 
die  Überdeckungswahrscheinlichkeit  des  approximativen  Konfidenzintervalls  für 
Exponentialmodelle  bei  gleichen  Dosisgruppen  und  Tierzahlen  wie  im  Experiment  von 
Schmähl  und  Kollegen  untersucht.  Es  stellte  sich  heraus,  dass  die                        
Überdeckungswahrscheinlichkeit für alle betrachteten Zensierungsprozentsätze sehr nahe am 
approximativen Wert lagen, die Variabilität des BMDLs aber wie erwartet insbesondere für 
hohe Zensierungssätze zunahm, wobei dann auch der Median der geschätzten BMDLs kleiner 
wurde. Das kann als vorsichtiger Hinweis interpretiert werden, dass hohe Zensierungssätze im 
Mittel zu konservativeren Schätzern führen könnten.  
 
Die Arbeit schließt mit Überlegungen dazu, wie dieser Ansatz weiter entwickelt werden kann, 
z.B.  für  andere  Modelle  von  Tumor-Daten,  und  welche  Maßnahmen  getroffen  werden 
können,  so  dass  ein  solcher  Ansatz  von  praktisch  arbeitenden  Forscher  in  der 
Risikobeurteilung angenommen wird.  ￿
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Extending the BMD approach to censored time-to-tumor data for applications in 
quantitative risk assessment of carcinogens 
 
Summary 
The Benchmark Dose (BMD) approach, which was suggested firstly in 1984 by K. Crump 
[CRUMP  (1984)],  is  a  widely  used  instrument  in  risk  assessment  of  substances  in  the 
environment and in food. In this context, the BMD approach determines a reference point 
(RfP) on the statistically estimated dose-response curve, for which the risk can be determined 
with adequate certainty and confidence. In the next step of risk characterization a threshold is 
calculated, based on this RfP and toxicological considerations. The ‘success’ of the BMD 
approach can be led back to the fact that it avoids some disadvantages of the traditionally used 
No-Observed-Adverse-Health-Effect-Level  (NOAEL)  approach.  The  NOAEL  approach 
determines the exposition dose for which no statistically significant difference in the response 
(endpoint) compared to the control group can be detected as reference point. In contrast, the 
BMD  approach  bases  upon  the  fit  of  a  dose-response  model  on  the  data.  For  this  fit  a 
stochastic  distribution  of  the  response  endpoint  is  taken  as  a  basis.  Ultimately,  the  BMD 
reflects the dose for which a pre-specified increase in an adverse health effect (the benchmark 
response) can be expected.   
The BMD approach consists of four steps: 
1.) A statistical distribution model for the endpoint variable and an empirically justified 
model of the dose-response interrelationship have to be fitted on the data. 
2.)  A Benchmark Response (BMR) is determined, which reflects a small but measurable 
increase in the adverse health effect. For dichotomous endpoints the default value for 
the BMR is an increase of 10%, for continuous endpoints of 5% compared to the 
predicted response of the non-exposed individuals (background response).  
3.) The dose, for which this BMR is predicted by the fitted model, is determined and is 
called Benchmark Dose (BMD). 
4.) An (one-sided) lower 95% confidence bound is estimated and as so called BMDL 
(Benchmark Dose Lower Limit) determined to build the reference point for the further 
risk assessment. 
 ￿
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Typically, the BMD and BMDL are determined on the basis of data from animal studies and 
afterwards an extrapolation from animal to human, such as from relatively high exposition 
doses to doses for which the risk of an adverse effect in humans is much less than the BMR, 
has to be performed. It is also possible to apply the BMD approach to observational data for 
humans, which has the advantage that no extrapolation from animal to human is needed. 
Although  not  subject  of  this  thesis,  the  methods  developed  here  have  the  potential  to  be 
applied therefore as well.  
The following figure provides an illustration of the approach:  
 
Fig. 1: Key concepts of the BMD approach, illustrated by using hypothetical continuous data, taken from  EFSA 
(2009) 1150, 10. The triangles denote the observed mean responses in the different dose groups, and are plotted 
together with their confidence intervals. The solid curve represents a fitted dose-response model. The BMD 
corresponds to a 5% change in response relative to the modeled background response (BMR=5%). The lower 
dashed curve is the lower one sided 95% confidence bound for the effect size as a function of dose. Analogously, 
the upper dashed curve represents the upper one sided 95% confidence bound for the effect size. 
 
Until now, the BMD approach has been specified only for quantal and continuous endpoints. 
But  in  risk  assessment  of  carcinogens  especially  so  called  time-to-event  data  are  of  high 
interest since they contain more information on the tumor development than quantal incidence 
data. Many animal experiments have recorded the time until a tumor occurs (time-to-tumor) 
but  that  endpoint  has  been  rarely  investigated  for  dose-response  in  risk  assessment.  This 
endpoint is much more complicated because censoring has to be taken into account. The goal 
of this diploma thesis is to extend the BMD approach to such time-to-tumor (TTT) data. ￿
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Following the steps outlined before, the contents and results of the thesis can be summarized 
as follows:  
1.) We have chosen the Weibull distribution (including the Exponential distribution) to model 
the  endpoint  time-to-tumor.  The  Weibull  distribution  has  the  survival  function                 
￿￿￿￿ ￿ exp ￿￿￿￿
￿
￿, where ￿,￿,￿ ￿ 0. The Hazard function is given by ￿￿￿￿ ￿ ￿￿￿
￿
￿
￿
 and 
the  density  function  by  ￿￿￿￿ ￿  ￿￿￿
￿
￿
￿
 exp ￿￿￿￿
￿
￿.  If  ￿ ￿ 1,  this  characterizes  the 
Exponential distribution. 
In  the  next  step,  ￿  was  re-parameterized  through  exp ￿￿
￿ ￿ ￿
￿ ￿ ￿￿￿￿￿￿  or  equivalently 
through  exp ￿￿￿ ￿
￿ ￿ ￿ ￿
￿ ￿ ￿￿￿￿￿￿,  which  led  to  a  regression  model  that  fulfills  two 
essential assumptions often considered in survival analysis: proportional hazards (PH) and 
accelerated failure times (AFT). PH models suppose that the effect of covariates (in our case 
the dose) is proportional with respect to the risk of a tumor (hazard). On the other hand, AFT 
models assume the effect of covariates to be proportional with respect to the endpoint (time to 
tumor). In other words, AFT suppose the time to tumor to be “accelerated” with increasing 
dose.  A  unique  property  of  the  Weibull  distribution  is  the  equivalence  of  PH  and  AFT 
assumption (pretended that the parameter ￿ does not vary over different levels of covariates) 
[KALBFLEISCH (2002), 45f.]. 
 
2.) In order to define a BMR for time-to-event data different possibilities are thinkable, but 
not  all  of  them  are  equally  appropriate.  One  possibility  would  be  to  define  the  BMR  as 
reduction  of  the  survival  probability  at  a  fixed  time  point  ￿
￿
.  This  reduction  of  survival 
probability can be stated either in absolute or in relative terms with respect to the survival 
probability of the non-exposed individuals predicted by the model. Then, the BMD equals 
￿:   ￿￿￿
￿
,￿￿ ￿ ￿￿￿
￿
,0￿ ￿ ￿  for the definition in terms of an absolute reduction 
resp. 
￿:   ￿￿￿
￿
,￿￿ ￿ ￿1 ￿ ￿￿ ￿￿￿
￿
,0￿ for the definition in terms of a relative reduction. 
 
Another possibility is to define the BMR as reduction in median survival time. An extension 
to any other quantile would be obvious, however this thesis focuses on the median as the most 
used parameter in praxis. 
 ￿
IVa￿
￿
Again, the reduction can be defined either in absolute or in relative terms. The BMD is 
￿:   ￿
￿
￿
￿￿￿￿ ￿ ￿
￿
￿
￿￿0￿ ￿ ￿ for the definition in terms of an absolute reduction 
resp. 
￿:   ￿
￿
￿
￿￿￿￿ ￿ ￿1 ￿ ￿￿ ￿
￿
￿
￿￿0￿ for the definition in terms of an relative reduction. 
 
Defining the BMR as relative reduction has the advantage that the BMD calculated on the 
basis of this definition does not depend on the choice of the quantile when the Weibull model 
is assumed due to its AFT property. Other possibilities of defining the BMR seem to be only 
reasonable if additional information is on hand, e.g. suggesting the evaluating of a specific 
quantile or a key time point during tumor development. 
 
3.) We suggest determining the BMD for a pre-specified BMR with Maximum Likelihood 
estimates. The formulas have been calculated individually for the Exponential and Weibull 
models.  
 
4.) In order to estimate a confidence interval for the BMD, a re-parameterization of the model 
is  suggested,  which  includes  the  BMD  as  a  parameter  itself.  Then  a  so  called  profile 
likelihood confidence interval can be estimated. It can be shown that for ￿ ￿ ￿￿￿ the set 
 ￿: ! "
￿￿￿￿ # ￿
1
2
 %
￿
￿
 
!
￿1￿& 
builds an approximate (two-sided) confidence interval for the BMD. An important result for 
the proof is the asymptotic normality of Maximum Likelihood estimates. Here, ! "
"￿￿￿ denotes 
the logarithm of the profile likelihood, i.e. log*+ ,
#￿￿￿ -￿
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0.. The main idea of a profile 
likelihood function is to ‘concentrate’ on only one parameter of a likelihood function that 
depends on several parameters. The likelihood function is maximized for every fixed value of 
the parameter of interest: 
+
1￿￿￿ ￿ max
2 +￿￿,1￿ ￿ +2￿,1̂
3
4￿￿￿4. 
In our case, ￿ denotes the BMD and all other parameters of the dose-response model are 
summarized  in  the  nuisance  paramter  1,  which  denotes  a  parameter(vector)  of  the  re-
parameterized regression model that is not of interest for our analysis. ￿
Va￿
￿
To gain the lower limit of a (one-sided) confidence interval 6￿￿￿+,∞￿, finally 
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has to be determined. Note, that for a one-sided confidence interval the ￿1 ￿ 2￿)-quantile 
instead of the ￿1 ￿ ￿)-quantile of the chi-squared distribution has to be used.  
 
 
The approach and methods outlined above were then applied to data of an animal experiment 
conducted at the German Cancer Research Center by Schmähl, Port and Wahrendorf in 1977, 
which investigated the carcinogenicity of ethyl carbamate (urethane) in mice and rats and for 
which the original time-to-tumor data were available, more precisely tumor specific survival 
time, namely time-to-death with tumor. The experiment investigated two species (mouse  and 
rat) and two sexes (male and female) and was therefore divided into four sub-experiments: 
Mouse male, mouse female, rat male and rat female. In each sub-experiment there were five 
dose groups analyzed: 0 (control), 100, 500, 2500, 12500 µg urethane/kg BW/day. For the 
Weibull  model,  the  estimated  values  of  BMD10  lay  in  the  range  of  4030  to  8523 
µg/kg BW/day for a relative BMR of 10% loss in each quantile of survival. The values for 
BMDL10 lay between 2590 and 3666 µg/kg BW/day. The exponential model led to smaller 
estimates (probably due to the poorer fit). Here, the values for the BMD10 lay between 786.6 
and 2198 µg/kg BW/day and for the BMDL10 in the range of 541.7 to 902.8 µg/kg BW/day. 
All  calculated  estimates  for  BMDs  and  BMDLs  were  compared  with  the  results  for 
dichotomous  models  (loglogistic  and  Weibull)  and  values  published  in  the  literature.  We 
could observe the trend that the dichotomous models, which use only a smaller amount of 
information, led to lower estimates for the BMD and BMDL. But one has to keep in mind that 
the underlying BMRs for dichotomous and TTT models might not be equivalent.  
Finally,  a  simulation  study  was  performed  to  evaluate  the  influence  of  the  censoring 
percentages on the coverage probability of the approximate confidence interval. We used the 
same dose groups and numbers of animals as in the experiment of Schmähl and colleagues. 
The  coverage  probability  was  found  to  be  very  close  to  the  approximate  value  for  all 
censoring percentages. As expected, the variability of the BMDLs increased especially for 
higher censoring percentages, whereby the median of the estimated BMDLs decreased. This 
can be interpreted as a hint that high censoring percentages could lead to more conservative 
estimates. ￿
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The thesis closes with some considerations on how the approach could be further extended, 
e.g.  for  other  models  for  time-to-tumor  data  and  which  steps  could  be  done  so  that  this 
approach becomes accepted by practical working researchers in risk assessment. Contents 
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1. Introduction  
 
„Alle ding sind gifft u. nichts ohn gifft / Allein die dosis macht das ein ding kein gifft ist.“
1 
Paracelsus (7 Defensiones: 3. Defension II, 1537/38) 
 
1.1. Risk assessment and the need for quantitative methods 
Almost 500 years ago the famous scientist Paracelsus pointed out that every substance must 
essentially be regarded as poison and only the dose dictates whether it is harmful or not. Of 
course, the field of toxicology has made huge progress since then; however, this medieval 
insight  has  remained  an  indisputable  concept  among  toxicologists  –  at  least  for  non-
carcinogenic substances. Therefore the search for a threshold dose that can be defended to be 
not  harmful  to  humans  is  the  essential  goal  of  modern  risk  assessment.  In  general,  risk 
assessment is an important prerequisite step for the risk management process and means the 
determination  of  a  qualitative  or  quantitative  value  of  the  risk  attributed  to  a  substance 
considered to be hazardous. If carcinogenic substances are analyzed, the results of modern 
cancer research suggest that no threshold dose can be found below which no adverse health 
effect could occur [e.g. OEHLMANN, MARKERT (1997)]. This property has been postulated, in 
particular, for carcinogenic substances which are genotoxic, i.e. having mutational activity 
and react directly with the DNA. Therefore, it is an important task in toxicology and in risk 
assessments to find doses which cause only a small increase of cancer risk. 
In a nut shell, risk assessment aims to find the maximum dose of a substance which is not 
harmful to humans. As clear as this goal is, as complicated it is to achieve. For ethical reasons 
these doses cannot be determined through straight experiments on humans. Hence, they must 
be estimated either from available epidemiological data or data from animal studies. Both data 
sources  have  constraints.  Epidemiological  data  are  in  most  cases  obtained  through 
observational studies which are accompanied with a series of difficulties such as uncertainties 
in estimating the quantity of human exposure or distorting effects due to confounding factors. 
On  the  other  hand,  when  data  from  animal  studies  are  used,  the  conclusions  have  to  be 
extrapolated  to  environmentally  relevant  exposure  levels  for  humans.  Note  that  risk 
assessment often faces the problem of extrapolating from high exposure doses to lower doses 
since one is interested in a human exposure dose which does not constitute a risk to human 
￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
1 Translation: “All things are poison and nothing is without poison. Only the dose makes that a thing is no 
poison.” 2 
￿
health or which is such low, that it is negligible. When using animal data that extrapolation is 
usually in the order of several magnitudes (e.g. extrapolating by a factor between 100 and up 
to 10 000) whereas when using human data that factor is usually smaller and could be not 
larger than 10 [EDLER (1998), BOKKERS (2009)].  
In risk assessment of substances in the environment and in food the Benchmark Dose (BMD) 
approach  has  become  a  widely  used  instrument.  In  this  context,  the  BMD  approach 
determines  a  reference  point  (RfP)  on  the  statistically  estimated  dose-response  curve,  for 
which the risk can be determined with adequate certainty and confidence. In the next step of 
risk  characterization  a  threshold  is  calculated,  based  on  this  RfP  and  toxicological 
considerations. 
This thesis will concentrate on the analysis of data generated in animal studies, i.e. we will 
consider experimental data to determine dose levels which can be used as reference points in 
the further proceeding of risk assessment.  The data type studied here is called time-to-tumor 
(TTT) data: Each individual (animal) is observed from the start of the experiment until a 
tumor occurred and is recorded. The time span from start to that event is denoted as time-to-
tumor. This endpoint is an important example of time-to-event (TTE) data studied in the field 
of  survival  analysis  and  the  analysis  for  failure  time  data,  see  e.g.  KALBFLEISCH  AND 
PRENTICE (2002).  Note that in practice the determination and interpretation of such a time-to-
tumor could be rather complicated, see e.g. GART ET AL. (1986), due to restricted observability 
and events occurring to the animal in a manner competing with the tumor event. For this 
thesis and the development of the BMD approach for TTT data we assume that the tumor 
event  can  be  observed  and  recorded  exactly  as  time,  however,  we  allow  (independent) 
censoring, e.g., when the animal dies and had no tumor developed by that time. Our goal is to 
calculate a so called Benchmark Dose, i.e. a dose producing a predetermined level of change 
in adverse response compared to the response in untreated animals, and its lower confidence 
bound. In the further proceeding of risk assessment, the lower confidence bound of this dose 
can be used as RfP for deriving health-based guidance values for humans, for example an 
Acceptable Daily Intake (ADI) or margins of exposure (MOE) [EFSA (2005), CONSTABLE, 
BARLOW (2009)].      
We will consider in the following classes of parametric survival distributions focusing at the 
Weibull distribution.  3 
￿
The approach we will present is an extension of the Benchmark Dose approach described in a 
scientific opinion of 2009 requested by the European Food Safety Authority [EFSA (2009)], 
which was basically influenced by the work of the “pioneer” of this approach K. Crump in the 
1980s [CRUMP (1984)] and many other biostatisticians doing research in that field.  
Traditionally, the No-Observed-Adverse-Effect-Level (NOAEL) has been used as a reference 
point  in  risk  assessment,  which  reflects  a  dose  level  where  no  statistically  significant 
differences in response (compared with the observed background response) are found. But 
this  approach  has  several  disadvantages.  Most  prominent  is  that  its  outcome  is  strongly 
influenced by the study design.
2 The ‘success’ of the BMD approach can be led back to the 
fact that it avoids some disadvantages of the NOAEL approach. 
 
The  general  proceeding  of  the  Benchmark  Dose  (BMD)  approach  can  be  summarized  as 
follows:  
•  Firstly,  a  model  of  the  outcome  variable  (response)  has  to  be  fitted,  including  a 
reasonable model of the dose effect (dose-response).  
•  Secondly, a so called Benchmark Response (BMR) has to be defined, which is a small 
but measurable change in adverse response in contrast to the non-exposed individuals. 
For quantal data a default value of 10% and for continuous data a default value of 5% 
is  commonly  used.    In  order  to  avoid  misunderstandings,  we  should  already  here 
mention as a side note that the reference is the background response predicted by the 
fitted model and not the response observed in the control group.  
•  Thirdly, the dose has to be found for which this BMR is predicted. This dose is called 
Benchmark Dose (BMD).  
•  Because risk assessment always has to be performed very cautiously, finally, a 95% 
confidence interval of the BMD has to be calculated and especially the (one sided) 
95% lower limit, denoted by the abbreviation BMDL, is of interest. To include the 
chosen value of the BMR, the notation BMDBMR/ BMDLBMR is common, i.e. BMD10/ 
BMDL10 for a BMR of 10% change in response. 
 
 
￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
2 For more details see e.g. EFSA (2009) 1150. 4 
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The following figure provides an illustration of the BMD approach:  
 
Fig.1: Key concepts of the BMD approach, illustrated by using hypothetical continuous data, taken from  EFSA 
(2009) 1150, 10. The triangles denote the observed mean responses in the different dose groups, and are plotted 
together with their confidence intervals. The solid curve represents a fitted dose-response model. The BMD 
corresponds to a 5% change in response relative to the modeled background response (BMR=5%). The lower 
dashed curve is the lower one sided 95% confidence bound for the effect size as a function of dose. Analogously, 
the upper dashed curve represents the upper one sided 95% confidence bound for the effect size. 
 
The BMD approach can be used for all experimental data that show at least a significant dose-
related trend in the considered endpoint which hints at a graded monotonic (non-decreasing) 
response with dose. It is applicable to all toxicological effects (non-carcinogenic as well as 
carcinogenic  ones)  and  to  studies  in  which  all  dose  groups  show  statistically  significant 
changes in response compared to the control group, a case where there would no NOAEL be 
defined.  
 
Naturally, the question which doses of critical substances can be tolerated is a question of risk 
management and therefore also a societal and political one because certain guidelines have to 
be adopted. In the European Union the European Food Safety Authority (EFSA) performs the 
task of scientifically informing about how to deal with health risks in connection with food, 
providing advice for the European Commission and Parliament, which have to decide how the 
risk management should be performed on the European scale. Therefore the EFSA as well as 
its counterparts in the USA, the Food and Drug Administration (FDA) and the Environmental 5 
￿
Protection Agency (EPA) have spent considerable effort in developing sustainable statistical 
methods of determining these doses as RfPs. Nevertheless, this work has so far concentrated 
on quantal tumor incidence dose-response data or continuous data such as body weight or 
liver size – but almost never on time-to-event data and on the special case of survival data. 
The work of this thesis was motivated by a presentation given by Prof. Wout Slob (RIVM, 
The  Netherlands)  at  an  ILSI  Workshop  and  the  EUROTOX  Meeting  in  2008  on  Rhodes 
Island where he addressed the importance to extend the BMD approach to time-to-tumor data. 
Given the experience with those data at the Department of Biostatistics and the interest in 
further developing the statistical methods for the BMD approach the theme of this thesis was 
developed in cooperation between the Mathematical Institute of the University of Frankfurt 
(JProf  G.  Schneider) and  the  Department  of  Biostatistics  of  the  German  Cancer  Research 
Center (Dr. L. Edler) with the aim to find a statistical solution for calculating Benchmark 
Doses for this type of data which is much more difficult to handle because both censoring and 
(dependent on the study design) also competing risks have to be taken into account. 
 
1.2. Research Questions 
The research questions underlying the task of extending the BMD approach to TTE data to be 
solved in this thesis are as follows: 
1)  How can a reasonable model be formulated for the data, if the outcome variable is a 
TTE? 
2)  Which  meaningful  risk  functionals  can  be  defined  in  order  to  state  a  Benchmark 
Response (BMR)? Which criteria are useful to evaluate their appropriateness? 
3)  Which  statistical  method  is  most  appropriate  to  estimate  the  BMD  and  its  lower 
confidence limit (BMDL)? 
We will suggest estimating the BMD and BMDL using the concept of Maximum Likelihood 
Estimation. This will lead to the following mathematical tasks: 
a)  The models chosen for fitting the dose-response data have to be re-parameterized in a 
way that makes it possible to determine a profile likelihood confidence interval for the 
BMD. 
b)  The  coverage  of  the  estimated  profile  likelihood  confidence  interval  and  its 
dependence on the percentage of censoring in the sample has to be investigated. 6 
￿
Firstly,  we  try  to  answer  the  questions  posed  above  rather  theoretically  and  describe  the 
statistical and numerical methods. Then we will apply the approach and methods outlined 
before to real data, taking an experimental study as a basis which had been conducted at the 
German  Cancer  Research  Center  (DKFZ)  by  Schmähl,  Port  and  Wahrendorf  [SCHMÄHL 
(1977)] and for which the original time-to-tumor data were available, more precisely time-to-
death with tumor. These researchers tried to investigate the carcinogenicity of ethyl carbamate 
(urethane) in female and male mice as well as in female and male rats. Afterwards we will 
attempt  to  examine  the  validity  of  the  approach  using  simulated  data,  focusing  on  the 
influence of the censoring percentages on the coverage probability of the approximate profile 
likelihood confidence intervals. Finally, we will discuss the results as well as the methods 
used in this work and make some remarks on how these results obtained for TTE data can be 
transferred to the risk analysis of humans. The thesis closes with some considerations on how 
the approach could be further extended, e.g.  for other models for time-to-tumor data and 
which  steps  could  be  done  so  that  this  approach  becomes  accepted  by  practical  working 
researchers in risk assessment. 
 7 
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Part I: Statistical and numerical Methods  
The risk analysis methods presented in this thesis have the overall  goal to determine the 
carcinogenic  potential  of  substances  studied  in  animal  experiments  for  human  risk 
assessment.  In  contrast  to  most  carcinogenic  risk  analyses  which  merely  consider  tumor 
incidence data we are interested in two endpoints at the same time related to the two questions  
“How many animals in different dose groups develop a tumor or not during the experimental 
observation time?” and “If they have developed a tumor, when did it occur?”. That means, we 
do not have to deal with quantal data (tumor: yes or no) but with survival data, which contain 
information about the dose of the analyzed substance an individual was exposed to during the 
study and either the time until a tumor occurred or – if no tumor was observed – the time until 
the animal left the study. This type of data is in the following called “time-to-tumor” (TTT) 
data.  
Before  the  research  questions  formulated  in  the  introduction  will  be  approached  some 
background information is provided next, including a short description of survival data and 
the (two parameter) Weibull distribution. In this context, the so-called Kaplan-Meier curves 
are introduced, which are an important instrument of non-parametric survival analysis. We 
will finish this section making some remarks on the numerical methods used in this thesis. 
The subsequent section will contain a stepwise description of our proposed procedure for 
applying the BMD approach to time-to-tumor data. To become not too theoretical, we will 
illustrate the proceeding using some small example data sets. 
 
2. Basic concepts 
2. 1. Introduction to survival data 
Survival  data  occur  in  very  different  fields  such  as  economics,  sociology,  biology  or 
medicine. They are always dealing with the same outcome variable: the time until an event 
(sometimes also called failure) occurs. In our case, the event is specified by occurrence of a 
malignant tumor. Therefore we speak of time-to-tumor (TTT) data. This survival time (or 
time to event) is denoted by a capital ￿, indicating that it is a random variable, with possible 
values the nonnegative real numbers, ￿
￿
￿. 8 
￿
A typical situation in survival analysis is that not all individuals face the event during the 
study period. The explanation can be e.g. death from other reasons or end of the experiment 
and the individual is still alive. Those individuals are called (right) censored because we only 
know that they did not face the event until a specific time point - but not the primary endpoint 
“tumor”. Therefore, in a typical survival analysis, there are two specifications given for each 
individual: The time after which the individual has left the study and the reason, why it has 
left it. In principle, each individual ￿ is characterized by two random variables: the time of 
observation,  denoted  ￿
￿
￿
,  and  the  type  of  the  event  which  terminates  the  observation,  the 
status, denoted ￿
￿. For ￿ individuals we denote this information using two (vector) variables 
￿
￿
￿ ￿￿
￿
￿
,…,￿
￿
￿
￿ and ￿ ￿ ￿￿
￿,…,￿
￿), where ￿
￿
 gives the observed times and ￿ the status, i.e. 
￿
￿ ￿ 1 if the individual ￿ has faced the event at time point ￿
￿
￿
 or ￿
￿ ￿ 0 if it has been censored 
at time point ￿
￿
￿
.  
The observed time ￿
￿
￿
 can be specified as minimum of two random variables: The time to 
event ￿
￿ and the censoring time ￿
￿: ￿
￿
￿
￿ min￿￿
￿,￿
￿￿. Following this definition, the status 
variable is a censoring indicator:  ￿
￿ ￿ ￿￿￿
￿ ￿ ￿
￿￿. The focus of survival analysis is modeling 
the real time to event ￿
￿ appropriately.  
Next we introduce two essential functions used in survival analysis – the survival function 
and the hazard function of T: 
Definition: The survival function ￿￿￿￿ gives the probability that an individual survives a time 
point ￿ (without facing the event), i.e. the probability ￿￿￿ ￿ ￿￿.  
A survival function is non-increasing and, by definition of T on ￿
￿
  we know that ￿￿0￿ ￿ 1, 
since at the start of the study no one has faced the event yet. When time increases the survival 
function should approach the value zero: lim
!
"
#￿￿￿￿ ￿ 0. 
Definition: The hazard function ￿￿￿￿ is defined to be the following limit: 
￿￿￿￿ ￿ lim
$
%
&
'
￿￿￿ ￿ ￿ ￿ ￿ ￿ Δ￿ | ￿ ! ￿￿
Δ￿
 
So the hazard is the conditional probability that an individual’s survival time lies in the time 
interval  between  ￿  and ￿ ￿ Δ￿,  given  that  the  survival  time  is  greater  than  or  equal  to ￿, 
divided by the length of the interval Δ￿. Therefore the hazard function is sometimes called a 9 
￿
conditional failure rate and it can take values between zero and infinity. In practical terms, 
this rate can be interpreted as the instantaneous potential per unit time for the event to occur, 
given that the individual has survived up to time ￿. In contrast to a survival function, the graph 
of ￿￿￿￿ can start at any nonnegative value and can go up and down in any direction over time 
with  no  upper  bound,  pretended  that  it  does  not  become  smaller  than  zero
  [KLEINBAUM 
(2005), 8-14]. 
In general, these two functions are connected as follows: 
￿￿￿￿ ￿ exp%& ' ￿￿(￿ )(
(
) *   or equivalently     ￿￿￿￿ ￿ &
)￿￿￿￿ )￿ ⁄
￿￿￿￿
. 
The density function ,￿￿￿  is then given by ,￿￿￿ ￿ ￿￿￿￿ ￿￿￿￿. 
Note, that we have excluded the possibility of competing risks in these definitions, i.e. we 
have assumed that only one event is possible for each individual. 
 
2. 2. The Weibull distribution  
2. 2. 1. Definition and basic properties 
Sometimes  it  is  possible  to  reasonably  assume  the  variable  ￿  to  follow  some  family  of 
distributions.  The  most  widely  used  parametric  family  for  times  to  event  is  the  Weibull 
distribution,  also  called  Weibull  model  below,  with  survival  function  ￿￿￿￿ ￿ exp￿&-￿
*
￿, 
hazard function ￿￿￿￿ ￿ -.￿
+
,
-
 and density function ,￿￿￿ ￿ -.￿
.
/
0
exp￿&-￿
1
￿, ￿ ￿ 0, - ￿
0, . ￿ 0. The parameter . is often called shape parameter and we can differentiate between 
three cases: 
•  If  . ￿ 1, the hazard increases over time. 
•  If  . ￿ 1, the hazard decreases over time. 
•  If  . ￿ 1, the hazard is constant over time. 10 
￿
 
Fig.2.: These graphs show the three possible appearances of the Weibull hazard function dependent on the 
shape parameter 
2. 
Note, that in all three cases the hazard function is monotonic. Thus, when using the Weibull 
distribution a hazard cannot change directions during time.  
The  third  case,  i.e.  . ￿ 1,  leads  to  survival  function  ￿￿￿￿ ￿ exp￿&-￿￿,  hazard  function 
￿￿￿￿ ￿ -  and  density  function  ,￿￿￿ ￿ ￿￿￿￿￿￿￿￿ ￿ -exp￿&-￿￿,  which  characterizes  the 
Exponential distribution. This shows that the Exponential distribution is a special case of the 
Weibull  distribution.  The  Exponential  distribution  has  a  constant  hazard  function:           
-￿￿￿ ￿ - ￿ 0, over the range of T. As the instantaneous failure rate is independent of ￿, the 
conditional  potential  of  an  event  per  unit  time  is  the  same  regardless  of  how  long  the 
individual has been on study. This characteristic is referred to as the memoryless property of 
the exponential distribution.  
 
2. 2. 2. Goodness of fit 
When a dataset is on hand, we probably want to know at first how appropriate a Weibull or 
Exponential  model  would  be  for  the  given  data.  Fortunately,  in  case  of  the  Weibull  or 
Exponential distribution there is a very straight graphical test for assessing its adequacy. That 
is the so called log-log plot which makes use of the fact that log￿&log￿ of ￿￿￿￿ is linear with 
the ￿￿￿ of time: 
Weibull: log￿&log￿exp￿&-￿
3
￿￿￿ ￿ log￿-￿ ￿ . log ￿￿￿ 
Exponential: log￿&log￿exp￿&-￿￿￿￿ ￿ log￿-￿ ￿ log ￿￿￿ 
Kaplan-Meier Curves. In order to make use of this property, we have to introduce the so 
called Kaplan-Meier estimates for survival times. In order to determine these estimates we 
proceed as follows: At first, only the non-censored individuals are taken into account because 11 
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they  give  the  times  to  event  (survival  times/  failure  times)  observed  in  the  study  of  full 
information.  We  order  these  times  from  smallest  to  largest.  With ￿
4
5
6 ￿ ￿
7
8
9 ￿ ...￿  ￿
:
;
<, 
2 ￿ ￿, we denote the distinct times to event. Then we count the number of failures 3
= at each 
distinct failure time, 3
> ! 1, and afterwards we count the number 4
? , 4
@ ! 0, of individuals 
censored in the time interval 5￿
A
B
C,￿
D
E
F
G
H￿ starting with failure time ￿
I
J
K up to but not including 
the next failure time ￿
L
M
N
O
P. At last we note the size of risk set ￿
Q, which is given by the 
number of individuals who have survived at least to time ￿
R
S
T. Now we are able to estimate the 
probabilities  ￿67￿ ￿ ￿
U
V
W8 ￿ ! ￿
X
Y
Z9  by  the  relative  frequencies  of  survivors  of  time  ￿
[
\
], 
pretended availability (i.e. being in the risk set) at time ￿
^
_
`.  
Definition: The Kaplan-Meier estimate or Product-limit estimate is defined to be 
￿ :7￿
a
b
c9 ￿ ;￿ <67￿ ￿ ￿
d
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f8 ￿ ! ￿
g
h
i9 ￿ ;
￿
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￿
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With the law of total probability it follows that ￿ :7￿
u
v
w9 ￿ ￿ :7￿
x
y
z
{
|9 = ￿ <67￿ ￿ ￿
}
~
•8 ￿ ! ￿
€
￿
‚9, 
> ! 1, ￿￿￿
ƒ ￿ 0￿ ￿ 1. 
Example  (Kaplan-Meier):  The  proceeding  is  illustrated  using  a  small  simulated  data  set 
(Exponential distribution with rate - ￿ 0.1).  
￿￿￿￿￿?
„￿
…
†
‡
ˆ
‰
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Tab.1: Simulated example data set with underlying distribution 
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The calculation of the Kaplan-Meier estimates can be performed as follows: 
>  ￿
—
˜
™  ￿
š  3
›  4
œ  ￿ :7￿
￿
ž
Ÿ9 
￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿
￿￿ ￿￿ 5 & 0 & 0 ￿ 5￿ ￿￿ ￿￿ 1 =
 
¡
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£ ￿￿￿￿￿￿￿
￿￿ ￿￿ 5 & 1 & 1 ￿ 3￿ ￿￿ ￿￿ 0.8 =
¤
¥
¦
§ ￿ ￿0.5￿￿
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©
ª
« ￿ ￿￿￿￿￿
￿￿ ￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿ ￿￿
0.27 =
1 & 1
1
￿ 0￿
Tab.2: Calculation of Kaplan-Meier estimates 
¬
-
®
¯
°
±
²
³ for the example data set of Tab.1.  
 
 12 
￿
A plot of the Kaplan Meier survival probabilities estimates leads to a Kaplan Meier curve, 
which provides an empirical approximation of the survival function.   
 
Fig.3: Kaplan-Meier curve for the example data set of Tab.1. A censoring is marked with a small tick. 
Now we return to our test of the appropriateness of a Weibull model: We only have to plot the 
￿￿￿ negative ￿￿￿ Kaplan-Meier survival estimates against the ￿￿￿￿of time (“log-log survival 
plot”). Approximately straight lines would indicate that the Weibull assumption is reasonable 
and a slope . of 1 hints at an exponential distribution of the survival times. Further, the slope 
and y intercept provide a rough estimate of . and log- , respectively. 
Note, that this test constitutes only an approximate method because it yields a qualitative 
assessment of the goodness of fit. Quantitative methods can be found in EVANS (1989).  
Because Exponential and Weibull models are ‘nested’, it is possible to evaluate whether the 
Weibull distribution is more appropriate than the Exponential with the so called Likelihood 
ratio statistic. The term ‘nested’ means, that a simpler model can be extended to a more 
complex one (with more parameters) such that the more complex one includes the simpler 
one.  Usually,  one  starts  with  a  simple  model  and  then  checks  whether  including  more 
parameters leads to significant improvement of the fit [EFSA (2009), 27]. We will describe 
this statistical test in section 3.3.2. 
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Example:  As an illustration of this graphical goodness of fit test with a log-log-plot we again 
use the example data set of Tab.1. The values for the plot are summarized in the following 
table: 
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Tab.3: Calculations for a Log-log-plot of the example data set of Tab.1.: Only the event times and associated 
Kaplan-Meier estimates printed in bold can be used for the graphical assessment of the goodness of fit. 
 
 
This leads to the following plot, which provides rough estimates for the parameters - and . of 
the Weibull model due to the small number of events: 
 
 
Fig.4: Log-log-plot of the example data set of Tab.1.: The red line reflects the straight line 
%
&
'
(
)
*
+ expected 
from the underlying distribution Exp(0.1) out of which the sampling was performed. The lines printed in grey are 
a frequency polygon of the” observed” values (black points) and the black line displays a linear regression line 
of these values. The equation of the regression line is 
,
-
.
/
0
1
2
3
4
5
6
7
8
, which leads to (the rough) estimates 
9
:
;
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R of 
S.  
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3.3. Numerical Methods 
In our further calculations we will need to determine a maximum of a nonlinear function 
numerically and will use the procedure nlm implemented in the software package R. This 
procedure can only determine a minimum, i.e. we have to consider the negative function. The 
algorithm in nlm is a ‘generalization’ of Newton’s method [DENNIS/SCHNABEL (1983)]. In its 
default mode nlm uses finite differences to calculate the derivatives but it is also possible to 
supply them.  
The general form of an unconstrained minimization problem  is: 
     Given ,: ￿
T F ￿ 
     find G
U H ￿
V for which ,￿G
W￿ ￿ ,￿G￿    I G  H ￿
X, abbreviated by min
Y
Z
[
\ ,: ￿
] F ￿. 
 
The usual scenario in the numerical solution of a nonlinear minimization problem is that the 
user is asked to provide a subroutine to evaluate the considered function, and a starting point 
G
^  that  should  be  a  rough  approximation  to  the  solution  G
_.  A  widely  used  method  for 
minimization purposes is to re-formulate it as a ‘zeros-problem’, i.e. finding the root of the 
equation J￿,￿ ￿ 0, where J￿,￿ denotes the gradient of ,, and use Newton’s method to solve 
it. Afterwards it has to be checked, whether the Hessian matrix is positive definite for the 
possible solution. 
One  has  to  keep  in  mind  that  numerical  procedures  for  finding  numerical  solutions  of 
minimization problems usually are not able to find the “global minimum”, i.e. the absolute 
lowest point of the function , in the case when there are several distinct local minimizers. The 
nlm procedure can also provide only local minimizers, but it is “global” in another sense: The 
numerical method “line searches” used in nlm converges to a local minimizer from almost any 
starting point and thus is called a globally convergent algorithm.  
Newton’s Method can be shown to have the very convenient characteristic of being locally 4-
quadratically convergent (inside its convergence region!) but has the disadvantage that it is 
highly dependent on the starting point. Therefore, a good approximation of the solution by the 
starting  point  could  be  essential.  The  basic  idea  of  improved  nonlinear  minimization 
algorithms is to combine the fast local Newton Method with a globally convergent strategy (in 
our case the “line searches method”). This approach can be very briefly summarized by the 
three steps [DENNIS/SCHNABEL (1983)]: 15 
￿
•  Try Newton’s method (or some modification of it) first at each iteration. 
 
•  Decide, whether it seems to be taking a reasonable step (in a minimization process: if 
value of , decreases). 
 
•  If it seems to be appropriate, use it. If not, fall back on a step dictated by a global 
method, e.g. linear searches. 
 
•  Terminate when KJ,￿G
`￿K ￿ tol. 
 
The advantage of such a quasi-Newton algorithm is that it combines the advantages of both 
global methods and Newton’s method as it will always end up using Newton’s method close 
to  the  solution  and  thus  holds  on  to  its  fast  convergence  rate,  but  being  also  globally 
convergent.  
The basic idea of a global method for unconstrained minimization problems is intuitive and 
geometrically obvious: it takes steps that lead “downhill” for the function ,. That means, one 
has to take a direction . from the current point G
a in which , decreases initially, and a new 
point  G
b  in  this  direction  from  G
c  such  that  ,￿G
d￿ ￿ ,￿G
e￿.  Such  a  direction  is  called  a 
descendent direction. More precisely, . is a descendent direction from G
f if the directional 
derivative of , at G
g in the direction of . is negative:  
J,￿G
h￿
i . ￿ 0. 
Under  this  circumstances  it  is  guaranteed  that  ,￿G
j ￿ ￿.￿ ￿ ,￿G
k￿  for  sufficiently  small 
￿ ￿ 0. 
A very natural application of this concept is the method of line searches. The idea behind this 
algorithm  is  simple:  After  the  calculation  of  a  descendent  direction  .
l,  it  is  set               
G
m
n
o L G
p ￿ -
q .
r  for some -
s ￿ 0 . That makes G
t
u
v an acceptable next iterate.  
The direction .
w is set to &M
x
y
z
 J,￿G
{￿, where M
| ￿ J
},￿G
~￿ ￿ N
•O is positive definite with 
N
€ ￿ 0 if J
￿,￿G
‚￿ is safely positive definite and J
ƒ, the Hessian matrix of ,. For more 
details and numerical background see [DENNIS/SCHNABEL (1983)].  
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3. Description of a BMD approach for TTT data 
Now we describe the BMD approach for TTT data. The study design we have in mind is an 
animal experiment with 2 different dose groups )
„, … , )
…. Following the notation introduced 
before, the observed times are given by ￿
†
‡
￿ ￿￿
ˆ
‰
Š
,…,￿
‹
Œ
￿
Ž
￿ for dose group ￿ and the related 
status by ￿
￿ ￿ ￿￿
￿
‘,…,￿
’
“), where ￿, ￿  ￿  1,… ,2, denotes the dose group. Note, we do not 
assume here that )
”= 0  and that necessarily the experiment must have a control of dose equal 
to 0. However, in most applications the data are based on a design with such a control group. 
Actually, it is a prerequisite of a good experiment that a control with dose )
•= 0  is present. 
 
Dose group  Observed Times  Status 
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Tab. 4: Design of dose- response data with k dose groups. 
 
3.1. Question 1: A reasonable model for TTT data, assuming a Weibull distribution 
The underlying  assumption of our approach is that the outcome variable time-to-tumor ￿ 
follows a Weibull distribution. The next step in finding an adequate model for the dose-
response  data  above  (Tab.4)  is  to  include  appropriately  the  predictor  variables,  i.e. 
generalizing  it  to  obtain  a  regression  model.  We  assume  the  hazard  of  an  event  to  be 
dependent on the dose. The typical strategy for Weibull models is to re-parameterize - while 
the shape parameter . is usually held fixed over the doses. A common re-parameterization for 
-, is exp￿R
¬ ￿ R
- = pred￿ where pred  denotes the predictor variable – in our case the dose. 
This form of a re-parameterization can be seen as natural since it takes only positive values (- 
has to be positive, see section 2.2.). 17 
￿
The Weibull regression procedure in the R-package use a slightly different but – as we will 
see later – equivalent re-parameterization, namely - ￿ exp￿&. U
® & . U
¯ = pred￿, where . 
denotes the shape parameter of the Weibull distribution. 
Thus we will suggest modeling the survival function of time-to-tumor ￿ with 
￿￿￿,)￿ ￿ exp￿&exp￿& . U
°& . U
± = dose￿ = ￿
²￿. 
This model is convenient because it fulfills two assumptions, which are often considered in 
survival models: proportional hazards and accelerated failure times. Both properties will be 
briefly presented next.  
The  underlying  assumption  of  the  proportional  hazard  (PH)  models  is  that  the  effect  of 
explanatory  variables  (covariates)  is  proportional  (i.e.  multiplicative)  with  respect  to  the 
hazard, where the proportionality constant is independent of time. That means the hazard ratio 
comparing any two individuals is constant over time. PH regression models treat the hazard 
function as a product of a baseline hazard ￿
³￿￿￿ and an exponential expression with a linear 
combination of covariates in its argument: 
￿￿￿,W￿ ￿ ￿
´￿￿￿ = expXYR
µ G
¶
·
¸
¹
º
Z,   where W denotes a vector of covariates. 
We will consider only one covariate, namely the )[\], which then leads to the form 
￿￿￿,W￿ ￿ ￿
»￿￿￿ = exp￿R
¼ = )[\]￿. 
The  class  of  PH  regression  models  is  applied  frequently  in  survival  analysis  because  it 
includes the Exponential, Weibull and Gompertz parametric models. It is widely used as Cox 
semi-parametric  model,  where  the  baseline  hazard  has  not  to  be  specified  [KLEINBAUM 
(2005)]. 
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Example: Let HR ￿
½
¾  be the hazard ratio of two dose groups )
¿ and )
À. Then, at any time 
point, the hazard of an event in group )
Á is 4 times higher than in group )
Â:   
 
Fig. 5: Proportional Hazard (PH) characteristic: The graph constructed with R reflects the hazard functions for 
two different dose groups. The Hazard Ratio is constant over time, namely   
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The PH assumption can also be evaluated by plotting log￿&log￿ :￿￿￿￿ against log￿￿￿. Parallel 
curves support the PH assumption. For more details see [KLEINBAUM (2005)]. 
The accelerated failure time (AFT) assumption takes a slightly different perspective: Here,  
the effect of predictor variables is assumed to be multiplicative with respect to survival time, 
i.e. AFT models describe the contraction or “stretching out” of survival time as a function of 
covariates [KLEINBAUM (2005), KALBFLEISCH (2002), NIKOLIN (2005)]: 
Definition:  Let  ￿ ! 0  be  a  survival  time  and  W ￿ ￿G
à,…,G
á￿
â  a  p-dimensional  vector  of 
explanatory variables. An AFT model is defined through the following connection: 
                                                     ￿￿￿|W￿ ￿ ￿
ã￿exp￿￿^
ä￿
åW￿￿￿,    ￿ ! 0,                                 (2.1.) 
where ^
æ ￿ ￿U
ç
è
,…,U
é
ê
￿
ë H ￿
ì denotes a vector of regression coefficients and ￿
í the baseline 
survival function, i.e. the survival function of an individual with vector of covariates W ￿ _. 
` ￿ exp￿￿^
î￿
ïW￿ is called accelerating factor. 
The AFT assumption can also be expressed in terms of random variables. If ￿
ð is a random 
variable (following some distribution) which represents the survival time for individuals when 
the vector of covariates W ￿ _, the AFT assumption can be expressed as: 
￿ ￿ ` ￿
ñ, 19 
￿
where  `  is  the  accelerating  factor.  Alternatively,  AFT  models  can  be  described  as  linear 
models for the logarithm of the survival time a ￿ log ￿￿￿:  
Theorem: Let ￿ ! 0 be a survival time, a ￿ log￿￿￿ and W ￿ ￿G
ò,…,G
ó￿
ô a p-dimensional 
vector of explanatory variables. An AFT model describes the influence of the covariates on 
the survival time in the following manner: 
                                                              a ￿ log￿￿￿ ￿ U
õ ￿ ^
öW ￿ bc,                                 (2.2) 
where ^ ￿ ￿U
÷,…,U
ø￿
ù denotes a vector of regression parameters and c denotes a random 
error, following some distribution. 
 
Proof: If ￿
ú denotes the survival function of  ￿ ￿ exp￿a￿ with W ￿ _, the following equation 
holds for the survival probability of an individual with arbitrary vector W: 
￿￿￿|W￿ ￿ ￿￿exp￿U
û ￿ ^
üW ￿ bc￿ ￿ ￿￿ ￿ ￿￿exp￿U
ý ￿ bc￿ ￿ ￿ exp￿&^
þW￿￿
￿ ￿
ÿ￿￿ exp￿&^
￿W￿￿. 
Therefore, the linear model (2.2.) is equivalent to (2.1.) with ^
￿
￿ &^. 
                                                                                                                                           d 
 
Thus, AFT models are additive in terms of log￿￿￿ and multiplicative with respect to ￿. 
AFT regression models are even easier to interpret than PH models because the accelerating 
factor  describes  the  direct  effect  of  an  exposure  on  every  quantile  of  survival  time.  A 
commonly used distribution for AFT models is the log-logistic distribution because it can 
model non-monotonic hazard functions. Other suitable distributions for ￿ besides the Weibull 
are the log-normal, Gamma and inverse Gaussian distributions. The Weibull distribution is 
the only family that can be parameterized as either a PH or as AFT model. We will see later 
that  if  ￿  follows  a  Weibull  distribution,  log ￿￿￿  follows  an  extreme  value  distribution 
ef￿(,b￿  with  density  function  ,￿g￿ ￿
￿
￿exph
￿
￿
￿
￿ & exph
￿
￿
￿
￿ ii,g H ￿&∞,∞￿ 
[KALBFLEISCH (2002), LAWLESS (2002)]. 20 
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The accelerating factor  ` is illustrated in Fig. 6: Let ` be the accelerating factor, e.g. ` ￿ 2. 
That means that for all fixed values of ￿￿￿￿ the ratio of the survival time in group 2 divided by 
the survival time in group 1 equals 2. 
 
Fig.6:  Accelerated  Failure  Time  (AFT)  characteristic:  Survival  curves  for  Group  1 
￿
￿
￿
￿
￿
  and  Group  2 
￿
￿
￿
￿
￿
. The horizontal lines are twice as long to 
￿
￿
￿ compared to 
￿
￿
￿ because 
￿
￿
￿. [KLEINBAUM 
(2005), 268].  
A graphical test of the appropriateness of an AFT model would be a so called “QQ-Plot”, 
where estimated survival quantiles of two different dose groups are plotted against each other. 
If the AFT assumption holds, the points (referring to the observed survival times) of this plot 
should approximately lie on a straight line [e.g. PATEL (2006)]. 
Now we return to the Weibull model. As already mentioned, a unique property of the Weibull 
model is the equivalence of AFT and PH assumption pretended that . does not vary over 
different levels of covariates [KALBFLEISCH (2002), 45f.]. That means, if . is held fixed, a 
Weibull model fulfills the PH assumption as well as the AFT assumption and can therefore be 
interpreted in either framework. If in the log-log survival plot parallel and straight lines occur, 
we can conclude, that the Weibull assumptions as well as the PH (and thus also the AFT) 
assumption hold. If parallel but not straight lines arise, the Weibull assumption is violated. If 
non parallel but straight lines occur, we can conclude that the Weibull assumption holds but 
not the PH (and therefore also not the AFT) assumption and thus that . is not constant across 
levels  of  covariates.  A  Weibull  PH  model  with  ‘)[\]’  as  explanatory  variable  can  be 
formulated  
￿￿￿￿ ￿ exp￿R
￿￿ . ￿
 
!
"exp￿R
# )[\]￿ ￿ exp￿R
$ ￿ R
% )[\]￿.￿
&
'
(, 
where the baseline hazard is specified parametrically as ￿
)￿￿￿ L exp￿R
*￿. ￿
+
,
-.  21 
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This  is  equivalent  to  a  re-parameterization  of  -  by  exp￿R
. ￿ R
/ = dose￿.  Thus,  we  gain 
￿￿￿￿ ￿ exp￿&￿R
0 ￿ R
1 = dose￿ = ￿
2￿. 
 
How do then two individuals exposed to different doses differ in their hazard? The hazard 
ratio for two arbitrary individuals in dose groups )
3 and )
4 equals a constant: 
HR ￿
exp￿R
5 ￿ R
6 )
7￿ . ￿
8
9
:
exp7R
; ￿ R
< )
=9 . ￿
>
?
@
￿
exp￿R
A )
B￿
exp￿R
C )
D￿
. 
Because of the equivalence of PH and AFT for Weibull regression models with fixed shape 
parameter ., we can formulate this model also in the AFT framework. 
We first solve for ￿ in terms of a fixed value of  ￿￿￿￿: 
￿￿￿￿ ￿ exp￿&- ￿
E￿       ￿￿ ￿ ￿ ￿&log￿￿￿￿￿￿￿
F
G
 -
H
I
J 
Using the parameterization - ￿ exp￿R
K ￿ R
L = dose￿ of the PH model, we get 
-
M
N
O ￿ exp￿R
P ￿ R
Q = dose￿
R
S
T ￿ exph&
U
VR
W &
X
YR
Z = dosei L exp ￿U
[ ￿ U
\ = dose￿      
and thus 
 ￿￿￿￿ ￿ exp￿&exp￿&. U
] & . U
^ = dose￿ = ￿
_￿. 
 
Then for any fixed probability ￿￿￿￿ ￿ 4 we obtain for doses )
` and  )
a: 
￿&log￿4￿￿
b
c
 exp ￿U
d ￿ U
e )
f￿
￿&log￿4￿￿
g
h
 exp ￿U
i ￿ U
j )
k￿
￿
exp￿U
l )
m￿
exp￿U
n )
o￿
, 
which is a constant, that does not depend on 4.  
The survival time of an individual in dose group  )
p in comparison to that of an unexposed 
individual is accelerated with factor  ` ￿
q
r
s
t
u
v
w
x
y
z
{
|
}
~
•
€
￿
‚ ￿ exp7&U
ƒ )
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￿7￿8 )
…9 ￿ ￿
†7exp7&U
‡ )
ˆ9￿9 ￿ exp7&exp￿&. U
‰￿7exp7&U
Š )
‹9￿9
Œ
9
￿ exp ￿&exp7&. U
￿ & . U
Ž )
￿9￿
￿￿    ￿ ! 0. 
If, for example, U
‘ ￿ &1.5, an individual in dose group  )
’ ￿ 1 can be viewed, on average, as 
accelerating through life ` ￿ exp￿&￿&1.5￿￿ n 4.5 times faster than an unexposed one. 
In terms of log ￿￿￿ we gain the following model: 
                                                    log￿￿￿ ￿ U
“ ￿ U
” = )[\] ￿
1
.
 c,                                          ￿2.3.￿      
c following a standard extreme value distribution. 
 
Proof: We use the density transformation theorem [HELD (2008), 264]. Let a ￿ log ￿￿￿, then 
we gain with substitutions . ￿
•
– and - ￿ exp h&
—
˜i: 
,
™￿g￿ ￿ ,
š￿log
›
œ￿g￿￿ p
) log
￿
ž￿g￿
)g
p ￿ ,
Ÿ￿exp￿g￿￿ |exp ￿g￿| 
           ￿ - . ￿exp￿g￿￿
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          ￿ exph&
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b
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(
b
iexph
g
b
iiexp￿y￿ 
          ￿ 
1
b
 exp %
g & (
b
& exp h
g & (
b
i* 
Thus,  if  ￿  follows  a  Weibull  distribution  t]￿￿-,.￿,  log ￿￿￿  follows  an  extreme  value 
distribution ef￿( ￿ &blog￿-￿,b ￿ .
¤
¥￿.  
The re-parameterization - ￿ exp ￿& . U
¦ & . U
§ )￿ leads to ( ￿ U
¨ ￿ U
© )  and thus to the 
linear model 
                     log￿￿￿ ￿ U
ª ￿ U
« ) ￿
¬
- c,        c following a standard extreme value distribution. 
d 
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Note, that the corresponding coefficients of the PH and AFT model formulations are related in 
the following manner: R
® ￿ & . U
¯, j=1,2. 
In the case of an Exponential distribution, the relationship of the coefficients occurring in the 
PH and AFT model is simply given by R
° ￿ & U
±, > ￿ 1,2.   
 
Conclusion: A reasonable model for the outcome variable TTT in our case should be of the 
form ￿￿￿,)￿ ￿ exp￿&exp￿R
² ￿ R
³ = d￿ = ￿
´￿, where ) denotes the dosage.  
The hazard function of our model is given by ￿￿￿,)￿ ￿ exp￿R
µ ￿ R
¶ = d￿ and the density 
function by ,￿￿,)￿ ￿ exp￿&exp￿R
· ￿ R
¸ = d￿ = ￿
¹￿ = exp￿R
º ￿ R
» = d￿. 
This PH model is equivalent to the AFT model with survival function given by ￿￿￿,)￿ ￿
exp￿&exp￿& . U
¼& . U
½ = d￿ = ￿
¾￿.  
 
 
3.2. Question 2: Risk functionals for the Benchmark Response (BMR) 
3.2.1. Definitions of BMRs for TTT data in general 
The Benchmark Response (BMR) is a small but measurable change in adverse response in 
contrast to non-exposed individuals. Ideally, the BMR would reflect an effect size that can be 
tolerated because it is negligible or even non-adverse. However, there is a practical constraint 
when animal data are used: The increase in effect should not be too small because otherwise 
the estimate of the BMD will lie outside the range of observation and its lower confidence 
limit will heavily depend on the chosen model [CRUMP (1984), EFSA (2009)]. 
In principle, there are two different approaches possible in specifying it, referring to TTT: 
The first point of view is to consider the survival curves of different dose groups at a fixed 
time point ￿
¿ and define the BMR in terms of reduction in survival probability compared to 
the predicted one in the control group () ￿ 0) at that time ￿
À: 24 
￿
 
Fig.7.  BMR  in  terms  of  reduction  in  survival  probability  at  fixed  time:  The  BMR  is  defined  in  terms  of  a 
reduction   in survival probability at fixed time 
Á
Â
Ã
Ä
Å
 (in contrast to the unexposed individuals). The goal is 
then to determine the dose 
Æ, for which this reduction is expected. 
 
This reduction can be declared either in absolute or in relative terms. 
In the first case, we state an absolute reduction ￿ that can be just tolerated and the dose ) 
which leads to the survival function with value ￿￿￿
Ç,0￿ & ￿ at point ￿
È is the dose we define 
as Benchmark Dose (BMD): 
):   ￿￿￿
É,)￿ ￿ ￿￿￿
Ê,0￿ & ￿. 
In the second case, we state a relative reduction ￿ ￿
Ë
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Ø
Ù
Ú
Û
Ü
Ý
Þ
ß
à  and the BMD is given by 
the dose   for which holds 
):   ￿￿￿
á,)￿ ￿ ￿1 & ￿￿ ￿￿￿
â,0￿. 
 
The second point of view is to consider the BMR as reduction in time at a fixed quantile of 
the  survival  distribution,  e.g.  the  median  survival  time.  Note  that  again  we  refer  to  the 
background values predicted by the model, not the observed ones: 25 
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Fig. 8. BMR in terms of reduction in median survival time: The BMR is defined in terms of a reduction in median 
survival in contrast to the unexposed individuals. The dose
ã for which this reduction is expected, has to be 
determined. 
 
 
 
 
Once more, we can define the BMR in absolute and relative terms: 
In the first case, we consider the BMR as a reduction of ￿ units (in animal experiments most 
conveniently in weeks) in median survival. Then we are looking for the dose ) for which 
holds 
):   ￿
ä
å
æ￿)￿ ￿ ￿
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In the second case, we define the relative BMR as ￿ ￿
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￿
￿￿0￿. 
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3.2.2. Definitions of BMRs for TTT data under assumption of a Weibull model 
For our case of Weibull models not all of the presented ways of defining a BMR are similarly 
suitable. Especially the definitions in terms of a reduction of survival probability at a fixed 
time point ￿
￿
 are accompanied with difficulties: The main problem is that the calculated BMD 
depends highly on the choice of  ￿
￿
 - which becomes crucial when the value of ￿
￿
 is chosen 
rather arbitrarily. For a definition of the BMR in absolute terms, the estimates for the BMD do 
not even decrease monotonically for increasing values of ￿
￿
 (Fig.9a).  
 
Fig. 9: Dependence of the resulting value for the BMD for different choices of  
￿
￿, illustrated using a Weibull 
model of the form  
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.  Note, that the underlying formulas used for the calculation of the BMDs will be derived in section 3.3. 
On  the  other  hand,  defining  the  BMR  in  terms  of  a  reduction  in  a  specified  quantile  of 
survival seems to be more appropriate. If the BMR is stated in absolute terms, it is also highly 
dependent  on  the  choice  of  the  quantile  –  nevertheless,  the  choice  of  the  median  can  be 
defended to be quite “natural” and therefore the whole proceeding does not seem as arbitrary 
as in the case discussed above.  
If the BMR is formulated in relative terms, the situation becomes very comfortable because 
this way of definition makes use of the characteristic that Weibull models are accelerated 
failure time models. Therefore, following simply the definition of AFT, the value of the BMD 
is independent of the choice of the quantile used for the definition of the relative BMR.  27 
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Fig.10: Dependence of the resulting value for the BMD for different choices of the quantile, illustrated using a 
Weibull  model  of  the  form 
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i. If the BMR is stated in terms of a relative reduction, the value of the BMD is independent of the 
specific choice of a  quantile because of the AFT property of Weibull models.  
Beside of this, the definitions of a BMR which base on an absolute reduction either in survival 
probability at a fixed time point or in a specified quantile of survival generally lead to the 
question of which value should be chosen. It seems that considerations of relative reductions 
can be handled easier because – as already mentioned – here some “default” values like 5% or 
10% already exist from non-cancer contexts. 
 
Conclusion:  If  no  specific  circumstances  are  fulfilled  which  would  suggest  another 
proceeding, the most appropriate way of defining a BMR for a Weibull model seems to be 
stating  the  BMR  in  terms  of  a  relative  reduction  in  the  median  and  thereby  quasi 
automatically  in  all  quantiles  of  the  TTT  distribution.  Nevertheless,  we  will  provide  the 
further calculations for all ways of defining the BMR presented above because in some cases 
one could be interested in analyzing the absolute or relative reduction at a certain time point 
(e.g.  the  1  year  or  5  year  survival  probability,  which  are  common  measures  in  clinical 
applications) or an absolute reduction in median survival time  
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3.3. Question 3: Estimating the BMD and its lower confidence limit (BMDL) 
3.3.1. Maximum Likelihood Estimation of the BMD 
In order to find the BMD we have to estimate the unknown parameters of our model at first. 
Therefore  we  have  to  calculate  the  Maximum  Likelihood  Estimates  (MLEs)  of  the 
parameters, which can be summarized in a vector u.  
We  consider  the  AFT  form  of  the  models.  Thus,  in  the  Exponential  case  we  have  u ￿
￿U
j, U
k￿ and in the general Weibull case we have u ￿ ￿U
l, U
m, .￿.  
The likelihood for partly censored data is given by  
v￿u￿ ￿ ;;,7G
n,)
o;u9
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€
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Recall  that  under  presumption  of  a  statistical  model,  parameterized  by  a  yet  unknown 
parameter vector u, the probability of the observed data as a function of u is called likelihood 
function or just likelihood. In our case, the individual observations are assumed independent 
and therefore we can write the likelihood as product of the individual contributions to it. The 
contribution of an individual who faced the event is given by  ,7G
￿,)
‚;u9.
1 This notation 
indicates that one has to plug in the observed time of event G
ƒ and the dose group )
„ the 
individual belongs to and to interpret the result as function of u. In contrast, the contribution 
of an individual who was censored is given by S7G
…,)
†;u9 because we only know that the 
(event-free) survival time of the individual exceeds G
‡.  
The  maximum  likelihood  estimate  u <
ˆ
‰  of  u  is  obtained  through  maximization  of  the 
likelihood function: 
u <
Š
‹ ￿ argmax
Œ
￿
Žv￿u￿ 
or – because of the monotony of the logarithm – through maximization of the log likelihood 
function  
y￿u￿ ￿ log7v￿u￿9 ￿ ∑ ∑ ,7G
￿,)
￿;u9
‘
’
=
“
”
•
–
—
˜
™
š
›  ￿7G
œ,)
￿;u9
ž
Ÿ
 
¡
:         (2.1) 
￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
1 For discrete models it would be obvious that this is the individual contribution. For continuous models it can 
also be defended that the individual contribution is equal to the value of the density function with plugged-in 
time of event 
¢
£ and dosage 
¤
¥. The argumentation can be found e.g. in Held, 15f., cited above. 29 
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u <
¦
§ ￿ argmax
¨
©
ªy￿u￿. 
Because the log likelihood can often be handled easier, we will continue with (2.1). In order 
to find the maximum of y￿u￿, where u consists of the 2 unknown parameters, we need the 2 
first partial derivatives of the log likelihood function. The MLEs are determined through the 
so called system of score equations 
\￿u￿ ￿ {
|
|u
«y￿u￿,…,
|
|u
¬ y￿u￿}
-
￿ 0. 
 
The  negative  Hessian  matrix  of  y￿u￿,  which  is  a  symmetric  2
® 2  matrix  whose  ￿￿,>￿ 
elements are ￿
¯
°
±
²
³
´
µ
¶
·
¸
¹
º, is called Fisher information matrix O￿u￿. Because we are searching for 
a  maximum  of  y￿u￿,  the  Fisher  information  matrix  of  u <
»
¼,  i.e.  the  observed  Fisher 
information matrix O7u <
½
¾9, has to be positive definite for a solution. This is the case when all 
eigenvalues are positive respectively all main minors of  O7u <
¿
À9. 
 
Now we want to present the calculation of the MLEs for the Weibull AFT model introduced 
in section 3.1 with survival function 
￿￿￿,)￿ ￿ exp￿&exp￿& . U
Á& . U
Â = d￿ = ￿
Ã￿. 
Before considering the general Weibull model we look at the easier Exponential case. 
i. ML estimation in Exponential AFT models  
For . ￿ 1 the likelihood function is given by  
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With ￿
¯ L ∑ ￿
°
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´
µ
¶ , the number of events in dose group ￿, and G
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¸
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¾  we obtain: 
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This leads to the log likelihood 
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and thus to the non-linear system of score equations 
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which has to been solved numerically. 
 
Example: As an illustration an Exponential AFT model is fitted to an example data set. 
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Tab. 5. Example data set for three dose groups.  
Fitting an exponential model with R is shown next when using the procedure survreg from 
the R-Package. The R-code lines are indicated by >. After the call of survreg the output is 
displayed. 
> rm(list=ls()) 
> library(splines) 
> library(survival) 31 
￿
>    
> bsp<-read.table("bsp.txt",header=T) 
> attach(bsp) 
> out<-survreg(Surv(weeks,status)~dose,dist='weib',scale=1) 
> out 
Call: 
survreg(formula = Surv(weeks, status) ~ dose, dist = "weib",  
    scale = 1) 
 
Coefficients: 
(Intercept)        dose  
  3.3983780  -0.1956325  
 
Scale fixed at 1  
 
Loglik(model)= -35.6   Loglik(intercept only)= -39 
        Chisq= 6.78 on 1 degrees of freedom, p= 0.0092  
n= 12 
 
Thus the estimates for the parameters U
! and U
" are: U
# ￿  3.3984 and U
$ ￿ &0.1956.   
Alternatively, we can minimize the negative log-Likelihood function, which leads to the same 
results: 
The log-Likelihood is given by 
y￿U
%,U
&￿ ￿ &7∑ ￿
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                  ￿  &10U
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Using R we obtain (the function g is the negative log-Likelihood): 
> f=function(x){10*x[1]+43*x[2]+95*exp(-x[1])+69*exp(-x[1]-x[2])+17*exp(-
x[1]-10*x[2])} 
> nlm(f,c(5,3)) 
$minimum 
[1] 35.57158 
 
$estimate 
[1]  3.3983779 -0.1956325 
 
￿￿  U
C ￿  3.3984 ,  U
D ￿ &0.1956  (R) 
 
Now we are able to compare the observed and expected survival probabilities. For each dose 
group the Kaplan Meier curve is plotted and the survival curve predicted by the Exponential 
model  
￿￿￿￿ ￿ exp￿&exp￿&3.3984  ￿  0.1956 = d￿ =  ￿￿. 
rm(list=ls()) 
library(splines) 
library(survival) 
   32 
￿
bsp<-read.table("bsp.txt",header=T) 
attach(bsp) 
 
#Kaplan Meier estimates 
kmbsp<-survfit(Surv(weeks, status==1)~ dose, data=bspw) 
 
#KM-plot 
plot (kmbsp, col=c("red", "blue", "green"),main="Example: 'observed' (KM) 
and expected Survival probabilities",xlab="time [weeks]", ylab="survival 
probability",legend.text=c("dose 0","dose 1", "dose 10")) 
 
#survival curves predicted by the Exponential model 
x<-(0:84) 
y0<-y1<-exp(-exp(-3.3983)*x) 
y1<-exp(-exp(-3.3983+0.1956)*x) 
y10<-exp(-exp(-3.3983+0.1956*10)*x) 
 
#expected for dose=0 
for (i in 1:85) 
  { 
   lines(c(x[i-1],x[i]),c(y0[i-1],y0[i]),col="red") 
  } 
 
#expected for dose=1 
for (i in 1:85) 
  { 
   lines(c(x[i-1],x[i]),c(y1[i-1],y1[i]),col="blue") 
  } 
 
#expected for dose=10 
for (i in 1:85) 
  { 
   lines(c(x[i-1],x[i]),c(y10[i-1],y10[i]),col="green") 
  } 
 
Fig.11.  ‘Observed’  (i.e.  Kaplan-Meier  estimates  obtained  from  the  observed  times)  and  expected  survival 
probability of the example dataset when an Exponential model is fitted. 33 
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ii. ML estimation in Weibull AFT models  
It is technically more comfortable to use for the following calculation the PH form of the 
Likelihood, which is given by 
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With ￿
S L ∑ ￿
T
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W
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Z , the number of events in dose group ￿ we obtain: 
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This leads to the log likelihood 
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Thus, the AFT form is given by 
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Similar to the Exponential model the proceeding is illustrated using the same dataset as before 
(Tab.5). Firstly, the estimates for  U
ú,  U
û and . are calculated using the survreg procedure 
implemented in R. Note, that the output of the survreg procedure includes the estimates for 
U
ü(intercept), U
ý and 
þ
ÿ (scale), following the AFT model form (2.3.): 
> rm(list=ls()) 
> library(splines) 
> library(survival) 
>    
> bspw<-read.table("bsp.txt",header=T) 
> attach(bspw) 
>   
> out<-survreg(Surv(weeks,status)~dose,dist='weib') 
> out 
Call: 
survreg(formula = Surv(weeks, status) ~ dose, dist = "weib") 
 
Coefficients: 
(Intercept)        dose  
  3.3803461  -0.1948039  
 
Scale= 1.044804  
 
Loglik(model)= -35.6   Loglik(intercept only)= -37.9 
        Chisq= 4.75 on 1 degrees of freedom, p= 0.029  
n= 12  
￿￿  U
￿ ￿  3.3803 ,  U
￿ ￿ &0.1948,
￿
￿ ￿ 1.0448 ￿￿ . ￿ 0.9571    
 
Secondly, the estimates are obtained via maximizing the log likelihood with R. We use the 
procedure nlm to minimize the negative log likelihood. 
> #Weibull example: MLE for alpha0, alpha1, p 
>  
> #Tools for loglikelihood 
> delta<-sum(status) 
> delta 35 
￿
[1] 10 
>  
> deltad<-sum(status*dose) 
> deltad 
[1] 43 
>  
> #x=(alpha0,alpha1,p) 
> 
f=function(x){delta*x[3]*x[1]+deltad*x[3]*x[2]+(sum(weeks[dose==0]^x[3]))*e
xp(-x[3]*x[1]-x[3]*x[2]*0)+(sum(weeks[dose==1]^x[3]))*exp(-x[3]*x[1]-
x[3]*x[2]*1)+(sum(weeks[dose==10]^x[3]))*exp(-x[3]*x[1]-x[3]*x[2]*10)-
delta*log(x[3])-(x[3]-1)*sum(status*log(weeks))} 
>  
> nlm(f,c(4,1,1)) 
$minimum 
[1] 35.55586 
 
￿￿ U
￿ ￿ 3.3803,  U
￿ ￿ &0.1948, . ￿ 0.9571 
 
These estimates are almost the same as for the Exponential model.   
After having determined the MLEs for the parameters included in our model we can compute 
the  BMD  for  a  pre-specified  BMR.  Again,  the  calculation  will  be  presented  for  the 
Exponential model at first. 
 
iii. Calculation of BMDs for Exponential AFT models 
The calculation of a BMD depends on the way the BMR is defined. As we have seen in 
section B.2. there are in total four different ways of specifying the BMR with respect to TTT. 
a) Absolute value for the BMR at a fixed time point ?
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b)  Relative value for the BMR at a fixed time point ?
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c)  Absolute value for the BMR as reduction in a specified quantile of survival 
Now we state the BMR as reduction of   units in median survival (for any other quantile of 
survival the proceeding is analogous): 
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d)  Relative value for the BMR as reduction in a specified quantile of survival 
Let the BMR be a ￿ = 100%  reduction of a quantile 4 of survival (in relation to control 
group), 
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As already mentioned, the dose we determine through plugging in the value ￿ for the BMR 
and the estimated values for U
ç and U
è is the BMD.  
 
 
Illustration: For our example data set (Tab.5.) we obtained the ML estimates U
é ￿  3.3984  
and U
ê ￿ &0.1956. Thus we can easily  calculate the estimated BMD for a pre-specified 
BMR.  
For example: Let the BMR be a reduction of 5 weeks in median survival. Then the BMD is 
given by )
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iv. Calculation of BMDs for Weibull AFT models 
Next,  we  present  the  formulas  of  the  BMD  for  the  different  ways  of  defining  the  BMR, 
assuming a general Weibull model with three parameters U
$, U
% and .. The calculation can be 
done analogously to the Exponential case. 
 
a) Absolute value for the BMR at a fixed time point ?
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In this case, the BMD is given by 
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c)  Absolute value for the BMR as reduction in a specified quantile of survival, e.g. in 
median survival time: ￿
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d)  Relative  value  for  the  BMR  as  reduction  in  a  specified  quantile  of  survival: 
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Example: For our example dataset (Tab.5) we obtain for a BMR of 5 weeks loss in median 
survival the BMD 
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                   n 1.474. 
 
This estimate of the BMD is slightly higher than the estimate gained via the Exponential 
model. Because of the additional parameter, the Weibull model is more flexible and leads to a 
more appropriate estimate. As risk assessment has to be done always very cautiously it is an 
appeasing result that the less adequate model leads to a smaller estimate of the BMD. The 40 
￿
very small difference can be explained by the estimated value of the shape parameter . of the 
Weibull model, which is almost equal to 1 ￿. n 0.96￿. 
 
3.3.2. Estimation of the BMDL 
Whereas  the  determination  of  the  MLEs  for  the  unknown  parameters  of  the  models  and 
thereupon the calculation of the BMD is rather straightforward, the estimation of a lower 
confidence  limit  is  more  complicated.  In  general,  three  different  methods  to  calculate 
confidence  intervals  for  the  benchmark  dose  in  risk  analysis  are  often  discussed  in  the 
literature: Beneath the method we will suggest (profile likelihood ratio method), the delta and 
bootstrap method occur. Moerbeek and collaborators compared these methods in fitting non-
linear dose response models for continuous, ordinal and quantal data. They recommend the 
likelihood ratio method because it is less time consuming than the bootstrap method and leads 
to similar results. The delta method appeared to be unreliable for nonlinear dose response 
models  because  it  led  to  different  and  usually  narrower  intervals  compared  to  the  other 
methods [MOERBEEK (2004)].  
We suggest parameterizing the model in a way that the dose itself becomes a parameter and 
determine a so called profile likelihood confidence interval for it. Therefore we have to re-
parameterize our model in order to include the BMD as a parameter itself. The idea is – after 
having defined a  BMR  – solving the formula of the dose found in the last section for a 
parameter  of  the  original  parameterized  model  (e.g.  U
©)  and  plug  it  in.  The  following 
explanation  is  oriented  on  [HELD  (2008)],  [SERFLING  (1980)],  [PAWITAN  (2001)]  and 
[BARNDORFF-NIELSON (1994)]. 
After having introduced the concept of profile likelihood confidence intervals, we will again 
illustrate  the  approach  for  the  Exponential  case  and  have  a  look  at  the  Weibull  case 
afterwards, using the example from above. 
 
i. Introduction to profile likelihood confidence intervals 
In order to find a confidence interval for a parameter in a single parameter model the so called 
likelihood ratio statistic is often used. Its definition is based on the relative likelihood: 41 
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Definition: Let v￿u,G￿ ￿ ∏ ,￿G
ª,u￿,
«
¬
-
®  u ˆ Θ Š ￿ be the likelihood function of a sample. 
The relative likelihood is defined to be 
v ‹￿u￿ ￿
v￿u￿
v￿u <
¯
°￿
 
and the relative log likelihood is y Œ￿u￿ ￿ y￿u￿ & y￿u <
±
²￿. 
The construction of a confidence interval using the likelihood ratio statistic t ￿ &2 y Œ￿u￿ is 
based on the following insight, which holds under regularity conditions [SCHIPP (2008)]: 
￿￿1￿ The parameter space Θ is an open subset of ￿, 
￿￿2￿ the support of the distribution Ž L ￿G:,￿G,u￿ ￿ 0￿ does not depend on u, 
￿￿3￿ 
³
´
µ
¶
·
¸
¹
º
»
¼
½
¾  exists and is finite for u ˆ Θ and G ˆ Ž, 
￿￿4￿ differentiation and integration are commutable for a function ￿￿G￿, i.e. 
         
¿
À
Á ￿￿… ￿￿￿G￿,￿G,u￿)G
Â… )G
Ã￿ ￿ ￿… ￿￿￿G￿￿
Ä
Å
Æ,￿G,u￿‘ )G
Ç… )G
È ￿ ∞. 
 
(These conditions guarantee the existence of the expected Fisher information matrix ’￿u￿ ￿
e￿O￿u￿￿.) 
 
In order to avoid “pathological cases” and prove the asymptotical properties of ML estimates 
we need some additional conditions: 
￿￿5￿ v￿.,G￿: Θ “ 50,∞￿ is continuous for all u ˆ Θ, 
￿￿6￿ for all u
É ” u
Ê ˆ Θ it holds ,￿G,u
Ë￿ ”  ,￿G,u
Ì￿, 
￿￿7￿ e￿log,￿•,u￿￿ exists, 
￿￿8￿ 
Í
Îlogv￿u,G￿
Ï
Ð
Ñ
Ò
– — e￿log,￿•,u￿￿  I u ˆ Θ, 
￿￿9￿ logv￿u,G￿ is twice differentiable in an open interval around u. 
 
A very important result is the asymptotic normality of the ML estimate u <
Ó
Ô 
u <
Õ
Ö ~  ™ hu,šO7u <
×
Ø9›
Ù
Ú
i. 
A proof can be found e.g. in [SERFLING (1980), p.144-148] or in [HELD (2008), p.79-81]. 
 
 
 
￿￿￿￿￿￿￿￿￿￿￿￿
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Theorem: Under assumption of the regularity conditions listed above  
&2 y Œ￿u￿
Ü
“ œ
Ý￿1￿. 
Proof (outline): A Taylor expansion of second order of y￿u￿ at u <
Þ
ß  leads to 
y￿u￿ n y7u <
à
á9 ￿
) y7u <
â
ã9
)u ￿ž žŸž ž 
ä
å
7u & u <
æ
ç9 ￿
1
2
 
)
è y7u <
é
ê9
)u
ë ￿ž žŸž ž 
ì
í
î
ï
ð
ñ
ò
ó
ô
7u & u <
õ
ö9
÷
 
                                                                             
￿￿ y Œ￿u￿ ￿ y￿u￿ & y7u <
ø
ù9 n &
ú
û O￿u <
ü
ý￿ 7u & u <
þ
ÿ9
￿
 
￿￿ &2y Œ￿u￿ ￿ 2hy7u <
￿
￿9 & y￿u￿i n  O￿u <
￿
￿￿ 7u & u <
￿
￿9
￿
   
Because u <
￿
￿  ~  ™￿u,5O￿u <
￿
￿￿¡
￿
￿
￿ it follows  O7u <
￿
￿9￿u & u <
￿
￿￿
￿
 ~  œ
￿
￿1￿.                 d 
This theorem can be generalized for the multiparameter case and it can be shown that under 
generalized  regularity  conditions  the  likelihood  ratio  statistic  is  asymptotically  œ
￿
￿2￿ 
distributed, where 2 denotes the number of parameters that are to estimate. The proof is given 
e.g. in [SERFLING (1980),154-155]. 
Likelihood ratio test. The likelihood ratio test can be used to find the optimal model from a 
family of nested models. If the inclusion of more parameters does not lead to a significantly 
better fit, the simpler model with fewer parameters is chosen. The  likelihood ratio test is 
based on the insight that minus twice the difference of the log likelihood values associated 
with  two  nested  models  (‘generalized  likelihood  ratio  statistic’)  follows  a  Chi-square 
distribution with 2 parameters, where 2 is equal to the difference in number of parameters 
between the two models [EFSA (2009), 30-31, HELD (2008), 125-126]. In our case, this leads 
to  
t ￿ &2 
maxv
￿
￿
￿￿U
￿,U
￿￿
maxv
￿
￿
￿
￿￿U
￿,U
￿,.￿
￿ &2 7y
 
!
"￿U
# ¢
$
%,U
& ¢
'
(￿ & y
)
*
+
,￿U
- ¢
.
/,U
0 ¢
1
2,.̂
3
4￿9  
t ¤
~ œ
5
￿3 & 2￿ ￿ œ
6
￿1￿. 
 
Now we return to the introduction of profile likelihood confidence intervals. When we use a 
multi parameter model, it is not unusual, that we are really interested only in a subset of 
￿￿￿￿￿￿￿￿￿￿￿￿
7 ￿￿￿￿￿￿￿￿￿￿￿￿
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parameters or even in only one. But even if we are interested in several parameters, it is 
always  easier  to  describe  one  parameter  at  a  time.  Therefore  we  need  a  method  to 
‘concentrate’ the likelihood on a single parameter by eliminating the other parameter(s), the 
so called nuisance parameter(s). 
The approach to eliminate the nuisance parameter that we will use is the following: Replace 
the nuisance parameter by its ML estimate at each fixed value of the parameter of interest. 
The resulting likelihood is called the profile likelihood [PAWITAN (2001), p.61-67,256-259] / 
￿HELD (2008),p.112-138]: 
Definition: Let ￿u,¥￿ be the full parameter and u the parameter of interest. Given the joint 
likelihood v￿u,¥￿ the profile likelihood of u is 
v
9￿u￿ ￿ max
: v￿u,¥￿ ￿ v7u,¥̂
;
<￿u￿9, 
Where the maximization is performed at fixed value of u. 
The  easiest  way  to  obtain  the  profile  likelihood  is  to  solve  the  score  equation                
=
>
?
@
A
B
C
D
E ￿ 0 separately for the nuisance parameter in order to gain ¥̂￿u￿ and then plug it in in 
the joint likelihood v￿u,¥￿. But unfortunately that is not always possible and therefore the 
profile likelihood can often be only determined numerically.  
Our goal was to find a confidence interval for a parameter of our model. When the parameter 
of interest u is scalar, we can use the so called relative profile likelihood, which is defined to 
be v ‹
F￿u￿ ¦￿
G
H
I
J
K
L
M
N
O
P
Q
R
S. 
Thus, the relative profile log likelihood has the form the y Œ
T￿u￿ ¦￿ y
U￿u￿ & y
V￿u <
W
X￿. 
Under  assumption  of  generalized  regularity  conditions  it  can  be  shown  that  also  the 
distribution of &2 y Œ
Y converges for ￿ “ ∞ to a œ
Z distribution with 2 degrees of freedom, 
where  2  denotes  the  number  of  parameters  that  are  of  interest,  i.e.  the  number  of  all 
parameters minus the number of nuisance parameters. The proof can be found in [SERFLING 
(1980), p.156-160]. Because we are only interested in one parameter (the BMD), we have 
2 ￿ 1. 
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Therefore, the set 
§u: y Œ
[￿u￿ ! &
1
2
 œ
\
]
^
_
￿1￿¨ 
builds an approximate ￿1 & U￿ confidence interval for u. 
Note, that this confidence interval is a two-sided one. In order to gain the lower bound of a 
one-sided confidence interval of the form 5©
`,∞￿  we use the œ
a
b
c
d
e
￿1￿ quantile because we 
have to bring the probability mass of the critical area on one side only. A one-sided lower 
confidence limit ©
f equals 
                                           min§u: y Œ
g￿u￿ ￿ &
1
2
 œ
h
i
j
k
l
￿1￿ ￿: ©¨                                           ￿2.4.￿ 
 
The  (rounded)  values  for  c,  given  a  level  U,  are  summarized  in  the  following  table.  The 
calculations were done with R. 
 
U  © 
0.1  -0.82 
0.05  -1.35 
0.01  -2.71 
Tab.6. Profile Likelihood confidence intervals: values of 
m in 
n
o
p
q
r
s
 for different levels of 
t. 
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ii. BMDL for Exponential AFT models   
Now we solve the formula of the dose found in the last section for U
u and plug it in in our 
model. Again, we carry out these calculations for the four possibilities of defining the BMR: 
 
a) Absolute value for the BMR at a fixed time point ?
v: ￿￿￿
w,)
x
y
z￿ ￿ ￿￿￿
{,0￿ & ￿ 
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￿￿ ￿ U
‚ 
&U
ƒ
 
‚ U
„  ￿
log￿& log￿exp￿&exp￿&U
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‰
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‹
 
 
When plugging in this formula for U
Œ in the survival function we obtain: 
 ￿￿￿,)￿ ￿ exp%&exp%&U
￿ &
log7￿&log0.5￿exp￿U
Ž￿ & ￿9 & log￿&log0.5￿ & U
￿
&)
￿
‘
’
)* ￿* 
The accompanying log likelihood is given by 
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Using  this  parameterization  we  can  obtain  both  the  ML  estimate  for  the  BMD  and 
additionally the profile likelihood BMDL.  
The  value  for  the  BMD  gained  through  ML  estimation  is  of  course  the  same  as  if  it  is 
determined the way presented in the last section. The reason is the invariance property of 
Maximum Likelihood Estimates [PAWITAN (2001), p.45]. 
 
 
 46 
￿
b)  Relative value for the BMR at a fixed time point ?
#: ￿￿￿
$,)
%
&
'￿ ￿ ￿1 & ￿￿ ￿￿￿
(,0￿ 
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and the log likelihood has the form 
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c)  Absolute value for the BMR as reduction in a specified quantile of survival, e.g. in 
median survival time: ￿
º
»
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For this manner of specifying the BMR, we have 
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and thus the log likelihood 
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d)  Relative  value  for  the  BMR  as  reduction  in  a  specified  quantile  of  survival: 
￿
V￿)
W
X
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Z￿0￿ 
Finally, in this case  
U
[ ￿
log￿1 & ￿￿
)
\
]
^
 47 
￿
leads to the log likelihood 
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Example: We again use the example data set of Tab.5 and define the BMR as reduction of 5 
weeks in median survival. The ML estimates for the re-parameterized function is calculated 
with the R procedure nlm. 
> rm(list=ls()) 
>  f=function(x){10*x[1]+43*(log((-log(0.5))*exp(x[1])-5)-log(-log(0.5))-
x[1])/x[2]+95*exp(-x[1])+69*exp(-x[1]-(log((-log(0.5))*exp(x[1])-5)-log(-
log(0.5))-x[1])/x[2])+17*exp(-x[1]-(log((-log(0.5))*exp(x[1])-5)-log(-
log(0.5))-x[1])/x[2]*10)} 
> nlm(f,c(3,3)) 
$minimum 
[1] 35.57158 
 
$estimate 
[1] 3.398365 1.410442 
 
￿￿ U
® ￿ 3.3984,   ª«¬ ￿ 1.4104. 
 
Both approaches lead to the same estimates for U
¯ and ª«¬. In order to ensure that these 
estimates maximize the log likelihood we provide the following contour plot. 
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Fig.12. Contour plot of the log-likelihood function of the Exponential model, BMR(abs.) h=5: The log-likelihood 
function has a maximum of 
°
±
²
³
´
µfor the estimates 
¶
·
¸
¹
º
»
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Å
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Æ
 for a BMR defined as 
reduction of 5 weeks in median survival. The R code can be found in the appendix. 
 
With this re-parameterized log likelihood function, which includes the BMD as a parameter 
itself,  we  can  also  determine  the  95%  lower  bound  of  the  profile  likelihood  confidence 
interval for the BMD: 
 
Fig.13. Relative Profile Likelihood for Example data set (Exponential), BMR(abs.) h=5: The BMDL –estimated 
via the profile likelihood method outlined before – equals 
É
Ê
Ë
Ì
Í
Î
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Ð
Ñ
Ò
. The dashed horizontal lines in the 
plots of the profile likelihood functions indicate the value of 
Ó
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ã
ä The BMR was defined as a 
reduction of 5 weeks in median survival. The R code can be found in the appendix. 49 
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Next, a second illustration is provided, using another specification of the BMR. For a BMR 
defined  in  relative  terms  (10%  loss  in  every  quantile  of  survival)  we  get  the  estimates 
U
å ￿ 3.3984,   ª«¬ ￿ 0.539. The calculation of these estimates was done analogously to the 
example above, using the appropriate re-parameterized log likelihood function for this case. A 
log likelihood contour plot is given below. 
 
Fig.14.  Contour plot of the log-likelihood function of the Exponential model for the Example data set, BMR(rel.) 
h=0.1. The BMR was defined as 10% loss in every quantile of survival. 
 
 
The BMDL is estimated by ª«¬v ￿ 0.344. 
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Fig.15. Relative Profile Likelihood for Example data set (Exponential), BMR(rel.) h=0.1: The BMDL for a BMR 
defined as 10% loss in every quantile of survival is given by 
æ
ç
è
é
ê
ë
ì
í
î
î
. The R code can be found in the 
appendix. 
 
 
iii. BMDL for Weibull AFT models   
Because the proceeding is analogous to the Exponential case, we will only list the formulas 
for  U
ï  for  each  specification  of  the  BMR.  This  formula  has  to  be  plugged  in  in  the  log 
likelihood  
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a) Absolute value for the BMR at a fixed time point ?
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b)  Relative value for the BMR at a fixed time point ?
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c)  Absolute value for the BMR as reduction in a specified quantile of survival, e.g. in 
median survival time: ￿
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d)  Relative  value  for  the  BMR  as  reduction  in  a  specified  quantile  of  survival: 
￿
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The re-parameterized Exponential and Weibull log likelihood functions for each discussed 
definition of the BMR can be found in the appendix. 
Example: Again, we use the example dataset and state the BMR as 5 weeks loss in median 
survival. The ML estimates for U
Y, ª«¬ and . are determined via minimizing the negative 
re-parameterized log likelihood with the nlm procedure in R. 
> rm(list=ls()) 
> library(splines) 
> library(survival) 
>  
>  
> bsp<-read.table("bsp.txt",header=T) 
> attach(bsp) 
 
> #Tools for loglikelihood 
> delta<-sum(status) 
> delta 
[1] 10 
>  
> deltad<-sum(status*dose) 
> deltad 52 
￿
[1] 43 
> #BMR(absolute value) 
> h<-5 
> #x=(alpha0,BMD,p) 
>  
> f=function(x){delta*x[3]*x[1]+deltad*x[3]*((log(exp(x[1])*(-
log(0.5))^(1/x[3])-h)-(1/x[3])*log(-log(0.5))-
x[1])/x[2])+(sum(weeks[dose==0]^x[3]))*exp(-
x[3]*x[1])+(sum(weeks[dose==1]^x[3]))*exp(-x[3]*x[1]-
x[3]*((log(exp(x[1])*(-log(0.5))^(1/x[3])-h)-(1/x[3])*log(-log(0.5))-
x[1])/x[2]))+(sum(weeks[dose==10]^x[3]))*exp(-x[3]*x[1]-
x[3]*10*((log(exp(x[1])*(-log(0.5))^(1/x[3])-h)-(1/x[3])*log(-log(0.5))-
x[1])/x[2]))-delta*log(x[3])-(x[3]-1)*sum(status*log(weeks))} 
>  
> nlm(f,c(4,1,1)) 
$minimum 
[1] 35.55586 
 
$estimate 
[1] 3.3803322 1.4739423 0.9571154 
 
￿￿ U
Z ￿ 3.3803,  ª«¬ ￿ 1.4794, . ￿ 0.9571 
 
The relative profile likelihood which is used for the determination of the BMDL in that case is 
plotted in the following graphic. The BMDL is estimated by ª«¬v ￿ 0.393. 
 
Fig.16. Relative Profile Likelihood for Example data set (Weibull), BMR(abs.) h=5: If a Weibull model is fitted 
to the example data set, we get the estimates 
[
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]
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_
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b
 and 
c
d
e
f
g
h
i
j
k
j for a BMR defined as 5 weeks 
loss in median survival. The R code can be found in the appendix.  
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If we define the BMR in relative terms, e.g. 10% loss in every quantale of survival, we get the 
following  estimates:  U
l ￿ 3.3803,   ª«¬ ￿ 0.5409, . ￿ 0.9571.  The  relative  profile 
likelihood is shown in the following figure. The estimate for the BMDL is ª«¬v ￿ 0.33. 
 
Fig.17. Relative Profile Likelihood for Example data set (Weibull), BMR(rel.) h=0.1: For a BMR defined as 10% 
loss in every quantile of survival we get the estimates 
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Part II: Application to experimental and simulated data 
In this section the proceeding suggested in Part I will be applied to experimental data and 
afterwards  the  results  will  be  compared  with  values  obtained  using  dichotomous  models. 
Furthermore,  a  simulation  study  will  be  presented  that  tries  to  evaluate  the  influence  of 
censorings  on  the  coverage  probability  of  the  one-sided  profile  likelihood  confidence 
intervals. Finally, the estimates from the Urethane study are compared with those published in 
the literature. 
 
4.  The Urethane study  
At first we apply the methods developed in Part II on data from a dose-response study in 
animals performed by Schmähl, Port and Wahrendorf [SCHMÄHL (1977)] when investigating   
urethane induced carcinogenesis. We used this experiment as application because the data 
were as individual data on hand, the investigation seemed to be appropriate for our approach 
and  the  study  was  to  our  knowledge  totally  completed  with  no  ongoing  follow  up 
investigations after that publication.  
Data source: Personal communication of the data by Dr. R. Port to Dr. L. Edler when Dr. Port 
was employed at the DKFZ in the department of Prof. Dr. W. Kunz. 
 
4.1. Some background information on Urethane 
Urethane (ethyl carbamate), the ethyl ester of carbamic acid, occurs in spirituous beverages 
and fermented food such as bread (<1 – 8 µg/l), beer (0.3 – 18 µg/l), soy sauce (<1-95 µg/l), 
wine  (<1  –  110 µg/l)  and  yoghurt  (0  –  3 µg/l)  [RÖMPP  (2007)].  Especially  stone  fruits 
liqueurs can have very high contents of ethyl carbamat (100 – 200000 µg/l ) because cyanide, 
which is contained in the stones naturally, reacts under light and in presence of ethanol to 
form ethyl carbamate. [RÖMPP (2007)]. Therefore, an attempt to reduce urethane in these 
beverages  is  the  exclusion  of  light  in  bottle  spirits.  Another  source  for  urethane  is 
diethylpyrocarbonate,  an  inhibitor  of  fermentation  used  as  an  antimicrobial  agent  for  the 
preservation of soft drinks (and until 1973 also for wine), which can form ethyl carbamate 
during  its  decomposition  in  the  presence  of  ammonia  [JECFA  (2005),  RÖMPP  (2007), 
SCHMÄHL (1977)].  55 
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Urethane has also been used for medical and industrial purposes but at the present time the 
major  route  of  exposure  to  urethane  in  the  human  population  is  through  consumption  of 
comestibles listed above [JECFA (2005), NTP (2004)].   
Urethane  is  listed  as  “possibly  carcinogenic  to  humans”  (Group  2B)  by  the  International 
Agency for Research on Cancer [IARC (1987)] and as “reasonably anticipated to be a human 
carcinogen” in the Report on Carcinogens of the US National Toxicology Program [NTP 
(2004)]. These assessments are based on the results of various animal studies on Urethane 
which could prove the substance to be genotoxic and a multisite carcinogen in the species 
tested. Nevertheless, no adequate human studies have been reported which investigated the 
relationship between exposure and human cancer [JECFA (2005), NTP (2004)].  
In 1986 the Federal Republic of Germany adopted a guideline value for urethane of max. 
0.4 ml/l in stone fruits liqueurs. On the European scale does not exist a guideline at present 
[Positionspapier (2006)].  
 
4.2. Description of the study and summary of the data 
The study on urethane of SCHMÄHL ET AL. (1977) consisted of a rat and a mouse experiment, 
both with five identical dose groups: 0, 100, 500, 2500 and 12500 µg/kg BW/day . Planned 
were 40 female and 40 male animals in each group. The animals were chronically fed with 
urethane in the drinking water during their life-time. Throughout the study, they were kept 
until spontaneous death, or killed when they became moribund. At the end of the study, the 
animals still alive were sacrificed (8% of the total effective number in the rat and 13% in the 
mouse experiment).  
The rat experiment ended after 670 days in the groups receiving the three highest dosages, 
after 730 days in the 100 µg/kg BW/day group and after 680 days in the control group. The 
mouse experiment ended in the 12500 µg/kg BW/day group after 660 days, in the 2500, 500 
and 100 µg/kg BW/day groups after 730 days and in the control group after 760 days. 
For our analysis, we will only consider the malignant tumors and ignore the benign ones. 
They will be treated as “no (malignant) tumors”.  
The following table shows the numbers of benign and malignant tumors in the mouse and rat 
experiments per dose groups and therefore prepares a rough summary of the data. The data we 
had at our disposal slightly differ from the published ones in the number of animals and 56 
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tumors [SCHMÄHL (1977)]. Following the paper, in the rat experiment about 50% of the total 
effective  number  was  lost  between  350  and  450  days,  most  of  them  probably  due  to  an 
unspecified virus infection. 
 
Experiment 
 
Dose group 
￿µg/kg BW/day
Number of 
animals 
Number of 
animals with 
benign tumors 
Number of animals 
with malignant 
tumors 
Mouse male  0 
100 
500 
2500 
12500 
42 
39 
41 
40 
40 
2 (4.8%) 
0 
7 (17.1%) 
8 (20%) 
8 (20%) 
4 (9.5%) 
6 (15.4%) 
3 (7.3%) 
9 (22.5%) 
14 (35%) 
Mouse female  0 
100 
500 
2500 
12500 
38 
41 
39 
40 
40 
2 (7.9%) 
7 (17.1%) 
5 (12.8%) 
5 (12.5%) 
5 (12.5%) 
3 (5.3%) 
7 (17.1%) 
13 (33.3%) 
12 (30%) 
18 (45%) 
Rat male  0 
100 
500 
2500 
12500 
40 
40 
40 
40 
40 
1 (2.5%) 
0 
0 
0 
2 (5%) 
0 
1 (2.5%) 
2 (5%) 
2 (5%) 
2 (5%) 
Rat female  0 
100 
500 
2500 
12500 
38 
41 
39 
40 
40 
0  
3 (7.5%) 
2 (5%) 
4 (10%) 
4 (10%) 
2 (5%) 
1 (2.5%) 
2 (5%) 
6 (15%) 
12 (30%) 
Tab.7. Numbers of animals such as benign and malignant tumors in the mouse and rat experiments of Schmähl 
et al. (1977) per dose groups.  
 
We can observe the trend that the number of malignant tumors increases with increasing 
doses. As a kind of qualitative pre-test we investigate the interrelationship between the dose 
and  the  effect  (i.e.  incidence  of  malignant  tumors)  using  the  Cochran-Armitage  test  for 
(linear) trend in proportions. The Cochran-Armitage test is a modified chi squared test, which 
incorporates a suspected order in the effect of one explanatory variable with ￿ categories (in 
our case the dose) on a response variable with only 2 categories (in our case the presence or 
absence of a tumor) and tests for a trend among binomial proportions. The following passage 
is written on the basis of AGRESTI (2002) and GART (1986). 
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Summarized,  the  Cochran-Armitage  test  analyzes  a  2 ￿ ￿  contingency  table  with  ordered 
columns: 
Response  Dose 
      1                     2                     …                       ￿             
Sum 
1  
(e.g. tumor) 
￿
￿
￿  ￿
￿
￿    ￿
￿
￿  ￿
￿
￿ 
0  
(e.g. no tumor) 
￿
￿
￿  ￿
￿
￿    ￿
￿
￿  ￿
￿
￿ 
Sum  ￿
￿
￿  ￿
￿
￿    ￿
￿
￿  ￿ 
 
Let ￿
￿
￿
￿ denote the real underlying probability of response ￿ in column ￿ and let ￿
￿
￿
￿ denote 
the observed sample proportion of response ￿, ￿ ￿ 1,…,￿. Let {￿
￿} be scores assigned to the 
columns. In our case, for each column the numeric value of the dose group can be taken as 
score. The Cochran-Armitage test  can be interpreted as score test in a logistic regression 
model: 
For the linear probability model 
￿
￿
￿
￿ ￿ ￿ ￿  ￿
￿ 
the hypotheses are 
!
 : ￿
!
"
# ￿ ￿
$
%
& ￿  ...  ￿ ￿
'
(
)      (#￿$   ￿ 0) 
         (i.e. no linear trend in binomial proportions of response across increasing levels of dose) 
versus the one-sided alternative 
!
*: ￿
+
,
- % ￿
.
/
0 %  ...  % ￿
1
2
3   with at least one strict inequality 
         (i.e. linear trend in binomial proportions of response across increasing levels of dose). 
The prediction equation under ordinary least squares is  
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a  (standard formula for weighted regressions). 58 
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It can be shown that the test statistic for the Cochran – Armitage trend test 
,
b ￿ -
'
c
￿
d
e(1 ) ￿
f
g+
./￿
h
i (￿
j ) ￿*+
k 
has an asymptotic 0
l(1+ distribution. 
Note, that the Cochran-Armitage test has the same null hypothesis as the chi square test of 
independence but a narrower alternative and therefore uses a different test statistic. This test 
statistic is based upon Pearson’s test statistic, which is partitioned into the test statistic ,
m 
shown above, which includes the assumption of   ￿ 0 and is 0
n(1+ distributed, and a second 
statistic, which only accounts for the residual variance (independent of   ￿ 0 or   1 0) and is 
0
o(2 ) 2+ distributed. The second statistic has one degree of freedom less than the original 
Pearson statistic which is due to the fact that   is estimated. The Cochran-Armitage test uses 
only that part of the original Pearson test statistic that tests the suspected linear trend. 
For more mathematical details see COCHRAN (1954) and ARMITAGE (1955). If no trend could 
be  observed,  it  would  not  be  meaningful  to  fit  a  dose-response  model.  For  our  data,  the 
Cochran-Armitage tests (with SAS 9.1.) support the trend hypothesis for all experimental 
groups except for Rat male. 
 
Experiment 
 
Statistic (Z)  Asymptotic Test 
One sided 
Exact Test 
One sided 
Mouse male￿ -3.4100  0.0003  6.865E-04 
Mouse female￿ -3.1916  0.0007  0.0011 
Rat male￿ -0.7459  0.2279  0.1835 
Rat female￿ -4.3353  < 0.0001  4.201E-05 
Tab.8. Results of the Cochran-Armitage trend tests (calculated with the proc freq procedure in SAS 9.1.). The 
small right sided p-values for all experiments except Rat male indicate that the probability of a tumor increases 
as dose increases.  
￿
The Kaplan Meier point estimates for the quartiles of survival time are summarized in the 
following table in order to prepare an overview of the observed survival times in the different 
dose groups. In each experimental group, we would expect a reduction in each quantile of 
survival  with  increasing  doses.  Due  to  the  low  incidence  in  some  doses  groups  and,  in 
particular, in the control group not all quantiles could be calculated. The female mice seem to 
provide the most useful data for a dose-response analysis. 
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Experiment 
 
Dose group 
p
q
r
s
t
u
v
w
x
y
z
{
| 
75% quartile 
of survival 
50% quartile of 
survival (median) 
25% quartile 
of survival 
Mouse male  0 
100 
500 
2500 
12500 
- 
680 
- 
595 
547 
- 
- 
- 
729 
662 
- 
- 
- 
729 
662 
Mouse female  0 
100 
500 
2500 
12500 
- 
667 
555 
667 
492 
- 
730 
729 
729 
565 
- 
- 
- 
729 
639 
Rat male  0 
100 
500 
2500 
12500 
- 
- 
- 
605 
- 
- 
- 
- 
605 
- 
- 
- 
658 
605 
- 
 
Rat female  0 
100 
500 
2500 
12500 
- 
- 
- 
- 
- 
- 
- 
- 
- 
646 
- 
- 
- 
648 
577 
Tab.9. Kaplan Meier point estimates of quartiles of survival time for the mouse and rat experiments per dose 
groups. 
 
The expectation of a dose related reduction in each quantile of survival seems to hold but 
actually only a few point estimates can be calculated. The explanation for that unfavorable 
result is the huge percentage of censoring in each group not allowing the calculation of the 
quantiles chosen above. The number and percentages of censorings, i.e. of animals not facing 
the event during the study period are summarized in the following table: 
 
Experiment 
 
Dose group 
[
}
~
•
€
￿
‚
ƒ
„
…
†
‡] 
Number of events 
(malignant 
tumors) 
Number of 
censorings 
Percentage of 
censoring [%] 
Mouse 
male 
0 
100 
500 
2500 
12500 
4 
6 
3 
9 
14 
38 
33 
38 
31 
26 
90.48 
84.62 
92.68 
77.5 
65 
Mouse 
female 
0 
100 
500 
2500 
12500 
3 
7 
13 
12 
18 
35 
34 
26 
28 
22 
92.11 
82.93 
66.67 
70 
55 60 
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Rat male  0 
100 
500 
2500 
12500 
0 
1 
2 
2 
2 
40 
39 
38 
38 
38 
100 
97.5 
95 
95 
95 
Rat female  0 
100 
500 
2500 
12500 
2 
1 
2 
6 
12 
38 
39 
38 
34 
28 
95 
97.5 
95 
85 
70 
Tab.10. Numbers of events and censorings per dose group in the four experiments. 
 
After having summarized the data we will present the results of the modeling as described in 
part II. We fitted both, the Exponential and Weibull AFT/PH models and calculated values for 
the  BMDs  and  BMDLs.  The  analysis  was  done  for  each  of  the  four  sub-experiments 
irrespective how good a dose-response was expressed. By this way we could also learn about 
the robustness of the model given data of different quality.    
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4.3. Fitting an Exponential AFT model 
We fitted Exponential AFT/PH models and defined the BMRs as 25%, 10% and 5% relative 
loss in each quantile of survival. According to section 3.2.2. defining the BMR in terms of a 
relative reduction in any (and thus because of the AFT property in each) quantile of survival 
is most appropriate. The BMDs are calculated as the Maximum Likelihood estimates and the 
BMDLs,  the  lower  (one-sided)  95%  confidence  limits,  are  calculated  using  the  profile 
likelihood method. The analysis was done for each experiment: mouse male, mouse female, 
rat male und rat female. We describe the proceeding in detail for mouse male and show only 
the results for the other experiments in order to avoid redundancy. 
 
4.3.1. Mouse male 
The Kaplan-Meier curves per dose groups and the Log-log-plot take the following forms:  
 
Fig.18. Kaplan-Meier curves and Log-log-plot for Mouse male.  
The Weibull model assumes the Kaplan-Meier estimated survival curves to be of the same 
form and to be only ‘stretched out’ or contracted for different dose groups. The curves in the 
log-log  plot  should  be  parallel  straight  lines.  The  Exponential  model  assumes  them 
additionally to have a slope equal to 1. 
Although these assumptions seem not to be perfectly adequate they seem at least not fully 
unreasonable. The Kaplan-Meier estimated survival curves intersect but have rather similar 
forms. The figures which appear in the Log-log-plot are close to be parallel straight lines. One 
has to note that although the Cochran-Armitage trend test showed a significant dose-response 62 
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interrelationship, especially for the three lowest doses it seems not to be monotonic. But on 
the other hand, one should not forget that only a few events could be observed in these dose 
groups, which leads to additional uncertainty.  
Thus it seems to be reasonable to apply a Weibull (and also an Exponential) model to these 
experimental data.  
For  an  Exponential  AFT/PH  model  we  get  the  estimates  ￿
ˆ ￿ 8.274875  and  ￿
‰ ￿
)8.836129 9 10
Š
‹
Œ
.  
A comparison of the ‘observed’ (in the sense of estimated Kaplan-Meier survival curves) and 
‘expected’  (in  the  sense  of  predicted  by  the  fitted  Exponential  model)  survival  curves  is 
performed  graphically  in  the  following  figure.  This  model  seems  not  to  be  appropriate 
because the fit is rather poor. (Therefore, we will also fit a Weibull model later.) 
 
Fig.19. ‘Observed’ and expected survival probabilities  (Exponential model) for Mouse male.  The predicted 
survival curves nearly overlap for the three lowest dose groups. The estimates of survival probabilities are rough 
compared to the ‘observed’ ones. 
 
Next we calculated the BMDs and BMDLs for three different (relative) BMRs: 25%, 10% and 
5%  loss  in  every  quantile  of  survival  (including  the  median).  We  used  re-parameterized 
models with parameters ￿
￿ and :
Ž
￿
￿ ￿ ;<=. Additionally, we generated contour plots of 
the re-parameterized log-likelihood functions, which serve as a control of the ML estimates 
for ￿
‘ and :
’
“
”. The profile likelihood function, which was used for the calculation of the 
BMDL, is also shown below. The BMDLs are determined with the formula  
min@A: B C
•(A+ ￿ )
–
— 0
˜
™
š
›
(1+ D ￿1.352772E. 63 
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Fig.20. Log-likelihood contour plots and relative Profile Likelihood functions for different definitions of BMR 
for Mouse male. The dashed horizontal lines in the plots of the profile likelihood functions indicate the value of 
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Note, that the shape of all curves shown above is identical, the different appearances are only 
caused by different scaling because of the different values for the BMR. We used the re-
parameterized  likelihood  function  for  the  calculations,  which  already  includes  the  value 
chosen for the BMR and has the parameters ￿
® and ;<=. This explains the different regions 
for the “interesting” ;<=-values in the contour plots. Of course, the maximum value of the 
Likelihood function is always the same. 
 
The (rounded) estimates for the BMDs and BMDLs are summarized in the following table. 
The values for the BMDLs were about 2/3 of the value for the BMDs: 
 
 
BMR (rel.)   BMD  BMDL 
25%  3256  2124 
10%  1192  778 
5%  580.5  378.7 
Tab.11.  Values  for  BMDs  and  BMDLs  for  different  BMRs  for  the  Mouse  male  experiment  under  fit  of  an 
Exponential model. 
 
 
4.3.2. Mouse female 
Because the proceeding is analogous to section 4.3.1. we summarize only the estimates for the 
BMDs and BMDLs for different specifications of the BMR. The estimates are a bit higher 
than those obtained for the Mouse male experiment but still in the same region of size. 
 
BMR (rel.)   BMD  BMDL 
25%  3721  2465 
10%  1363  902.8 
5%  663.4  439.5 
Tab.12. Values for BMDs and BMDLs for different BMRs for the Mouse female experiment under fit of an 
Exponential model. 
 
 
The Kaplan-Meier curves and Log-log-plot are shown in the following figure.  65 
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Fig.21. Kaplan-Meier curves and Log-log-plot for Mouse female. A Weibull (or Exponential) AFT/PH model 
seems not to be appropriate. 
 
Fitting an Exponential model leads to the following estimates: ￿
¯ ￿ 7.884931 and ￿
° ￿
)7.732023 9 10
±
²
³
.  
 
Fig.22. ‘Observed’ and expected survival probabilities (Exponential model) for Mouse female. 66 
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Fig.23. Log-likelihood contour plots and relative Profile Likelihood functions for different definitions of BMR 
for  Mouse female. 
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4.3.2. Rat male 
Kaplan-Meier curves and Log-log-plot:  
 
Fig.24. Kaplan-Meier curves and Log-log-plot for Rat male. A Weibull (or Expoential) AFT/PH model seems not 
to be appropriate. 
 
Fitting an Exponential model leads to the following estimates: ￿
´ ￿ 9.482464 and ￿
µ ￿
)4.793905 9 10
¶
·
¸
.  
 
Fig.25. ‘Observed’ and expected survival probabilities (Exponential model) for Rat male. 68 
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Fig.26. Log-likelihood contour plots and relative Profile Likelihood functions for different definitions of BMR 
for  Rat  male.  The  appearance  of  the  relative  profile  likelihood  function  differs  from  those  of  the  other 
experimental groups because no (finite) upper confidence limit for the BMD could be found. Anyway, the results 
of  this  experiment  should  be  interpreted  with  caution  because  even  the  Cochran-Armitage  test  showed  no 
significant dose-response interrelationship.  69 
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4.3.2. Rat female 
Kaplan-Meier curves and Log-log-plot:  
 
Fig. 27. Kaplan-Meier curves and Log-log-plot for Rat female. A Weibull (or Expoential) AFT/PH model seems 
not to be appropriate.  
 
Fitting an Exponential model leads to the following estimates: ￿
¹ ￿ 9.0691749467 and 
￿
º ￿ )0.0001339523.  
 
Fig. 28. ‘Observed’ and expected survival probabilities (Exponential model) for Rat female. 70 
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Fig.29. Log-likelihood contour plots and relative Profile Likelihood functions for different definitions of BMR 
for Rat female. 
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4.4. Fitting a Weibull AFT model 
In  this  section,  we  summarize  the  results  of  fitting  Weibull  AFT/PH  models.  Again,  the 
BMDs for three different BMRs are estimated via Maximum Likelihood: 25%, 10% and 5% 
reduction in each quantile of survival compared to the unexposed individuals. The BMDLs 
are  determined  with  the  profile  likelihood  method.  Because  the  likelihood  function  of  a 
Weibull model contains three parameters, no contour plots are plotted. 
 
4.4.1. Mouse male 
For the Mouse male  experiment we  get the  estimates ￿ ￿ 6.178721, ￿
» ￿ 6.724810 and 
￿
¼ ￿ )1.991917 9 10
½
¾
¿
. 
A comparison of the ‘observed’ and expected survival probabilities shows that this model is 
much more appropriate than the Exponential one – even though the Kaplan-Meier curves and 
Log-logistic plot (Fig.18.) would also not suggest a Weibull AFT/PH model at once. 
 
Fig.30. ‘Observed’ and expected survival probabilities (Weibull model) for Mouse male. 
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The following figure depicts the profile likelihood functions for each definition of BMR: 
     
 
Fig.31.  Relative  Profile  Likelihood  functions  for  different  definitions  of  BMR  for  Mouse  male.  The  dashed 
horizontal lines in the plots of the profile likelihood functions indicate the value of 
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Exponential case the different shapes only result from different scaling. 
 
 
The (rounded) estimates for the BMDs and BMDLs are: 
BMR (rel.)   BMD  BMDL 
25%  14442  10010 
10%  5290  3666 
5%  2575  1785 
Tab.13. Values for BMDs and BMDLs for different BMRs for the Mouse male experiment under fit of an Weibull 
model. 
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4.4.2. Mouse female 
The  estimates  for  a  Weibull  AFT/PH  model  for  the  Mouse  female  experiment  are:              
￿ ￿ 5.792518, ￿
Ò ￿ 6.714603 and ￿
Ó ￿ )2.597749 9 10
Ô
Õ
Ö
. 
The (rounded) estimates for the BMDs and BMDLs are a bit smaller than those obtained for 
the Mouse male experiment but still in the same region. 
 
BMR (rel.)   BMD  BMDL 
25%  11074  8578 
10%  4056  3147 
5%  1975  1529 
Tab.14. Values for BMDs and BMDLs for different BMRs for the Mouse female experiment under fit of a Weibull 
model. 
 
 
Fig.32. ‘Observed’ and expected survival probabilities (Weibull model) for Mouse female. 
 
Profile likelihood functions for each definition of the BMR and estimates for the respective 
BMDs and BMDLs: 74 
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Fig.33. Relative Profile Likelihood functions for different definitions of BMR for Mouse female. 
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4.4.3. Rat male 
The  estimates  for  a  Weibull  AFT/PH  model  are:  ￿ ￿ 6.254374,  ￿
× ￿ 6.701951  and 
￿
Ø ￿ )1.236188 9 10
Ù
Ú
Û
. 
 
Fig.34. ‘Observed’ and expected survival probabilities (Weibull model) for Rat male. 
 
Profile likelihood functions for each definition of the BMR and estimates for the respective 
BMDs and BMDLs: 
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Fig.35. Relative Profile Likelihood functions for different definitions of BMR for Rat male.  
 
 
4.4.4. Rat female 
The  estimates  for  a  Weibull  AFT/PH  model  are:  ￿ ￿ 5.470178,  ￿
Ü ￿ 6.859511  and 
￿
Ý ￿ )2.614513 9 10
Þ
ß
à
. 
A  graphical  comparison  of  the  Kaplan-Meier  survival  curves  and  the  survival  estimates 
predicted by the model is shown in the following figure: 
 
Fig.36. ‘Observed’ and expected survival probabilities (Weibull model) for Rat female. 
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Profile likelihood functions with estimates for BMDs and BMDLs: 
  
 
Fig.37. Relative Profile Likelihood functions for different definitions of BMR for Rat female. 
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4.5. Summary of the BMDs and BMDLs obtained with Exponential and Weibull models 
Model 
(TTT) 
Animals  BMD25  BMDL25   BMD10  BMDL10  BMD5  BMDL5 
Exponential  Mouse ♂  3256  2124  1192  778  580.5  378.7 
  Mouse ♀  3721  2465  1363  902.8  663.4  439.5 
  Rat ♂  6001  1837  2198  673.1  1070  327.6 
  Rat ♀  2148  1479  786.6  541.7  382.9  263.7 
Weibull  Mouse ♂  14442  10010  5290  3666  2575  1785 
  Mouse ♀  11074  8578  4056  3141  1975  1529 
  Rat ♂  23273  9271  8523  3395  4149  1653 
  Rat ♀  11003  7072  4030  2590  1962  1261 
Tab.15.  Summary of the estimates for the BMDs and BMDLs for Exponential and Weibull TTT models. 
 
For the Exponential models, all estimates are lower than the respective ones obtained for the 
Weibull  models.  When  interpreting  this  result,  one  should  keep  in  mind,  that  in  all 
experimental groups the Weibull models provide a statistically significant better fit than the 
nested Exponential models. We used the Likelihood ratio test statistic for a goodness of fit 
test:  
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Experiment  O
￿
￿
￿(P
￿ J
￿
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￿ J
￿
￿+  O
￿
￿
￿
￿(P
￿ J
￿
￿,P
￿ J
￿
￿,Q R
￿
￿+  W  p-value 
Mouse ♂  )316.3  )268.1  96.4  # 5 9 10
￿
￿
￿
 
Mouse ♀  )450.6  )385.9  129.4  # 3 9 10
￿
￿
￿
 
Rat ♂  )71.9  )59.3  25.2  # 3 9 10
￿
￿
 
Rat ♀  )209.3  )182  54.6  # 8 9 10
 
!
"
 
Tab.16. Comparison of goodness of fit for Exponential and Weibull models. For all experimental groups the 
difference between these nested models is highly significant. 
 
 
4.6. Comparison with calculations for dichotomous models 
An alternative approach of calculating BMDs and BMDLs for TTT data would be to reduce 
the information and analyze only tumor incidences. (This procedure especially is of interest if 
only summarized and no individual time to tumor data are available.) Then it is possible to fit 
a dichotomous (quantal) model with three underlying variables: dose group, total number of 
animals (per dose groups) and number of (malignant) tumors (per dose groups). This form of 
the data is reported in Tab.7.  
We  consider  two  dichotomous  models,  namely  Weibull  and  Log-logistic,  which  have  the 
following probability functions:  
Weibull: 
S(d+ ￿ b ￿ (1 ) b+ 9 (1 ) exp()s 9 d
#
++ 
Log-logistic: 
S(d+ ￿
1 ) b
1 ￿ exp ()c ￿ s 9 log (d++
, 
where  :  denotes  the  dose,  '  the  background  probability  of  an  effect,  ￿  the  power, Z  the 
intercept and [ the slope.  
The BMD analysis can be performed with the software BMDS 2.1., developed by US EPA. 80 
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To avoid having an infinite slope at zero dose, which would be biologically unrealistic and 
could lead to numerical problems when calculating confidence limits, the slope in the Log-
logistic and respectively the power in the Weibull dichotomous model was restricted to be 
greater than or equal to 1 [BMDS Online-Tutorial]. 
We have defined the BMRs as 25%, 10% and 5% increase of the fraction affected (death with 
tumor) compared to the unexposed animals: ‘extra risk’ 
$
%
&
'
(
)
*
+
,
-
.
/
0
1
2 , where S(:+ is the risk at 
the BMD and S(0+ is the background risk at dose 0. 
 
The estimated values for the respective BMDs and BMDLs are summarized in Tab.17 and the 
following figure is an illustration of the proceeding (Weibull: Mouse male): 
 
Fig.38. BMD analysis of Mouse male with BMDS 2.1. A dichotomous Weibull model is fitted with restricted 
power (red line). The BMD estimation is shown graphically (green lines) and the BMDL (blue line). 
 
Model 
(dichotomous) 
Animals  BMD25  BMDL25   BMD10  BMDL10  BMD5  BMDL5 
Weibull  Mouse ♂  10618  6300  3889  2307  1893  1123 
  Mouse ♀  8356  4943  3060  1810  1490  881.3 
  Rat ♂  115994  13251  42482  10178  20682  4955 81 
￿
  Rat ♀  10785  6792  3950  2487  1923  1211 
Log-logistic  Mouse ♂  10195  5455  3398  1818  1610  861.3 
  Mouse ♀  7289  3700  2430  1233  1151  584.2 
  Rat ♂  131081  13323  43694  9970  20697  4723 
  Rat ♀  10599  6159  3533  2053  1674  972.4 
Tab.17. Summary of the (rounded) estimates for the BMDs and BMDLs Weibull and Log-logistic dichotomous 
models, software: BMDS 2.1. The whole output including graphs for the default BMR of 10% extra risk can be 
found in the appendix. 
All estimates are higher than the corresponding ones for the Exponential TTT models. In 
comparison  to  the  Weibull  TTT  models,  all  corresponding  estimates  for  the  dichotomous 
models are lower but more or less in the same region of size (except for rat male). The 
estimates for the BMDL10 are compared in the following graphic. 
 
Fig.39. Comparison of the estimates for the BMDL10 for the Weibull TTT model and the quantal models Weibull 
and Log-logistic. The values are lower for the quantal models than for the Weibull TTT model in all experiments 
except for rat male. The Weibull TTT model leads to estimates for the BMDL10 that are in the same region of size 
for all experiments. 
 
In contrast to the quantal models, the Weibull TTT model leads to estimates for the BMDL10 
which are in the same region of size for all experiments. 
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5.  Simulation  study  to  the  coverage  evaluation  of  Confidence  Intervals  for 
Exponential TTT models 
In order to get an idea of the reliability of the BMDLs we have calculated with the profile 
likelihood method, a simulation study was done. We were especially interested in the effect of 
the censoring percentage. 
Therefore, we defined an Exponential model with survival function  
\(]+ ￿ exp ()exp ()5 ￿ 0.0001 9 :^[_++ 
and sampled data sets of 40 individuals per group for dosages of 0, 100, 500, 2500 and 12500 
with  censoring  percentages  in  the  range  of  0%  and  90%.    (Details  can  be  found  in  the 
appendix.) For each dose 1000 samples were drawn. In each case we estimated the BMDs and 
BMDLs for a relative BMR of 10% loss in each quantile of survival (AFT property).  
The  ‘true’  BMD  of  the  underlying  model  is  ;<= ￿ 1053.605.  In  order  to  evaluate  the 
coverage of the BMDLs, we compared the estimated BMDLs with that value. Approximately, 
it should hold  
S(;<=H # 1053.605+ ￿ 0.95 
Actually, the coverage was quite good because for all censoring percentages the coverage 
probability estimated from the simulations was either larger than or reasonably close to 0.95 
as compared to its standard error: 
Censoring   0%  10%  20%  30%  40%  50%  60%  70%  80%  90% 
Coverage  0.955  0.957  0.955  0.95  0.956  0.936  0.957  0.955  0.952  0.949 
std error  0.0066  0.0064  0.0066  0.0069  0.0065  0.0077  0.0064  0.0066  0.0068  0.0070 
Tab.18. Coverage probability. In about 95% the estimated BMDL was smaller than the ‘real’ BMD for all 
percentages of censoring investigated. The coverage probability can be interpreted as a binomial rate 
3 and 
standard error 
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Nevertheless, the percentage of censoring had an influence on the estimated BMDLs. As one 
might  expect,  the  variability  of  the  values  for  the  BMDLs  increased  especially  for  high 83 
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censoring  percentages.  The  median  BMDLs  show  a  trend  to  become  smaller  for  higher 
percentages of censoring: 
Fig.40. Dependence of the estimated BMDLs on the percentage of censoring. In the left figure, the red horizontal 
line indicates the value of the ’true’ BMD for the underlying Exponential model. The boxplots depicted in the 
right  figure  show  the  tendency  of  the  estimated  BMDLs  to  show  a  greater  variability  especially  for  high 
censoring percentages, whereby the median tends to become even smaller.  
 
Of course, it would be also interesting to evaluate this relationship for Weibull models. But in 
the case of Weibull data it is technically much more complicated to control the censoring 
percentages in the simulations and thus the investigation of the influence of censorings on 
BMD calculations for Weibull models was beyond the scope of present work.  
 
6. Comparison with BMDs and BMDLs for Urethane from other studies 
The  Joint  FAO/WHO  Expert  Committee  on  Food  Additives  (JECFA)  has  provided  a 
summary of values for BMDs and BMDLs from different studies on Urethane. In all cases, 
the analysis was done for the tumor incidences (dichotomous models) and the BMR was 
defined as 10% extra risk of tumors. The BMD values range from 500 to 630 µg/kg BW/day 
for lung adenoma or carcinoma and 470 to 760 µg/kg BW/day for harderian gland adenoma 
or  carcinoma.  The  corresponding  BMDLs  range  from  260  to  510  respective  280  to  610 
µg/kg BW/day. [JECFA (2005)] 
These values are smaller than the values we got for dichotomous models and the ones we 
calculated with our TTT models. But one has to keep in mind that this result also depends on 
the different definitions of the endpoint:  We analyzed only the malignant tumors, whereas the 
studies quoted included also the benign ones. ￿
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7. Discussion  
In this thesis, we suggested a statistical method on how the BMD approach can be extended to 
continuous  incomplete  (here  right  censored)  time-to-tumor  data  obtained  in  animal 
carcinogenesis studies. For this aim the four steps of the 
1.  identification of the statistical distribution model for the endpoint variable and of the 
dose-response model,  
2.  definition of the Benchmark Response (BMR) level,    
3.  estimation of the Benchmark Dose (BMD) and 
4.  calculation  of  the  (one-sided)  lower  95%  confidence  bound  as  so  called  BMDL 
(Benchmark Dose Lower Limit)   
were investigated for ways to adjust them to this type of data. Whereas by now those data 
were only analyzed in their aggregate form of tumor incidences in the risk assessment, the 
methods developed in this thesis allow the analysis of the original time-to-tumor data. The 
former quantal dose response models for dichotomous data (tumor present or absent) were 
thus replaced by dose-time response models which are more realistic since they account for 
the timely occurrence of the endpoint tumor. This approach could not be done without making 
assumptions  at  the  first  two  definition  steps  of  the  approach  listed  above.  This  will  be 
discussed next under “methods”.   
Methods. The distribution model chosen for the time-to-tumor data was the Weibull survival 
time distribution which has been often used as parametric survival model for data of animal 
experiments. Whereas this model is often used as a sort of “black box” model in standard 
software it was developed in this thesis analytically in detail (also its special case of the 
Exponential distribution) since we had to understand the analytical form of the distribution for 
two specific reasons 
a) for the implementation of the dose model in that survival distribution 
b) for the explicit definition of the form of the BMR. 
The dose model chosen was in essence a linear dose-response relationship postulated for a 
distribution  parameter.  It  should  be  not  too  difficult  to  extend  this  assumption  to  more 
complicated  functional  forms.  The  most  natural  extension  would  be  to  use  polynomials, 
starting with a quadratic form ￿
￿ ￿ ￿
￿ ￿￿￿￿ ￿ ￿
￿ ￿￿￿￿￿￿
￿
. Actually, it would be also possible 
to extend this model to non-monotone functions from a mathematical perspective. Ideas of ￿
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fractional polynomials [e.g. ROYSTON (1999)] as they are used for other biomedical problems 
when covariates have to be analyzed could be used. However, there is one hurdle in stepping 
into this direction when applying such models in risk assessment. One should be able to have 
an answer to the question: Why will this model be chosen? It would be hard if not impossible 
to  justify  more  complicated  models  only  for  mathematical  reasons  without  support  from 
toxicological arguments. Since in most applications not much is known on the mode of action 
of a carcinogen, the principle to use at first the simplest model and increase the complexity of 
the models only when those simple models do not fit, may hold also in our case. Therefore 
our choice of the linear form can be considered as the first but also very natural step in model 
development. 
In this thesis, we focused on Weibull and Exponential regression models with a linear dose-
response  relationship  assumed  for  the  distribution  parameter  ￿.  The  Weibull  distribution 
seems  to  be  appropriate  for  time-to-tumor  data  since  it  has  been  used  in  the  past.  Some 
arguments  for  its  appropriateness  for  this  type  of  data  were  summarized  by  PETO  ET  AL. 
(1972). Exponential models have also been used in the literature. However, we found in our 
examples that this class of distributions is insufficient for TTT data which is quite obvious 
when one notes the restriction of the hazard function to be constant over time. There are also 
biological arguments against such a rigid assumption: one has to expect the risk of a tumor 
increasing over time due to its development process [DOLL (1971)].  
Our choice of the BMR functional seems to be quite natural since it relates to the descriptive   
parametric Kaplan-Meier estimate for censored survival data describing the timely occurrence 
of tumors. The median TTT is a common measure in clinical trials to characterize the survival 
of a group of patients. Another common measure for clinicians to assess the prognosis of a 
patient by an easy comprehensible quantitative number is the 1-year or the 2-year survival 
probability, which we had in mind when suggesting defining the BMR as loss in survival 
probability  at  a  specific  time  point.  Nevertheless,  we  concluded  that  the  BMR  should  be 
stated in terms of a relative loss in median survival time and thereby quasi automatically in all 
quantiles of the TTT distribution because this definition makes use of the AFT property of 
Weibull models. Thus the crucial decision, which quantile or time point is most appropriate 
for the definition of the BMR is omitted, but it may become an issue when generalizing the 
approach to other distributions. Then, one may no more avoid the inclusion of toxicological 
knowledge for the definition of the BMR. ￿
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We like to make some further comments on the calculation of the BMDLs. An important 
methodological challenge on this work was the calculation of the confidence limits. In order 
to obtain estimates for the BMDLs we used the profile likelihood method, requiring a re-
parameterization of the model, which includes the BMD as a parameter itself. Although the 
application of this method has been used for the BMD approach, see e.g. the BMDS software 
(http://www.epa.gov/ncea/bmds), it was not at all easy to find this method well described in 
text books and surprisingly almost no reasonable explanation could be found on BMD related 
literature, in spite of its common use in the software. Therefore the profile likelihood method 
was applied to the special functions used in the thesis and it was implemented in R. We found 
it also important to illustrate this method beyond its formal derivation. The graphs used in the 
example were given in detail in order to communicate this method to non-statistical user of 
BMD software.   
Results. The evaluation of Moerbeek and colleagues [MOERBEEK (2004)], which suggested to 
use the profile likelihood ratio method for the estimation of the BMDL, is compatible with the 
results  of  our  simulation  study  we  performed  to  evaluate  the  coverage  probability  of  the 
BMDLs for different percentages of censoring. Indeed, the profile likelihood ratio method 
seems to be an appropriate way of estimating BMDLs for Exponential models. Of course, this 
hint  should  be  investigated  further  e.g.  in  larger  simulation  studies  where  the  simulation 
parameters are varied at a wider scope. The findings obtained in our simulation study were 
very intuitive: The coverage probability was found to be very close to the approximate value 
for all censoring percentages but the variability of the BMDLs increased especially for higher 
censoring percentages, whereby the median of the estimated BMDLs decreased.  
Note,  high  censoring  percentages  are  a  systematic  problem  in  these  dose-response 
experiments with data coming from animal experiments where the experimental doses are 
rather low. Thus, the overall incidence can be very low and the amount of censorings high. 
This is ultimately a question of the design of such experiments and the endpoint. The BMD is 
a tool in risk assessment which was particularly developed for dealing with the challenges of 
investigating the effect of substances at low doses. The underlying idea of the BMD approach 
of modeling the dose-response relationship instead of searching for a dose which leads to no 
statistically significant effect compared to the control group (NOAEL). The BMD has been 
shown to be useful for these settings. The important advantage of the BMD approach is that it 
not crucially dependent on the number of animals on a given dose. That, however would 
strongly influences the power of statistical tests, which could have been applied also for TTT ￿
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data using methods for censored survival data, e.g. the well known log-rank test. In contrast 
the BMD can interpolate between applied doses while the NOAEL approach is restricted to 
these doses. As with respect to human health especially low doses are of concern, it is very 
important to have an approach on hand that is powerful for investigating these low doses. 
Therefore, the methods developed in this work can be very valuable in risk assessment. 
We  want  to  stress  here  the  importance  of  the  calculation  of  the  one-sided  lower  95% 
confidence bound. It is actually the starting point of extrapolating the results of benchmark 
dose  analyses  of  animal  experiments  to  humans.  The  BMDL  is  used  as  reference  point 
because this value also accounts for the quality of the study as increasing the number of 
animals in the study leads to less conservative lower confidence limits. However, a purely 
numerical increase of the number may not suffice to increase the precision of the BMD and as 
such lead to BMDL values close to the value of the BMD. This is a very difficult statistical 
problem of optimal design since we deal in all the BMD application mostly with non-linear 
models, i.e. we encounter here the problem of optimal design in non-linear regression which, 
however, was not considered here further. 
 
Application. The data used as example in this thesis were data on the carcinogenicity of 
Urethane from an animal study conducted by Schmähl and colleagues at the DKFZ (1977). 
One should remark here, that the endpoint we analyzed was not the actual TTT (time-to-
tumor) but the time-to-death-with-tumor. This is the typical endpoint in animal studies which 
investigate occult (internal) tumors. For details how handling this complication see GART 
(1986). They discuss primarily the statistical testing for differences between dose  groups. 
Accounting for the difference between TTT and time-to death with tumor in dose-response 
modeling has so far not investigated in toxicology. It would need the use of other modeling, 
e.g. competing risk models, which have been developed for clinical applications [e.g. FINE 
(1999)]. 
We applied our new BMD approach to these experimental tumor data. The Exponential TTT 
models, which are less flexible than the Weibull models, led to estimates which are much 
more conservative, i.e. higher BMDs and BMDLs than those obtained with the dichotomous 
and Weibull TTT models. An explanation for the remarkable differences of the estimates 
could be found in the diagnostic the Log-log plots of the four experiments suggested. Actually 
the Exponential model type appears less appropriate for our data than the Weibull models and ￿
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the  Likelihood  ratio  tests  showed  the  Weibull  models  to  have  a  significantly  better  fit. 
Generally, these experimental data had the constraint that, although the Cochran-Armitage 
trend test showed a significant interrelationship, the dose-response was not strictly monotonic 
for the lower doses. 
The estimates for the BMDs and BMDLs for Weibull TTT models were compared with the 
results for dichotomous models (loglogistic and Weibull), which investigate only the tumor 
incidence.  A comparison of these different model types led to the observation that with the 
dichotomous models, which use only a smaller amount of information, lower estimates for the 
BMD and BMDL were obtained. Of course, one has to keep in mind that the underlying 
BMRs for dichotomous and TTT models might not be equivalent. For example, 10% loss in 
median tumor-free survival time is a different way of stating the risk of a substance than 10% 
increase  of  tumor  incidence.  But  nevertheless,  this  observation  could  be  a  hint  that  TTT 
models,  which  take  more  of  the  available  information  into  account,  could  lead  to  more 
appropriate, less conservative estimates (Fig. 39). 
Exceptions  of  this  observation  are  the  estimates  for  the  experiment  Rat  male.  Here,  the 
estimates  for  the  BMDs  and  BMDLs  are  much  higher  for  the  dichotomous  models.  The 
reason might be the fact that we cannot find a significant dose-related trend in the selected 
endpoint. Furthermore, as mentioned in the paper, this experiment has to be interpreted with 
extended caution because about half of the animals died due to an unspecified virus infection 
[SCHMÄHL (1977)] and thus the low incidence of tumors could also be caused by the fact that 
many animals were censored after a respectively short observation period. Nevertheless, even 
in that case the TTT models seem to be more appropriate as they lead to estimates for the 
BMDLs that are more or less in the same region of size for each experiment and thus more 
consistent than the values obtained with the quantal models. 
Finally the estimates for the BMDs and BMDLs obtained for the data of the urethane study of 
Schmähl and colleagues were compared to those cited in a JECFA report [JECFA (2005)]. In 
all reported calculations the analysis was performed for the tumor incidences (dichotomous 
models) and the BMR was defined as 10% extra risk of tumors. The estimates reported by 
JECFA,  based  on  other  studies,  were  even  lower  than  the  estimates  gained  with  the 
dichotomous  models  for  our  data.  This  result  could  be  explained  with  the  fact  that  the 
assessments reported by JECFA included also benign tumors in the endpoint – whereas we 
investigated  only  the  occurrence  of  malign  tumors.  The  question  how  to  deal  with  the 
occurrence  of  benign  tumors  leads  however  to  a  more  complex  problem  as  it  seems.  Of ￿
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course, treating animals with benign tumors as censored is a questionable decision because we 
cannot  exclude  the  possibility  that  the  benign  tumors  are  competing  risks  for  malignant 
tumors, e.g.  an animal  may be sacrificed because of a benign tumor.  On the other hand, 
benign  and  malignant  tumors  are  so  different  types  of  tumors  that  they  should  not  be 
combined. They differ significantly in their pathway of etiology and health consequences. 
From a methodological point of view one would have to look out for models for competing 
risks, mentioned above. Form a toxicological point of view, as open question in this context 
remains how the findings should be extrapolated to humans. 
 
Outlook. Finally, we would like to provide an outlook on how the approach could be further 
extended and which steps could be done so that this approach  gets accepted by practical 
working researchers in risk assessment. 
As we concentrated only on Exponential and Weibull models, it could be profitable to extend 
the approach suggested in this thesis to other distributions, which could be appropriate for 
modeling TTT data. Candidates which commonly appear in literature for survival analysis 
would be for example the lognormal and gamma distribution. 
In  order  to  make  the  approach  attractive  also  for  practical  working  researchers  in  risk 
assessment, further simulation studies should be done, which evaluate the coverage of the 
BMDLs  for  different  percentages  of  censoring.  Especially,  it  would  be  important,  to 
investigate  the  coverage  probability  for  underlying  Weibull  distributions  and  evaluate, 
whether the trend we observed for underlying Exponential distributions also holds for the 
Weibull case. 
In principle, the Weibull TTT model would be also applicable to epidemiological studies with 
a larger sample size, since often a large number of humans investigated there.  Human data 
have two other beneficial facts: the extrapolation from animal to human is avoided through 
this data type, and individual data cover mostly  the whole dose range of interest. But as 
observational  data  they  lead  also  to  some  methodological  challenges.  One  is  the  need  to 
systematically detect confounding factors and include them appropriately in the model. For 
further details on the BMD approach for epidemiological data see e.g. BUDTZ-JØRGENSEN 
(2001).    ￿
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￿
All models used in this thesis are parametric models. One should, however, note that the 
Weibull model is a special parametric family since it combines in its definition the PH as well 
as the AFT property. As such one could think of extensions to semi-parametric models. For 
this purpose especially the Cox semi-parametric PH models [e.g. Cox (1972), Cox (1984)] 
could  be  of  interest  and  the  work  of  Nikulin  [NIKULIN  (2005),  NIKULIN  (2006)]  on 
generalizations of AFT models could be also a source for further work. 
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￿
Selected R code  
Fig. 12. 
#Example: assumption Exponential distribution 
#MLE re-parameterized, BMR(abs) in median surv 
#profile likelihood contour plot 
 
# … 
 
#Tools for log likelihood 
delta<-sum(status) 
deltad<-sum(status*dose) 
t0<-sum(weeks[dose==0]) 
t1<-sum(weeks[dose==1]) 
t10<-sum(weeks[dose==10]) 
 
#BMR(absolute value) 
h<-5 
 
#contour plot 
l<-function(x){ 
alpha0<-x[1] 
BMD<-x[2] 
return(-(delta*x[1]+deltad*(log((-log(0.5))*exp(x[1])-h)-log(-log(0.5))-
x[1])/x[2]+t0*exp(-x[1])+t1*exp(-x[1]-(log((-log(0.5))*exp(x[1])-h)-log(-
log(0.5))-x[1])/x[2]*1)+t10*exp(-x[1]-(log((-log(0.5))*exp(x[1])-h)-log(-
log(0.5))-x[1])/x[2]*10))) 
} 
 
BMDgrid<-seq(from=0.8, to=3, by=0.01) 
alpha0grid<-seq(from=3, to=4, by=0.01) 
 
grid<-expand.grid(alpha0=alpha0grid, BMD=BMDgrid) 
werte<-matrix(data=apply(grid,1,FUN=l), nrow=length(alpha0grid)) 
 
contour(alpha0grid,BMDgrid,werte,main="Example: log-likelihood contour 
plot",xlab=expression(alpha0),ylab=expression(BMD),levels=-
c(36,35.8,35.7,35.6,35.58,35.572),xaxs="i",yaxs="i",ylim=c(0.9,3)) 
 
arrows(3.6,1.41,3.398365,1.41,col="red") 
text(3.73,1.41,"l(3.398,1.41)= -35.57",col="red",cex=0.8) 
 
Fig. 13. 
#Example: assumption Exponential distribution, prof. lik. CI, one-sided 
 
# … 
#re-parameterized log-likelihood 
#BMR(absolute value) 
h<-5 
#x=(alpha0,BMD) 
f=function(x){delta*x[1]+deltad*(log((-log(0.5))*exp(x[1])-h)-log(-
log(0.5))-x[1])/x[2]+t0*exp(-x[1])+t1*exp(-x[1]-(log((-log(0.5))*exp(x[1])-
h)-log(-log(0.5))-x[1])/x[2]*1)+t10*exp(-x[1]-(log((-log(0.5))*exp(x[1])-
h)-log(-log(0.5))-x[1])/x[2]*10)} 
 
nlm<-nlm(f,c(5,3)) 
esta0<-nlm$est[1] 
estBMD<-nlm$est[2] 
￿
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# profile likelihood CI 
start<-0.1 
end<-7 
step<-0.001 
BMDgrid<-seq(from=start, to=end, by=step) 
k<-length(BMDgrid) 
 
Wertalpha0<-function(BMD) 
{ 
res<-BMD 
for (i in 1:k) 
  { 
   f=function(x){delta*x+deltad*(log((-log(0.5))*exp(x)-h)-log(-
log(0.5))-x)/BMDgrid[i]+t0*exp(-x)+t1*exp(-x-(log((-log(0.5))*exp(x)-h)-
log(-log(0.5))-x)/BMDgrid[i]*1)+t10*exp(-x-(log((-log(0.5))*exp(x)-h)-log(-
log(0.5))-x)/BMDgrid[i]*10)} 
   nlmResult<-nlm(f,5) 
   res[i]<-nlmResult$estimate 
   } 
return(res) 
} 
 
y<-rbind(Wertalpha0(BMDgrid),BMDgrid) 
 
profilLoglik<-c(1:k) 
func<-function(x){delta*x[1]+deltad*(log((-log(0.5))*exp(x[1])-h)-log(-
log(0.5))-x[1])/x[2]+t0*exp(-x[1])+t1*exp(-x[1]-(log((-log(0.5))*exp(x[1])-
h)-log(-log(0.5))-x[1])/x[2]*1)+t10*exp(-x[1]-(log((-log(0.5))*exp(x[1])-
h)-log(-log(0.5))-x[1])/x[2]*10)} 
 
 
for(i in 1:k) 
  {x<-c(y[1,i],y[2,i])   
   profilLoglik[i]<-func(x) 
  } 
 
ProfilML<-c(1:k) 
 
for(i in 1:k) 
  {x<-c(esta0,estBMD)   
   ProfilML[i]<-func(x) 
  } 
 
relProfvals<--profilLoglik+ProfilML 
 
plot(BMDgrid, relProfvals, type="l", main="Rel. Profile Likelihood for 
Example data set, BMR(abs) h=5",xlab=expression(BMD), 
ylab=expression(tilde(l)[p](BMD))) 
abline(h=-1/2*qchisq(0.9,1),lty=2) 
 
# Find BMDL  
a<-relProfvals+1/2*qchisq(0.9,1) 
index=1 
for (i in 1:length(a))   
  {if (a[i]>=0) {index<-i-1  
             break} 
  } 
 
BMDL<-start+(index-1)*step 
BMDL 
# … 
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Fig. 15. 
#Example: assumption Exponential distribution, prof. lik. CI, one-sided 
 
# … 
##Re-parameterized log-likelihood 
#BMR(rel): 10% loss in median survival 
 
h<-0.10 
#x=(alpha0,BMD) 
f=function(x){delta*x[1]+deltad*(log(1-h)/x[2])+t0*exp(-x[1])+t1*exp(-x[1]-
(log(1-h)/x[2]))+t10*exp(-x[1]-10*(log(1-h)/x[2]))} 
 
nlm<-nlm(f,c(5,50)) 
esta0<-nlm$est[1] 
estBMD<-nlm$est[2] 
 
# profile likelihood CI 
start<-0.25 
end<-2 
step<-0.001 
BMDgrid<-seq(from=start, to=end, by=step) 
k<-length(BMDgrid) 
Wertalpha0<-function(BMD) 
{ 
res<-BMD 
for (i in 1:k) 
  { 
   f=function(x){delta*x+deltad*(log(1-h)/BMDgrid[i])+t0*exp(-
x)+t1*exp(-x-(log(1-h)/BMDgrid[i]))+t10*exp(-x-10*(log(1-h)/BMDgrid[i]))} 
   nlmResult<-nlm(f,5) 
   res[i]<-nlmResult$estimate 
   } 
return(res) 
} 
 
y<-rbind(Wertalpha0(BMDgrid),BMDgrid) 
 
profilLoglik<-c(1:k) 
func<-function(x){delta*x[1]+deltad*(log(1-h)/x[2])+t0*exp(-x[1])+t1*exp(-
x[1]-(log(1-h)/x[2]))+t10*exp(-x[1]-10*(log(1-h)/x[2]))} 
 
for(i in 1:k) 
  {x<-c(y[1,i],y[2,i])   
   profilLoglik[i]<-func(x) 
  } 
 
ProfilML<-c(1:k) 
for(i in 1:k) 
  {x<-c(esta0,estBMD)   
   ProfilML[i]<-func(x) 
  } 
 
relProfvals<--profilLoglik+ProfilML 
 
plot(BMDgrid, relProfvals, type="l", main="Rel. Profile Likelihood for 
Example data set, BMR(rel) h=0.1",xlab=expression(BMD), 
ylab=expression(tilde(l)[p](BMD))) 
abline(h=-1/2*qchisq(0.9,1),lty=2) 
 
# Find BMDL  
a<-relProfvals+1/2*qchisq(0.9,1) 
￿
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index=1 
for (i in 1:length(a))   
  {if (a[i]>=0) {index<-i-1  
             break} 
  } 
 
BMDL<-start+(index-1)*step 
BMDL 
 
# … 
 
Fig. 16. 
#Example: assumption Weibull distribution 
#MLE re-parameterized, BMR(abs) in median surv 
#profile likelihood CI, one-sided 
 
# … 
#Tools for loglikelihood 
delta<-sum(status) 
deltad<-sum(status*dose) 
 
#re-parameterized log-likelihood 
 
#BMR(absolute value) 
h<-5 
#x=(alpha0,BMD,p) 
f=function(x){delta*x[3]*x[1]+deltad*x[3]*((log(exp(x[1])*(-
log(0.5))^(1/x[3])-h)-(1/x[3])*log(-log(0.5))-
x[1])/x[2])+(sum(weeks[dose==0]^x[3]))*exp(-
x[3]*x[1])+(sum(weeks[dose==1]^x[3]))*exp(-x[3]*x[1]-
x[3]*((log(exp(x[1])*(-log(0.5))^(1/x[3])-h)-(1/x[3])*log(-log(0.5))-
x[1])/x[2]))+(sum(weeks[dose==10]^x[3]))*exp(-x[3]*x[1]-
x[3]*10*((log(exp(x[1])*(-log(0.5))^(1/x[3])-h)-(1/x[3])*log(-log(0.5))-
x[1])/x[2]))-delta*log(x[3])-(x[3]-1)*sum(status*log(weeks))} 
 
nlm<-nlm(f,c(4,1,1)) 
esta0<-nlm$est[1] 
estBMD<-nlm$est[2] 
estp<-nlm$est[3] 
 
# profile likelihood CI 
start<-0.1 
end<-12 
step<-0.001 
BMDgrid<-seq(from=start, to=end, by=step) 
k<-length(BMDgrid) 
 
#x=(alpha0,p) 
Wertalpha0<-function(BMD) 
{ 
res<-BMD 
for (i in 1:k) 
  { 
   f=function(x){delta*x[2]*x[1]+deltad*x[2]*((log(exp(x[1])*(-
log(0.5))^(1/x[2])-h)-(1/x[2])*log(-log(0.5))-
x[1])/BMDgrid[i])+(sum(weeks[dose==0]^x[2]))*exp(-
x[2]*x[1])+(sum(weeks[dose==1]^x[2]))*exp(-x[2]*x[1]-
x[2]*((log(exp(x[1])*(-log(0.5))^(1/x[2])-h)-(1/x[2])*log(-log(0.5))-
x[1])/BMDgrid[i]))+(sum(weeks[dose==10]^x[2]))*exp(-x[2]*x[1]-￿
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x[2]*10*((log(exp(x[1])*(-log(0.5))^(1/x[2])-h)-(1/x[2])*log(-log(0.5))-
x[1])/BMDgrid[i]))-delta*log(x[2])-(x[2]-1)*sum(status*log(weeks))} 
   nlmResult<-nlm(f,c(4,1)) 
   res[i]<-nlmResult$estimate[1] 
  } 
return(res) 
} 
 
Wertp<-function(BMD) 
{ 
res<-BMD 
for (i in 1:k) 
  { 
   f=function(x){delta*x[2]*x[1]+deltad*x[2]*((log(exp(x[1])*(-
log(0.5))^(1/x[2])-h)-(1/x[2])*log(-log(0.5))-
x[1])/BMDgrid[i])+(sum(weeks[dose==0]^x[2]))*exp(-
x[2]*x[1])+(sum(weeks[dose==1]^x[2]))*exp(-x[2]*x[1]-
x[2]*((log(exp(x[1])*(-log(0.5))^(1/x[2])-h)-(1/x[2])*log(-log(0.5))-
x[1])/BMDgrid[i]))+(sum(weeks[dose==10]^x[2]))*exp(-x[2]*x[1]-
x[2]*10*((log(exp(x[1])*(-log(0.5))^(1/x[2])-h)-(1/x[2])*log(-log(0.5))-
x[1])/BMDgrid[i]))-delta*log(x[2])-(x[2]-1)*sum(status*log(weeks))} 
   nlmResult<-nlm(f,c(4,1)) 
   res[i]<-nlmResult$estimate[2] 
  } 
return(res) 
} 
 
y<-rbind(Wertalpha0(BMDgrid),Wertp(BMDgrid),BMDgrid) 
 
 
profilLoglik<-c(1:k) 
func<-function(x){delta*x[3]*x[1]+deltad*x[3]*((log(exp(x[1])*(-
log(0.5))^(1/x[3])-h)-(1/x[3])*log(-log(0.5))-
x[1])/x[2])+(sum(weeks[dose==0]^x[3]))*exp(-
x[3]*x[1])+(sum(weeks[dose==1]^x[3]))*exp(-x[3]*x[1]-
x[3]*((log(exp(x[1])*(-log(0.5))^(1/x[3])-h)-(1/x[3])*log(-log(0.5))-
x[1])/x[2]))+(sum(weeks[dose==10]^x[3]))*exp(-x[3]*x[1]-
x[3]*10*((log(exp(x[1])*(-log(0.5))^(1/x[3])-h)-(1/x[3])*log(-log(0.5))-
x[1])/x[2]))-delta*log(x[3])-(x[3]-1)*sum(status*log(weeks))} 
 
for(i in 1:k) 
  {x<-c(y[1,i],y[3,i],y[2,i])   
   profilLoglik[i]<-func(x) 
  } 
 
ProfilML<-c(1:k) 
for(i in 1:k) 
  {x<-c(esta0,estBMD,estp)   
   ProfilML[i]<-func(x) 
  } 
 
relProfvals<--profilLoglik+ProfilML 
 
plot(BMDgrid, relProfvals, type="l", main="Rel. Profile Likelihood for 
Example dataset(Weibull), BMR(abs) h=5",xlab=expression(BMD), 
ylab=expression(tilde(l)[p](BMD))) 
abline(h=-1/2*qchisq(0.9,1),lty=2) 
 
# Find BMDL  
a<-relProfvals+1/2*qchisq(0.9,1) 
 
index=1 
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for (i in 1:length(a))   
  {if (a[i]>=0) {index<-i-1  
             break} 
  } 
 
BMDL<-start+(index-1)*step 
BMDL 
 
# … 
 
 
Fig. 17. 
#Example: assumption Weibull distribution 
#MLE re-parameterized, BMR(rel) in every quantale of surv 10% 
#profile likelihood CI, one-sided 
 
# … 
##Re-parameterized log likelihood 
#BMR(rel): 10% loss in median survival 
h<-0.1 
#x=(alpha0,BMD,p) 
 
f=function(x){delta*x[3]*x[1]+deltad*x[3]*(log(1-
h)/x[2])+(sum(weeks[dose==0]^x[3]))*exp(-
x[3]*x[1])+(sum(weeks[dose==1]^x[3]))*exp(-x[3]*x[1]-1*x[3]*(log(1-
h)/x[2]))+(sum(weeks[dose==10]^x[3]))*exp(-x[3]*x[1]-10*x[3]*(log(1-
h)/x[2]))-delta*log(x[3])-(x[3]-1)*sum(status*log(weeks))} 
 
nlm<-nlm(f,c(3,2,1)) 
esta0<-nlm$est[1] 
estBMD<-nlm$est[2] 
estp<-nlm$est[3] 
 
# profile likelihood CI 
start<-0.2 
end<-10 
step<-0.001 
BMDgrid<-seq(from=start, to=end, by=step) 
k<-length(BMDgrid) 
 
#x=(alpha0,p) 
Wertalpha0<-function(BMD) 
{ 
res<-BMD 
for (i in 1:k) 
  { 
   f=function(x){delta*x[2]*x[1]+deltad*x[2]*(log(1-
h)/BMDgrid[i])+(sum(weeks[dose==0]^x[2]))*exp(-
x[2]*x[1])+(sum(weeks[dose==1]^x[2]))*exp(-x[2]*x[1]-1* x[2]*(log(1-
h)/BMDgrid[i]))+(sum(weeks[dose==10]^x[2]))*exp(-x[2]*x[1]-10*x[2]*(log(1-
h)/BMDgrid[i]))-delta*log(x[2])-(x[2]-1)*sum(status*log(weeks))} 
   nlmResult<-nlm(f,c(3,1)) 
   res[i]<-nlmResult$estimate[1] 
   } 
return(res) 
} 
 
Wertp<-function(BMD) 
{ 
res<-BMD 
for (i in 1:k) ￿
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  { 
   f=function(x){delta*x[2]*x[1]+deltad*x[2]*(log(1-
h)/BMDgrid[i])+(sum(weeks[dose==0]^x[2]))*exp(-
x[2]*x[1])+(sum(weeks[dose==1]^x[2]))*exp(-x[2]*x[1]-1* x[2]*(log(1-
h)/BMDgrid[i]))+(sum(weeks[dose==10]^x[2]))*exp(-x[2]*x[1]-10*x[2]*(log(1-
h)/BMDgrid[i]))-delta*log(x[2])-(x[2]-1)*sum(status*log(weeks))} 
   nlmResult<-nlm(f,c(3,1)) 
   res[i]<-nlmResult$estimate[2] 
   } 
return(res) 
} 
 
y<-rbind(Wertalpha0(BMDgrid),Wertp(BMDgrid),BMDgrid) 
 
 
profilLoglik<-c(1:k) 
func<-function(x){delta*x[3]*x[1]+deltad*x[3]*(log(1-
h)/x[2])+(sum(weeks[dose==0]^x[3]))*exp(-
x[3]*x[1])+(sum(weeks[dose==1]^x[3]))*exp(-x[3]*x[1]-1* x[3]*(log(1-
h)/x[2]))+(sum(weeks[dose==10]^x[3]))*exp(-x[3]*x[1]-10*x[3]*(log(1-
h)/x[2]))-delta*log(x[3])-(x[3]-1)*sum(status*log(weeks))} 
 
for(i in 1:k) 
  {x<-c(y[1,i],y[3,i],y[2,i])   
   profilLoglik[i]<-func(x) 
  } 
 
ProfilML<-c(1:k) 
for(i in 1:k) 
  {x<-c(esta0,estBMD,estp)   
   ProfilML[i]<-func(x) 
  } 
 
relProfvals<--profilLoglik+ProfilML 
 
plot(BMDgrid, relProfvals, type="l", main="Rel. Profile Likelihood for 
Example data set (Weibull), BMR(rel) h=0.1",xlab=expression(BMD), 
ylab=expression(tilde(l)[p](BMD))) 
abline(h=-1/2*qchisq(0.9,1),lty=2) 
 
# Find BMDL  
 
a<-relProfvals+1/2*qchisq(0.9,1) 
 
index=1 
for (i in 1:length(a))   
  {if (a[i]>=0) {index<-i-1  
             break} 
  } 
 
BMDL<-start+(index-1)*step 
BMDL 
# … 
  
 
 
Mouse male (dichotomous model: Weibull), software: BMDS 2.1. 
 
BMR=25% 
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 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background + (1-background)*[1-EXP(-slope*dose^power)] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Power parameter is restricted as power >=1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
                  Default Initial (and Specified) Parameter Values   
                     Background =     0.104651 
                          Slope = 2.60708e-005 
                          Power =            1 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -Power    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             Background        Slope 
 
Background            1        -0.42 
 
     Slope        -0.42            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     Background         0.113047        0.0287171           0.0567621            
0.169331 
          Slope     2.70943e-005     1.01445e-005        7.21144e-006        
4.69771e-005 
          Power                1               NA 
 
NA - Indicates that this parameter has hit a bound 
     implied by some inequality constraint and thus 
     has no standard error. 
 
 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model         -87.909         5 
   Fitted model        -89.2243         2       2.63049      3          
0.4522 
  Reduced model        -94.6734         1       13.5288      4        
0.008961 
 
           AIC:         182.449 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.1130         4.748     4.000          42       -0.364 
  100.0000     0.1154         4.502     6.000          39        0.750 
  500.0000     0.1250         5.124     3.000          41       -1.003 
 2500.0000     0.1711         6.845     9.000          40        0.905 
12500.0000     0.3679        14.714    14.000          40       -0.234 
 
 Chi^2 = 2.58      d.f. = 3        P-value = 0.4618 
 
 
   Benchmark Dose Computation 
 
Specified effect =           0.25 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        10617.8 
 
            BMDL =       6300.18 
 
 
 
--------------------------------------------------------------------------------------------------------------------------- 
 
BMR=10% 
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 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background + (1-background)*[1-EXP(-slope*dose^power)] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Power parameter is restricted as power >=1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
                  Default Initial (and Specified) Parameter Values   
                     Background =     0.104651 
                          Slope = 2.60708e-005 
                          Power =            1 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -Power    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             Background        Slope 
 
Background            1        -0.42 
 
     Slope        -0.42            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     Background         0.113047        0.0287171           0.0567621            
0.169331 
          Slope     2.70943e-005     1.01445e-005        7.21144e-006        
4.69771e-005 
          Power                1               NA 
 
NA - Indicates that this parameter has hit a bound 
     implied by some inequality constraint and thus 
     has no standard error. 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model         -87.909         5 
   Fitted model        -89.2243         2       2.63049      3          
 
 
0.4522 
  Reduced model        -94.6734         1       13.5288      4        
0.008961 
 
           AIC:         182.449 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.1130         4.748     4.000          42       -0.364 
  100.0000     0.1154         4.502     6.000          39        0.750 
  500.0000     0.1250         5.124     3.000          41       -1.003 
 2500.0000     0.1711         6.845     9.000          40        0.905 
12500.0000     0.3679        14.714    14.000          40       -0.234 
 
 Chi^2 = 2.58      d.f. = 3        P-value = 0.4618 
 
 
   Benchmark Dose Computation 
 
Specified effect =            0.1 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        3888.66 
 
            BMDL =       2307.37 
 
 
 
-------------------------------------------------------------------------------------------------------------------------------- 
BMR=5% 
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 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background + (1-background)*[1-EXP(-slope*dose^power)] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Power parameter is restricted as power >=1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
                  Default Initial (and Specified) Parameter Values   
                     Background =     0.104651 
                          Slope = 2.60708e-005 
                          Power =            1 
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           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -Power    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             Background        Slope 
 
Background            1        -0.42 
 
     Slope        -0.42            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     Background         0.113047        0.0287171           0.0567621            
0.169331 
          Slope     2.70943e-005     1.01445e-005        7.21144e-006        
4.69771e-005 
          Power                1               NA 
 
NA - Indicates that this parameter has hit a bound 
     implied by some inequality constraint and thus 
     has no standard error. 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model         -87.909         5 
   Fitted model        -89.2243         2       2.63049      3          
0.4522 
  Reduced model        -94.6734         1       13.5288      4        
0.008961 
 
           AIC:         182.449 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.1130         4.748     4.000          42       -0.364 
  100.0000     0.1154         4.502     6.000          39        0.750 
  500.0000     0.1250         5.124     3.000          41       -1.003 
 2500.0000     0.1711         6.845     9.000          40        0.905 
12500.0000     0.3679        14.714    14.000          40       -0.234 
 
 Chi^2 = 2.58      d.f. = 3        P-value = 0.4618 
 
 
   Benchmark Dose Computation 
 
Specified effect =           0.05 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        1893.14 
 
            BMDL =       1123.31 
 
 
 
A 13 
 
 
Mouse male (dichotomous model: Log-logistic), software: BMDS 2.1. 
 
BMR=25% 
 
 ====================================================================  
       Logistic Model. (Version: 2.12; Date: 05/16/2008)  
      Input Data File: C:\USEPA\BMDS21\Data\lnlmousemaleSetting.(d)   
      Gnuplot Plotting File:  C:\USEPA\BMDS21\Data\lnlmousemaleSetting.plt 
               Tue Mar 30 20:21:14 2010 
 ====================================================================  
 
 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background+(1-background)/[1+EXP(-intercept-
slope*Log(dose))] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Slope parameter is restricted as slope >= 1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
   User has chosen the log transformed model 
 
 
                  Default Initial Parameter Values   
                     background =    0.0952381 
                      intercept =      -10.356 
                          slope =            1 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -slope    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             background    intercept 
 
background            1        -0.46 
 
 intercept        -0.46            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     background          0.11033            *                *                  
* 
      intercept         -10.3283            *                *                  
* 
          slope                1            *                *                  
* 
 
* - Indicates that this value is not calculated. 
 
 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model         -87.909         5 
   Fitted model        -89.1439         2       2.46976      3          
0.4808 
  Reduced model        -94.6734         1       13.5288      4        
0.008961 
 
           AIC:         182.288 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.1103         4.634     4.000          42       -0.312 
  100.0000     0.1132         4.416     6.000          39        0.800 
  500.0000     0.1246         5.110     3.000          41       -0.998 
 2500.0000     0.1776         7.102     9.000          40        0.785 
12500.0000     0.3684        14.738    14.000          40       -0.242 
 
 Chi^2 = 2.41      d.f. = 3        P-value = 0.4920 
 
 
   Benchmark Dose Computation 
 
Specified effect =           0.25 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        10195.1 
 
            BMDL =        5454.64 
 
-------------------------------------------------------------------------------------------------------------------------------- 
 
BMR=10% 
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 ====================================================================  
       Logistic Model. (Version: 2.12; Date: 05/16/2008)  
      Input Data File: C:\USEPA\BMDS21\Data\lnlmousemaleSetting.(d)   
A 14 
 
      Gnuplot Plotting File:  C:\USEPA\BMDS21\Data\lnlmousemaleSetting.plt 
               Tue Mar 30 20:23:06 2010 
 ====================================================================  
 
 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background+(1-background)/[1+EXP(-intercept-
slope*Log(dose))] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Slope parameter is restricted as slope >= 1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
   User has chosen the log transformed model 
 
 
                  Default Initial Parameter Values   
                     background =    0.0952381 
                      intercept =      -10.356 
                          slope =            1 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -slope    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             background    intercept 
 
background            1        -0.46 
 
 intercept        -0.46            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     background          0.11033            *                *                  
* 
      intercept         -10.3283            *                *                  
* 
          slope                1            *                *                  
* 
 
* - Indicates that this value is not calculated. 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model         -87.909         5 
   Fitted model        -89.1439         2       2.46976      3          
0.4808 
  Reduced model        -94.6734         1       13.5288      4        
 
 
0.008961 
 
           AIC:         182.288 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.1103         4.634     4.000          42       -0.312 
  100.0000     0.1132         4.416     6.000          39        0.800 
  500.0000     0.1246         5.110     3.000          41       -0.998 
 2500.0000     0.1776         7.102     9.000          40        0.785 
12500.0000     0.3684        14.738    14.000          40       -0.242 
 
 Chi^2 = 2.41      d.f. = 3        P-value = 0.4920 
 
 
   Benchmark Dose Computation 
 
Specified effect =            0.1 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        3398.36 
 
            BMDL =        1818.21 
 
-------------------------------------------------------------------------------------------------------------------------------- 
 
BMR=5% 
 
 ====================================================================  
       Logistic Model. (Version: 2.12; Date: 05/16/2008)  
      Input Data File: C:\USEPA\BMDS21\Data\lnlmousemaleSetting.(d)   
      Gnuplot Plotting File:  C:\USEPA\BMDS21\Data\lnlmousemaleSetting.plt 
               Tue Mar 30 20:23:53 2010 
 ====================================================================  
 
 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background+(1-background)/[1+EXP(-intercept-
slope*Log(dose))] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Slope parameter is restricted as slope >= 1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
   User has chosen the log transformed model 
 
 
                  Default Initial Parameter Values   
                     background =    0.0952381 
                      intercept =      -10.356 
                          slope =            1 
 
 
A 15 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -slope    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             background    intercept 
 
background            1        -0.46 
 
 intercept        -0.46            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     background          0.11033            *                *                  
* 
      intercept         -10.3283            *                *                  
* 
          slope                1            *                *                  
* 
 
* - Indicates that this value is not calculated. 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model         -87.909         5 
   Fitted model        -89.1439         2       2.46976      3          
0.4808 
  Reduced model        -94.6734         1       13.5288      4        
0.008961 
 
           AIC:         182.288 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.1103         4.634     4.000          42       -0.312 
  100.0000     0.1132         4.416     6.000          39        0.800 
  500.0000     0.1246         5.110     3.000          41       -0.998 
 2500.0000     0.1776         7.102     9.000          40        0.785 
12500.0000     0.3684        14.738    14.000          40       -0.242 
 
 Chi^2 = 2.41      d.f. = 3        P-value = 0.4920 
 
 
   Benchmark Dose Computation 
 
Specified effect =           0.05 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        1609.75 
 
            BMDL =        861.258 
 
 
 
A 16 
 
Mouse female (dichotomous model: Weibull), software: BMDS 2.1. 
 
BMR=25% 
 
 ====================================================================  
       Weibull Model using Weibull Model (Version: 2.12;  Date: 05/16/2008)  
      Input Data File: C:\USEPA\BMDS21\Data\weimousefemaleSetting.(d)   
      Gnuplot Plotting File:  
C:\USEPA\BMDS21\Data\weimousefemaleSetting.plt 
               Tue Mar 30 20:26:30 2010 
 ====================================================================  
 
 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background + (1-background)*[1-EXP(-slope*dose^power)] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Power parameter is restricted as power >=1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
                  Default Initial (and Specified) Parameter Values   
                     Background =    0.0897436 
                          Slope = 4.04822e-005 
                          Power =            1 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -Power    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             Background        Slope 
 
Background            1        -0.46 
 
     Slope        -0.46            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     Background         0.193359        0.0363137            0.122186            
0.264533 
          Slope     3.44303e-005     1.30704e-005        8.81282e-006        
6.00477e-005 
          Power                1               NA 
 
NA - Indicates that this parameter has hit a bound 
     implied by some inequality constraint and thus 
     has no standard error. 
 
 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model        -106.018         5 
   Fitted model        -109.952         2       7.86813      3         
0.04882 
  Reduced model        -115.025         1       18.0135      4        
0.001227 
 
           AIC:         223.905 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.1934         7.348     3.000          38       -1.786 
  100.0000     0.1961         8.041     7.000          41       -0.410 
  500.0000     0.2071         8.078    13.000          39        1.945 
 2500.0000     0.2599        10.395    12.000          40        0.578 
12500.0000     0.4755        19.019    18.000          40       -0.323 
 
 Chi^2 = 7.58      d.f. = 3        P-value = 0.0556 
 
 
   Benchmark Dose Computation 
 
Specified effect =           0.25 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =         8355.5 
 
            BMDL =       4942.66 
 
-------------------------------------------------------------------------------------------------------------------------------- 
 
BMR=10% 
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 ====================================================================  
A 17 
 
       Weibull Model using Weibull Model (Version: 2.12;  Date: 05/16/2008)  
      Input Data File: C:\USEPA\BMDS21\Data\weimousefemaleSetting.(d)   
      Gnuplot Plotting File:  
C:\USEPA\BMDS21\Data\weimousefemaleSetting.plt 
               Tue Mar 30 20:27:45 2010 
 ====================================================================  
 
 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background + (1-background)*[1-EXP(-slope*dose^power)] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Power parameter is restricted as power >=1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
                  Default Initial (and Specified) Parameter Values   
                     Background =    0.0897436 
                          Slope = 4.04822e-005 
                          Power =            1 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -Power    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             Background        Slope 
 
Background            1        -0.46 
 
     Slope        -0.46            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     Background         0.193359        0.0363137            0.122186            
0.264533 
          Slope     3.44303e-005     1.30704e-005        8.81282e-006        
6.00477e-005 
          Power                1               NA 
 
NA - Indicates that this parameter has hit a bound 
     implied by some inequality constraint and thus 
     has no standard error. 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model        -106.018         5 
   Fitted model        -109.952         2       7.86813      3         
0.04882 
 
 
  Reduced model        -115.025         1       18.0135      4        
0.001227 
 
           AIC:         223.905 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.1934         7.348     3.000          38       -1.786 
  100.0000     0.1961         8.041     7.000          41       -0.410 
  500.0000     0.2071         8.078    13.000          39        1.945 
 2500.0000     0.2599        10.395    12.000          40        0.578 
12500.0000     0.4755        19.019    18.000          40       -0.323 
 
 Chi^2 = 7.58      d.f. = 3        P-value = 0.0556 
 
 
   Benchmark Dose Computation 
 
Specified effect =            0.1 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        3060.11 
 
            BMDL =        1810.2 
 
 
-------------------------------------------------------------------------------------------------------------------------------- 
 
BMR=5% 
 
 ====================================================================  
       Weibull Model using Weibull Model (Version: 2.12;  Date: 05/16/2008)  
      Input Data File: C:\USEPA\BMDS21\Data\weimousefemaleSetting.(d)   
      Gnuplot Plotting File:  
C:\USEPA\BMDS21\Data\weimousefemaleSetting.plt 
               Tue Mar 30 20:28:30 2010 
 ====================================================================  
 
 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background + (1-background)*[1-EXP(-slope*dose^power)] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Power parameter is restricted as power >=1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
                  Default Initial (and Specified) Parameter Values   
                     Background =    0.0897436 
                          Slope = 4.04822e-005 
                          Power =            1 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
A 18 
 
 
           ( *** The model parameter(s)  -Power    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             Background        Slope 
 
Background            1        -0.46 
 
     Slope        -0.46            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     Background         0.193359        0.0363137            0.122186            
0.264533 
          Slope     3.44303e-005     1.30704e-005        8.81282e-006        
6.00477e-005 
          Power                1               NA 
 
NA - Indicates that this parameter has hit a bound 
     implied by some inequality constraint and thus 
     has no standard error. 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model        -106.018         5 
   Fitted model        -109.952         2       7.86813      3         
0.04882 
  Reduced model        -115.025         1       18.0135      4        
0.001227 
 
           AIC:         223.905 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.1934         7.348     3.000          38       -1.786 
  100.0000     0.1961         8.041     7.000          41       -0.410 
  500.0000     0.2071         8.078    13.000          39        1.945 
 2500.0000     0.2599        10.395    12.000          40        0.578 
12500.0000     0.4755        19.019    18.000          40       -0.323 
 
 Chi^2 = 7.58      d.f. = 3        P-value = 0.0556 
 
 
   Benchmark Dose Computation 
 
Specified effect =           0.05 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        1489.77 
 
            BMDL =       881.269 
 
 
A 19 
 
 
Mouse female (dichotomous model: Log-logistic), software: BMDS 2.1. 
 
BMR=25% 
 
 ====================================================================  
       Logistic Model. (Version: 2.12; Date: 05/16/2008)  
      Input Data File: C:\USEPA\BMDS21\Data\lnlmousefemaleSetting.(d)   
      Gnuplot Plotting File:  
C:\USEPA\BMDS21\Data\lnlmousefemaleSetting.plt 
               Tue Mar 30 20:30:13 2010 
 ====================================================================  
 
 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background+(1-background)/[1+EXP(-intercept-
slope*Log(dose))] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Slope parameter is restricted as slope >= 1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
   User has chosen the log transformed model 
 
 
                  Default Initial Parameter Values   
                     background =    0.0789474 
                      intercept =     -9.35842 
                          slope =            1 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -slope    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             background    intercept 
 
background            1        -0.52 
 
 intercept        -0.52            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     background         0.186714            *                *                  
* 
      intercept         -9.99274            *                *                  
* 
          slope                1            *                *                  
* 
 
 
 
* - Indicates that this value is not calculated. 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model        -106.018         5 
   Fitted model        -109.763         2        7.4894      3         
0.05783 
  Reduced model        -115.025         1       18.0135      4        
0.001227 
 
           AIC:         223.526 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.1867         7.095     3.000          38       -1.705 
  100.0000     0.1904         7.807     7.000          41       -0.321 
  500.0000     0.2049         7.991    13.000          39        1.987 
 2500.0000     0.2702        10.806    12.000          40        0.425 
12500.0000     0.4825        19.301    18.000          40       -0.412 
 
 Chi^2 = 7.31      d.f. = 3        P-value = 0.0627 
 
 
   Benchmark Dose Computation 
 
Specified effect =           0.25 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        7289.02 
 
            BMDL =        3699.77 
 
-------------------------------------------------------------------------------------------------------------------------------- 
 
BMR=10% 
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====================================================================  
       Logistic Model. (Version: 2.12; Date: 05/16/2008)  
      Input Data File: C:\USEPA\BMDS21\Data\lnlmousefemaleSetting.(d)   
      Gnuplot Plotting File:  
C:\USEPA\BMDS21\Data\lnlmousefemaleSetting.plt 
               Tue Mar 30 20:31:18 2010 
 ====================================================================  
 
 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background+(1-background)/[1+EXP(-intercept-
slope*Log(dose))] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Slope parameter is restricted as slope >= 1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
   User has chosen the log transformed model 
 
 
                  Default Initial Parameter Values   
                     background =    0.0789474 
                      intercept =     -9.35842 
                          slope =            1 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -slope    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             background    intercept 
 
background            1        -0.52 
 
 intercept        -0.52            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     background         0.186714            *                *                  
* 
      intercept         -9.99274            *                *                  
* 
          slope                1            *                *                  
* 
 
* - Indicates that this value is not calculated. 
 
 
 
                         
 
 
 
Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model        -106.018         5 
   Fitted model        -109.763         2        7.4894      3         
0.05783 
  Reduced model        -115.025         1       18.0135      4        
0.001227 
 
           AIC:         223.526 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.1867         7.095     3.000          38       -1.705 
  100.0000     0.1904         7.807     7.000          41       -0.321 
  500.0000     0.2049         7.991    13.000          39        1.987 
 2500.0000     0.2702        10.806    12.000          40        0.425 
12500.0000     0.4825        19.301    18.000          40       -0.412 
 
 Chi^2 = 7.31      d.f. = 3        P-value = 0.0627 
 
 
   Benchmark Dose Computation 
 
Specified effect =            0.1 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        2429.67 
 
            BMDL =        1233.26 
 
-------------------------------------------------------------------------------------------------------------------------------- 
BMR=5% 
 ====================================================================  
       Logistic Model. (Version: 2.12; Date: 05/16/2008)  
      Input Data File: C:\USEPA\BMDS21\Data\lnlmousefemaleSetting.(d)   
      Gnuplot Plotting File:  
C:\USEPA\BMDS21\Data\lnlmousefemaleSetting.plt 
               Tue Mar 30 20:32:03 2010 
 ====================================================================  
 
 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background+(1-background)/[1+EXP(-intercept-
slope*Log(dose))] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Slope parameter is restricted as slope >= 1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
   User has chosen the log transformed model 
 
 
                  Default Initial Parameter Values   
                     background =    0.0789474 
A 21 
 
                      intercept =     -9.35842 
                          slope =            1 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -slope    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             background    intercept 
 
background            1        -0.52 
 
 intercept        -0.52            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     background         0.186714            *                *                  
* 
      intercept         -9.99274            *                *                  
* 
          slope                1            *                *                  
* 
 
* - Indicates that this value is not calculated. 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model        -106.018         5 
   Fitted model        -109.763         2        7.4894      3         
0.05783 
  Reduced model        -115.025         1       18.0135      4        
0.001227 
 
           AIC:         223.526 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.1867         7.095     3.000          38       -1.705 
  100.0000     0.1904         7.807     7.000          41       -0.321 
  500.0000     0.2049         7.991    13.000          39        1.987 
 2500.0000     0.2702        10.806    12.000          40        0.425 
12500.0000     0.4825        19.301    18.000          40       -0.412 
 
 Chi^2 = 7.31      d.f. = 3        P-value = 0.0627 
 
 
   Benchmark Dose Computation 
 
Specified effect =           0.05 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =         1150.9 
 
            BMDL =        584.175 
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Rat male (dichotomous model: Weibull), BMDS 2.1. 
 
BMR=25% 
 
 ====================================================================  
       Weibull Model using Weibull Model (Version: 2.12;  Date: 05/16/2008)  
      Input Data File: C:\USEPA\BMDS21\Data\weiratmaleSetting.(d)   
      Gnuplot Plotting File:  C:\USEPA\BMDS21\Data\weiratmaleSetting.plt 
               Tue Mar 30 20:43:17 2010 
 ====================================================================  
 
 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background + (1-background)*[1-EXP(-slope*dose^power)] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Power parameter is restricted as power >=1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
                  Default Initial (and Specified) Parameter Values   
                     Background =    0.0121951 
                          Slope =  4.0515e-006 
                          Power =            1 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -Power    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             Background        Slope 
 
Background            1        -0.52 
 
     Slope        -0.52            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     Background        0.0275621         0.014861         -0.00156489            
0.056689 
          Slope     2.48015e-006     3.68816e-006       -4.74852e-006        
9.70881e-006 
          Power                1               NA 
 
NA - Indicates that this parameter has hit a bound 
     implied by some inequality constraint and thus 
     has no standard error. 
 
 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model        -28.4981         5 
   Fitted model        -30.0531         2       3.11003      3           
0.375 
  Reduced model        -30.3429         1       3.68959      4          
0.4496 
 
           AIC:         64.1062 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.0276         1.102     0.000          40       -1.065 
  100.0000     0.0278         1.112     1.000          40       -0.108 
  500.0000     0.0288         1.151     2.000          40        0.803 
 2500.0000     0.0336         1.343     2.000          40        0.577 
12500.0000     0.0572         2.290     2.000          40       -0.197 
 
 Chi^2 = 2.16      d.f. = 3        P-value = 0.5394 
 
 
   Benchmark Dose Computation 
 
Specified effect =           0.25 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =         115994 
 
            BMDL =       13250.6 
 
 
-------------------------------------------------------------------------------------------------------------------------------- 
BMR=10% 
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 ====================================================================  
       Weibull Model using Weibull Model (Version: 2.12;  Date: 05/16/2008)  
      Input Data File: C:\USEPA\BMDS21\Data\weiratmaleSetting.(d)   
      Gnuplot Plotting File:  C:\USEPA\BMDS21\Data\weiratmaleSetting.plt 
               Tue Mar 30 20:44:50 2010 
 ====================================================================  
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 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background + (1-background)*[1-EXP(-slope*dose^power)] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Power parameter is restricted as power >=1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
                  Default Initial (and Specified) Parameter Values   
                     Background =    0.0121951 
                          Slope =  4.0515e-006 
                          Power =            1 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -Power    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             Background        Slope 
 
Background            1        -0.52 
 
     Slope        -0.52            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     Background        0.0275621         0.014861         -0.00156489            
0.056689 
          Slope     2.48015e-006     3.68816e-006       -4.74852e-006        
9.70881e-006 
          Power                1               NA 
 
NA - Indicates that this parameter has hit a bound 
     implied by some inequality constraint and thus 
     has no standard error. 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model        -28.4981         5 
   Fitted model        -30.0531         2       3.11003      3           
0.375 
  Reduced model        -30.3429         1       3.68959      4          
0.4496 
 
           AIC:         64.1062 
 
 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.0276         1.102     0.000          40       -1.065 
  100.0000     0.0278         1.112     1.000          40       -0.108 
  500.0000     0.0288         1.151     2.000          40        0.803 
 2500.0000     0.0336         1.343     2.000          40        0.577 
12500.0000     0.0572         2.290     2.000          40       -0.197 
 
 Chi^2 = 2.16      d.f. = 3        P-value = 0.5394 
 
 
   Benchmark Dose Computation 
 
Specified effect =            0.1 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        42481.6 
 
            BMDL =       10178.3 
 
-------------------------------------------------------------------------------------------------------------------------------- 
 
BMR=5% 
 
 ====================================================================  
       Weibull Model using Weibull Model (Version: 2.12;  Date: 05/16/2008)  
      Input Data File: C:\USEPA\BMDS21\Data\weiratmaleSetting.(d)   
      Gnuplot Plotting File:  C:\USEPA\BMDS21\Data\weiratmaleSetting.plt 
               Tue Mar 30 20:45:33 2010 
 ====================================================================  
 
 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background + (1-background)*[1-EXP(-slope*dose^power)] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Power parameter is restricted as power >=1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
                  Default Initial (and Specified) Parameter Values   
                     Background =    0.0121951 
                          Slope =  4.0515e-006 
                          Power =            1 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -Power    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             Background        Slope 
 
Background            1        -0.52 
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     Slope        -0.52            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     Background        0.0275621         0.014861         -0.00156489            
0.056689 
          Slope     2.48015e-006     3.68816e-006       -4.74852e-006        
9.70881e-006 
          Power                1               NA 
 
NA - Indicates that this parameter has hit a bound 
     implied by some inequality constraint and thus 
     has no standard error. 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model        -28.4981         5 
   Fitted model        -30.0531         2       3.11003      3           
0.375 
  Reduced model        -30.3429         1       3.68959      4          
0.4496 
 
           AIC:         64.1062 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.0276         1.102     0.000          40       -1.065 
  100.0000     0.0278         1.112     1.000          40       -0.108 
  500.0000     0.0288         1.151     2.000          40        0.803 
 2500.0000     0.0336         1.343     2.000          40        0.577 
12500.0000     0.0572         2.290     2.000          40       -0.197 
 
 Chi^2 = 2.16      d.f. = 3        P-value = 0.5394 
 
 
   Benchmark Dose Computation 
 
Specified effect =           0.05 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        20681.6 
 
            BMDL =       4955.17 
 
 
 
A 25 
 
Rat male (dichotomous model: Log-logistic), BMDS 2.1. 
 
BMR=25% 
 
 ====================================================================  
       Logistic Model. (Version: 2.12; Date: 05/16/2008)  
      Input Data File: C:\USEPA\BMDS21\Data\lnlratmaleSetting.(d)   
      Gnuplot Plotting File:  C:\USEPA\BMDS21\Data\lnlratmaleSetting.plt 
               Tue Mar 30 20:47:10 2010 
 ====================================================================  
 
 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background+(1-background)/[1+EXP(-intercept-
slope*Log(dose))] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Slope parameter is restricted as slope >= 1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
   User has chosen the log transformed model 
 
 
                  Default Initial Parameter Values   
                     background =            0 
                      intercept =     -11.6339 
                          slope =            1 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -slope    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             background    intercept 
 
background            1        -0.53 
 
 intercept        -0.53            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     background        0.0274826            *                *                  
* 
      intercept         -12.8822            *                *                  
* 
          slope                1            *                *                  
* 
 
* - Indicates that this value is not calculated. 
 
 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model        -28.4981         5 
   Fitted model        -30.0511         2        3.1059      3          
0.3756 
  Reduced model        -30.3429         1       3.68959      4          
0.4496 
 
           AIC:         64.1021 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.0275         1.099     0.000          40       -1.063 
  100.0000     0.0277         1.109     1.000          40       -0.105 
  500.0000     0.0287         1.149     2.000          40        0.806 
 2500.0000     0.0336         1.345     2.000          40        0.574 
12500.0000     0.0574         2.298     2.000          40       -0.202 
 
 Chi^2 = 2.16      d.f. = 3        P-value = 0.5395 
 
 
   Benchmark Dose Computation 
 
Specified effect =           0.25 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =         131081 
 
            BMDL =        13322.5 
 
-------------------------------------------------------------------------------------------------------------------------------- 
 
BMR=10% 
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 ====================================================================  
       Logistic Model. (Version: 2.12; Date: 05/16/2008)  
A 26 
 
      Input Data File: C:\USEPA\BMDS21\Data\lnlratmaleSetting.(d)   
      Gnuplot Plotting File:  C:\USEPA\BMDS21\Data\lnlratmaleSetting.plt 
               Tue Mar 30 20:48:24 2010 
 ====================================================================  
 
 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background+(1-background)/[1+EXP(-intercept-
slope*Log(dose))] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Slope parameter is restricted as slope >= 1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
   User has chosen the log transformed model 
 
 
                  Default Initial Parameter Values   
                     background =            0 
                      intercept =     -11.6339 
                          slope =            1 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -slope    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             background    intercept 
 
background            1        -0.53 
 
 intercept        -0.53            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     background        0.0274826            *                *                  
* 
      intercept         -12.8822            *                *                  
* 
          slope                1            *                *                  
* 
 
* - Indicates that this value is not calculated. 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model        -28.4981         5 
   Fitted model        -30.0511         2        3.1059      3          
 
 
0.3756 
  Reduced model        -30.3429         1       3.68959      4          
0.4496 
 
           AIC:         64.1021 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.0275         1.099     0.000          40       -1.063 
  100.0000     0.0277         1.109     1.000          40       -0.105 
  500.0000     0.0287         1.149     2.000          40        0.806 
 2500.0000     0.0336         1.345     2.000          40        0.574 
12500.0000     0.0574         2.298     2.000          40       -0.202 
 
 Chi^2 = 2.16      d.f. = 3        P-value = 0.5395 
 
 
   Benchmark Dose Computation 
 
Specified effect =            0.1 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        43693.6 
 
            BMDL =         9970.4 
 
-------------------------------------------------------------------------------------------------------------------------------- 
 
BMR=5% 
 
 ====================================================================  
       Logistic Model. (Version: 2.12; Date: 05/16/2008)  
      Input Data File: C:\USEPA\BMDS21\Data\lnlratmaleSetting.(d)   
      Gnuplot Plotting File:  C:\USEPA\BMDS21\Data\lnlratmaleSetting.plt 
               Tue Mar 30 20:49:07 2010 
 ====================================================================  
 
 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background+(1-background)/[1+EXP(-intercept-
slope*Log(dose))] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Slope parameter is restricted as slope >= 1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
   User has chosen the log transformed model 
 
 
                  Default Initial Parameter Values   
                     background =            0 
                      intercept =     -11.6339 
                          slope =            1 
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           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -slope    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             background    intercept 
 
background            1        -0.53 
 
 intercept        -0.53            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     background        0.0274826            *                *                  
* 
      intercept         -12.8822            *                *                  
* 
          slope                1            *                *                  
* 
 
* - Indicates that this value is not calculated. 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model        -28.4981         5 
   Fitted model        -30.0511         2        3.1059      3          
0.3756 
  Reduced model        -30.3429         1       3.68959      4          
0.4496 
 
           AIC:         64.1021 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.0275         1.099     0.000          40       -1.063 
  100.0000     0.0277         1.109     1.000          40       -0.105 
  500.0000     0.0287         1.149     2.000          40        0.806 
 2500.0000     0.0336         1.345     2.000          40        0.574 
12500.0000     0.0574         2.298     2.000          40       -0.202 
 
 Chi^2 = 2.16      d.f. = 3        P-value = 0.5395 
 
 
   Benchmark Dose Computation 
 
Specified effect =           0.05 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        20696.9 
 
            BMDL =        4722.82 
 
 
A 28 
 
 
Rat female (dichotomous model: Weibull), software: BMDS 2.1. 
 
BMR=25% 
 
 ====================================================================  
       Weibull Model using Weibull Model (Version: 2.12;  Date: 05/16/2008)  
      Input Data File: C:\USEPA\BMDS21\Data\weiratfemaleSetting.(d)   
      Gnuplot Plotting File:  C:\USEPA\BMDS21\Data\weiratfemaleSetting.plt 
               Tue Mar 30 20:51:52 2010 
 ====================================================================  
 
 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background + (1-background)*[1-EXP(-slope*dose^power)] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Power parameter is restricted as power >=1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
                  Default Initial (and Specified) Parameter Values   
                     Background =    0.0641026 
                          Slope = 1.92824e-005 
                          Power =      1.02228 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -Power    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             Background        Slope 
 
Background            1        -0.37 
 
     Slope        -0.37            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     Background        0.0403044        0.0192118          0.00264992            
0.077959 
          Slope     2.66754e-005     8.49096e-006        1.00334e-005        
4.33174e-005 
          Power                1               NA 
 
NA - Indicates that this parameter has hit a bound 
     implied by some inequality constraint and thus 
     has no standard error. 
 
 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model        -59.9306         5 
   Fitted model        -60.3218         2      0.782315      3          
0.8537 
  Reduced model        -69.0688         1       18.2763      4         
0.00109 
 
           AIC:         124.644 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.0403         1.532     2.000          38        0.386 
  100.0000     0.0429         1.757     1.000          41       -0.584 
  500.0000     0.0530         2.068     2.000          39       -0.048 
 2500.0000     0.1022         4.089     5.000          40        0.476 
12500.0000     0.3124        12.497    12.000          40       -0.170 
 
 Chi^2 = 0.75      d.f. = 3        P-value = 0.8620 
 
 
   Benchmark Dose Computation 
 
Specified effect =           0.25 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        10784.5 
 
            BMDL =       6791.52 
 
-------------------------------------------------------------------------------------------------------------------------------- 
BMR=10% 
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 ====================================================================  
       Weibull Model using Weibull Model (Version: 2.12;  Date: 05/16/2008)  
      Input Data File: C:\USEPA\BMDS21\Data\weiratfemaleSetting.(d)   
      Gnuplot Plotting File:  C:\USEPA\BMDS21\Data\weiratfemaleSetting.plt 
               Tue Mar 30 20:52:50 2010 
A 29 
 
 ====================================================================  
 
 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background + (1-background)*[1-EXP(-slope*dose^power)] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Power parameter is restricted as power >=1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
                  Default Initial (and Specified) Parameter Values   
                     Background =    0.0641026 
                          Slope = 1.92824e-005 
                          Power =      1.02228 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -Power    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             Background        Slope 
 
Background            1        -0.37 
 
     Slope        -0.37            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     Background        0.0403044        0.0192118          0.00264992            
0.077959 
          Slope     2.66754e-005     8.49096e-006        1.00334e-005        
4.33174e-005 
          Power                1               NA 
 
NA - Indicates that this parameter has hit a bound 
     implied by some inequality constraint and thus 
     has no standard error. 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model        -59.9306         5 
   Fitted model        -60.3218         2      0.782315      3          
0.8537 
  Reduced model        -69.0688         1       18.2763      4         
0.00109 
 
           AIC:         124.644 
 
 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.0403         1.532     2.000          38        0.386 
  100.0000     0.0429         1.757     1.000          41       -0.584 
  500.0000     0.0530         2.068     2.000          39       -0.048 
 2500.0000     0.1022         4.089     5.000          40        0.476 
12500.0000     0.3124        12.497    12.000          40       -0.170 
 
 Chi^2 = 0.75      d.f. = 3        P-value = 0.8620 
 
 
   Benchmark Dose Computation 
 
Specified effect =            0.1 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        3949.72 
 
            BMDL =       2487.32 
 
-------------------------------------------------------------------------------------------------------------------------------- 
 
BMR=5% 
 
 
 ====================================================================  
       Weibull Model using Weibull Model (Version: 2.12;  Date: 05/16/2008)  
      Input Data File: C:\USEPA\BMDS21\Data\weiratfemaleSetting.(d)   
      Gnuplot Plotting File:  C:\USEPA\BMDS21\Data\weiratfemaleSetting.plt 
               Tue Mar 30 20:53:32 2010 
 ====================================================================  
 
 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background + (1-background)*[1-EXP(-slope*dose^power)] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Power parameter is restricted as power >=1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
                  Default Initial (and Specified) Parameter Values   
                     Background =    0.0641026 
                          Slope = 1.92824e-005 
                          Power =      1.02228 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -Power    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             Background        Slope 
A 30 
 
 
Background            1        -0.37 
 
     Slope        -0.37            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     Background        0.0403044        0.0192118          0.00264992            
0.077959 
          Slope     2.66754e-005     8.49096e-006        1.00334e-005        
4.33174e-005 
          Power                1               NA 
 
NA - Indicates that this parameter has hit a bound 
     implied by some inequality constraint and thus 
     has no standard error. 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model        -59.9306         5 
   Fitted model        -60.3218         2      0.782315      3          
0.8537 
  Reduced model        -69.0688         1       18.2763      4         
0.00109 
 
           AIC:         124.644 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.0403         1.532     2.000          38        0.386 
  100.0000     0.0429         1.757     1.000          41       -0.584 
  500.0000     0.0530         2.068     2.000          39       -0.048 
 2500.0000     0.1022         4.089     5.000          40        0.476 
12500.0000     0.3124        12.497    12.000          40       -0.170 
 
 Chi^2 = 0.75      d.f. = 3        P-value = 0.8620 
 
 
   Benchmark Dose Computation 
 
Specified effect =           0.05 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        1922.87 
 
            BMDL =       1210.92 
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Rat female (dichotomous model: Log-logistic), software: BMDS 2.1. 
 
BMR=25% 
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 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background+(1-background)/[1+EXP(-intercept-
slope*Log(dose))] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Slope parameter is restricted as slope >= 1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
   User has chosen the log transformed model 
 
 
                  Default Initial Parameter Values   
                     background =    0.0526316 
                      intercept =      -10.536 
                          slope =            1 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -slope    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             background    intercept 
 
background            1        -0.39 
 
 intercept        -0.39            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     background        0.0385894            *                *                  
* 
      intercept         -10.3671            *                *                  
* 
          slope                1            *                *                  
* 
 
* - Indicates that this value is not calculated. 
 
 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model        -59.9306         5 
   Fitted model        -60.2635         2      0.665837      3          
0.8812 
  Reduced model        -69.0688         1       18.2763      4         
0.00109 
 
           AIC:         124.527 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.0386         1.466     2.000          38        0.449 
  100.0000     0.0416         1.706     1.000          41       -0.552 
  500.0000     0.0535         2.085     2.000          39       -0.061 
 2500.0000     0.1087         4.347     5.000          40        0.332 
12500.0000     0.3099        12.396    12.000          40       -0.135 
 
 Chi^2 = 0.64      d.f. = 3        P-value = 0.8875 
 
 
   Benchmark Dose Computation 
 
Specified effect =           0.25 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        10598.7 
 
            BMDL =        6158.49 
 
-------------------------------------------------------------------------------------------------------------------------------- 
 
BMR=10% 
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 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background+(1-background)/[1+EXP(-intercept-
slope*Log(dose))] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Slope parameter is restricted as slope >= 1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
   User has chosen the log transformed model 
 
 
                  Default Initial Parameter Values   
                     background =    0.0526316 
                      intercept =      -10.536 
                          slope =            1 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -slope    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             background    intercept 
 
background            1        -0.39 
 
 intercept        -0.39            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     background        0.0385894            *                *                  
* 
      intercept         -10.3671            *                *                  
* 
          slope                1            *                *                  
* 
 
* - Indicates that this value is not calculated. 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
 
 
     Full model        -59.9306         5 
   Fitted model        -60.2635         2      0.665837      3          
0.8812 
  Reduced model        -69.0688         1       18.2763      4         
0.00109 
 
           AIC:         124.527 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.0386         1.466     2.000          38        0.449 
  100.0000     0.0416         1.706     1.000          41       -0.552 
  500.0000     0.0535         2.085     2.000          39       -0.061 
 2500.0000     0.1087         4.347     5.000          40        0.332 
12500.0000     0.3099        12.396    12.000          40       -0.135 
 
 Chi^2 = 0.64      d.f. = 3        P-value = 0.8875 
 
 
   Benchmark Dose Computation 
 
Specified effect =            0.1 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        3532.91 
 
            BMDL =        2052.83 
 
-------------------------------------------------------------------------------------------------------------------------------- 
 
BMR=5% 
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 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background+(1-background)/[1+EXP(-intercept-
slope*Log(dose))] 
 
 
   Dependent variable = resp 
   Independent variable = dose 
   Slope parameter is restricted as slope >= 1 
 
   Total number of observations = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 250 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
   User has chosen the log transformed model 
 
 
                  Default Initial Parameter Values   
                     background =    0.0526316 
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                      intercept =      -10.536 
                          slope =            1 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -slope    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             background    intercept 
 
background            1        -0.39 
 
 intercept        -0.39            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     background        0.0385894            *                *                  
* 
      intercept         -10.3671            *                *                  
* 
          slope                1            *                *                  
* 
 
* - Indicates that this value is not calculated. 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model        -59.9306         5 
   Fitted model        -60.2635         2      0.665837      3          
0.8812 
  Reduced model        -69.0688         1       18.2763      4         
0.00109 
 
           AIC:         124.527 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.0386         1.466     2.000          38        0.449 
  100.0000     0.0416         1.706     1.000          41       -0.552 
  500.0000     0.0535         2.085     2.000          39       -0.061 
 2500.0000     0.1087         4.347     5.000          40        0.332 
12500.0000     0.3099        12.396    12.000          40       -0.135 
 
 Chi^2 = 0.64      d.f. = 3        P-value = 0.8875 
 
 
   Benchmark Dose Computation 
 
Specified effect =           0.05 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        1673.49 
 
            BMDL =        972.393 
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Simulation study 
 
Idea: Simulate two independent random variables ‘￿￿￿￿￿’ and  ‘￿￿￿￿￿￿￿￿’, both from an 
Exponential distribution but with different rates ￿ and ￿. The random variable ‘￿￿￿￿￿’ gives 
the time of the event and ‘￿￿￿￿￿￿￿￿’ gives a time point of censoring for one individual. Then, 
the observed time of this individual is min￿￿￿￿￿￿, ￿￿￿￿￿￿￿￿￿.  
To get data sets with a pre-specified fraction ￿ of censorings, make use of the equation: 
￿ ￿
￿
￿
￿
￿  ￿  ￿ ￿
￿
￿
￿
￿
￿ . 
The rates are re-parameterized as usual to get an Exponential regression model with predictor 
variable ‘￿￿￿￿’. 
 
rm(list=ls()) 
library(survival) 
library(splines) 
 
sim<-function() { 
 
#Dosisvektor 
dose<-c(rep(0,40),rep(100,40),rep(500,40),rep(2500,40),rep(12500,40)) 
 
################# 
#censoring 0% 
#event 
a0<-5 
a1<--0.0001 
etime0<-c(rexp(40,rate=exp(-a0-a1*0)),rexp(40,rate=exp(-a0-
a1*100)),rexp(40,rate=exp(-a0-a1*500)), rexp(40,rate=exp(-a0-a1*2500)), 
rexp(40,rate=exp(-a0-a1*12500))) 
 
ctime0<-etime0 
obs0<-etime0 
for (i in 1:200) 
  { 
   if (etime0[i]>ctime0[i]) {obs0[i]<-ctime0[i]}  
  } 
 
tumor0<-c(rep(1,200)) 
 
for (i in 1:200) 
  { 
   if (etime0[i]>ctime0[i]) {tumor0[i]<-0}  
  } 
 
x<-matrix(c(dose, tumor0, obs0),ncol=3) 
 
write.table(x,file="expsim0.txt",sep=" ",row.names=FALSE, 
col.names=c("UDosis","Tumor","Time"))  
 
b<-read.table("expsim0.txt",header=T) 
attach(b) 
 
#Tools for log likelihood 
delta<-sum(Tumor) 
deltad<-sum(Tumor*UDosis) 
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t0<-sum(Time[UDosis==0]) 
t100<-sum(Time[UDosis==100]) 
t500<-sum(Time[UDosis==500]) 
t2500<-sum(Time[UDosis==2500]) 
t12500<-sum(Time[UDosis==12500]) 
 
#BMR(rel): 10% loss in median survival 
h<-0.1 
#x=(alpha0,BMD) 
f=function(x){delta*x[1]+deltad*(log(1-h)/x[2])+t0*exp(-x[1])+t100*exp(-
x[1]-100*(log(1-h)/x[2]))+t500*exp(-x[1]-500*(log(1-h)/x[2]))+t2500*exp(-
x[1]-2500*(log(1-h)/x[2]))+t12500*exp(-x[1]-12500*(log(1-h)/x[2]))} 
nlm<-nlm(f,c(5,500)) 
esta0<-nlm$est[1] 
estBMD<-nlm$est[2] 
 
start<-101 
end<-50001 
step<-100 
 
BMDgrid<-seq(from=start, to=end, by=step) 
k<-length(BMDgrid) 
 
Wertalpha0<-function(BMD) 
{ 
res<-BMD 
for (i in 1:k) 
  { 
   f=function(x){delta*x+deltad*(log(1-h)/BMDgrid[i])+t0*exp(-
x)+t100*exp(-x-100*(log(1-h)/BMDgrid[i]))+t500*exp(-x-500*(log(1-
h)/BMDgrid[i]))+t2500*exp(-x-2500*(log(1-h)/BMDgrid[i]))+t12500*exp(-x-
12500*(log(1-h)/BMDgrid[i]))} 
   nlmResult<-nlm(f,5) 
   res[i]<-nlmResult$estimate 
   } 
return(res) 
} 
 
y<-rbind(Wertalpha0(BMDgrid),BMDgrid) 
 
profilLoglik<-c(1:k) 
func<-function(x){delta*x[1]+deltad*(log(1-h)/x[2])+t0*exp(-
x[1])+t100*exp(-x[1]-100*(log(1-h)/x[2]))+t500*exp(-x[1]-500*(log(1-
h)/x[2]))+t2500*exp(-x[1]-2500*(log(1-h)/x[2]))+t12500*exp(-x[1]-
12500*(log(1-h)/x[2]))} 
 
for(i in 1:k) 
  {x<-c(y[1,i],y[2,i])   
   profilLoglik[i]<-func(x) 
  } 
 
ProfilML<-c(1:k) 
 
for(i in 1:k) 
  {x<-c(esta0,estBMD)   
   ProfilML[i]<-func(x) 
  } 
 
relProfvals<--profilLoglik+ProfilML 
# Find BMDL (rough estimate) 
a<-relProfvals+1/2*qchisq(0.9,1) 
index=1 A 37 
 
for (i in 1:length(a))   
  {if (a[i]>=0) {index<-i-1  
             break} 
  } 
BMDL<-start+(index-1)*step 
 
#smaller interval 
# profile likelihood CI 
start<-BMDL-100 
end<-BMDL+100 
step<-1 
BMDgrid<-seq(from=start, to=end, by=step) 
k<-length(BMDgrid) 
 
Wertalpha0<-function(BMD) 
{ 
res<-BMD 
for (i in 1:k) 
  { 
   f=function(x){delta*x+deltad*(log(1-h)/BMDgrid[i])+t0*exp(-
x)+t100*exp(-x-100*(log(1-h)/BMDgrid[i]))+t500*exp(-x-500*(log(1-
h)/BMDgrid[i]))+t2500*exp(-x-2500*(log(1-h)/BMDgrid[i]))+t12500*exp(-x-
12500*(log(1-h)/BMDgrid[i]))} 
   nlmResult<-nlm(f,5) 
   res[i]<-nlmResult$estimate 
   } 
return(res) 
} 
 
y<-rbind(Wertalpha0(BMDgrid),BMDgrid) 
 
profilLoglik<-c(1:k) 
func<-function(x){delta*x[1]+deltad*(log(1-h)/x[2])+t0*exp(-
x[1])+t100*exp(-x[1]-100*(log(1-h)/x[2]))+t500*exp(-x[1]-500*(log(1-
h)/x[2]))+t2500*exp(-x[1]-2500*(log(1-h)/x[2]))+t12500*exp(-x[1]-
12500*(log(1-h)/x[2]))} 
 
for(i in 1:k) 
  {x<-c(y[1,i],y[2,i])   
   profilLoglik[i]<-func(x) 
  } 
 
ProfilML<-c(1:k) 
 
for(i in 1:k) 
  {x<-c(esta0,estBMD)   
   ProfilML[i]<-func(x) 
  } 
 
relProfvals<--profilLoglik+ProfilML 
 
 
# Find BMDL  
a<-relProfvals+1/2*qchisq(0.9,1) 
index=1 
for (i in 1:length(a))   
  {if (a[i]>=0) {index<-i-1  
             break} 
  } 
BMDL<-start+(index-1)*step 
BMD0<-estBMD 
BMDL0<-BMDL 
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######################## 
#censoring 10% 
#event 
a0<-5 
a1<--0.0001 
etime10<-c(rexp(40,rate=exp(-a0-a1*0)),rexp(40,rate=exp(-a0-
a1*100)),rexp(40,rate=exp(-a0-a1*500)), rexp(40,rate=exp(-a0-a1*2500)), 
rexp(40,rate=exp(-a0-a1*12500))) 
 
a0<-7.197225 
a1<--0.0001003592 
ctime10<-c(rexp(40,rate=exp(-a0-a1*0)),rexp(40,rate=exp(-a0-
a1*100)),rexp(40,rate=exp(-a0-a1*500)), rexp(40,rate=exp(-a0-a1*2500)), 
rexp(40,rate=exp(-a0-a1*12500))) 
 
obs10<-etime10 
for (i in 1:200) 
  { 
   if (etime10[i]>ctime10[i]) {obs10[i]<-ctime10[i]}  
  } 
 
tumor10<-c(rep(1,200)) 
 
for (i in 1:200) 
  { 
   if (etime10[i]>ctime10[i]) {tumor10[i]<-0}  
  } 
 
x<-matrix(c(dose, tumor10, obs10),ncol=3) 
 
write.table(x,file="expsim10.txt",sep=" ",row.names=FALSE, 
col.names=c("UDosis","Tumor","Time"))  
 
b<-read.table("expsim10.txt",header=T) 
attach(b) 
 
# … 
 
BMD10<-estBMD 
BMDL10<-BMDL 
 
# … 
 
BMD<-c(BMD0,BMD10,BMD20,BMD30,BMD40,BMD50,BMD60,BMD70,BMD80,BMD90) 
BMDL<-
c(BMDL0,BMDL10,BMDL20,BMDL30,BMDL40,BMDL50,BMDL60,BMDL70,BMDL80,BMDL90) 
 
result<-c(BMD,BMDL) 
result 
} 
 
ausg<-matrix(c(rep(0,20000)),nrow=1000) 
for (i in 1:1000) 
  { 
   ausg[i,]<-sim() 
  } 
# … 
 
 